[{"content":"If you have cancer, you will not have just one scan. You will have many — often every two to three months, for years.\nThat is, in fact, a good sign: it means your team is watching closely. And there is good news in this guide — the best option near you may well be good enough, and where it isn\u0026rsquo;t, you have the right to ask for better. The goal is never \u0026ldquo;zero scans.\u0026rdquo; It is the right scan, on the best machine available to you.\nHere is what most patients are never told: when imaging becomes a regular part of your life, the scanner you are placed in quietly decides two things that matter enormously over time — how much radiation your body absorbs, and how early a change in your disease is caught. The difference between an older machine and a state-of-the-art one is not small, and there is often a choice.\nThis guide explains, in plain language, what makes one scanner better than another, and ranks the best PET-CT, CT and MRI machines in Romania, in Europe and Turkey, and then all of them together — so you can see exactly where the best option near you stands against the best in the world.\nThis is not an advertisement. Naming a centre means only that it operates a particular machine — it is not a judgement of that hospital\u0026rsquo;s doctors or quality of care. Use this as a map of technology, then choose your centre with your oncologist.\nWhat actually makes a scanner \u0026ldquo;better\u0026rdquo; — for you We rank machines by patient benefit, not by spec-sheet bragging rights. Four things matter, and the good news is that the newest scanners tend to win on all four at once:\nLess radiation. Lower dose per scan — and because you will be scanned repeatedly, the cumulative dose over years is what counts. (MRI has a special place here: it uses no ionizing radiation at all.) Better image quality. Higher sensitivity and resolution mean smaller lesions are seen earlier — the \u0026ldquo;earlier-detection window\u0026rdquo; — with fewer missed findings and fewer false alarms. Faster, more comfortable scans. The best PET scanners image your whole body in a few minutes, in one position — less time holding still, fewer breath-holds, fewer blurred (\u0026ldquo;motion\u0026rdquo;) images. This matters most when you are tired, in pain, or anxious. Reliable monitoring over time. When you are tracked across many scans, you need the change between scans to be real — not scanner noise. Newer, AI-assisted machines give more reproducible numbers, so a true progression isn\u0026rsquo;t missed and a harmless fluctuation isn\u0026rsquo;t mistaken for one. Important Performance and price are separate questions. Throughout this guide, machines are ordered only by performance — the four patient benefits above. We never let cost change the ranking. The only real trade-off is access: the very best scanners may be abroad or self-pay. That is why we show cost and Romanian CAS (national insurance) coverage separately, in the footer of each card — so you can weigh \u0026ldquo;best possible\u0026rdquo; against \u0026ldquo;best available to me.\u0026rdquo; Scanners with built-in AI image reconstruction carry an AI label. PET-CTMRICTPET-MR PET-CT — seeing where the cancer is active A PET-CT combines two scans in one. The PET part shows metabolic activity — where cells are burning energy abnormally, the signature of active tumour. The CT part shows anatomy — the exact size and location. Together they reveal what is there and how active it is, across your whole body. (It is usually the first scan in a full work-up — see our complete oncology diagnosis guide for where it fits in the bigger picture.)\nThe radiation in a PET-CT comes from two places This is the single most important thing to understand, and most patients never hear it:\nWarning A PET-CT exposes you to radiation from two sources: a radioactive tracer injected into your vein (usually a sugar molecule labelled with fluorine, called ¹⁸F-FDG) and the CT scan itself. The total varies widely — from under 1 mSv on the best total-body scanners to ~14–16 mSv on a conventional machine with a full diagnostic CT. As a rule of thumb, the tracer adds about 5–7 mSv and the CT adds anywhere from ~2 to ~10+ mSv, depending heavily on the CT settings.\nFor perspective, the natural background radiation you absorb just by living is about 2–3 mSv per year — so a PET-CT is a meaningful dose, which is exactly why a lower-dose machine matters when you are scanned again and again. The point is not to fear scans; it is to get them on the best machine available.\nThe newest \u0026ldquo;total-body\u0026rdquo; and long-axial scanners cut the tracer dose dramatically (or scan far faster) — but they do not automatically lower the CT part, which then becomes the larger share. So ask specifically about both parts.\nThe two bars on each card are the things that matter most: Radiation shows the scanner\u0026rsquo;s typical whole-body dose in mSv (a shorter bar means less radiation — better), and Coverage shows how much of your body it images at once (a longer bar is better). Coverage isn\u0026rsquo;t a technicality — a scanner that captures you from head to toe in one go can catch disease a shorter scan might miss, finds smaller lesions earlier (millimetres rather than a centimetre), and finishes faster, so you hold still less and the images are sharper. Use the tabs to switch between Romania, Europe + Turkey, and the combined ranking.\nTip Before you book: most centres want a recent blood test — kidney function (creatinine), and sometimes thyroid (TSH) — from within about 4 weeks of the scan, and some recommend an oncologist consultation first. Ask the centre exactly what it needs when you book, and what is included in the price. CombinedRomaniaEurope \u0026#43; Turkey 1 United Imaging uEXPLORER (total-body PET-CT)Total-body PET — 194 cm AI · HYPER DLR Policlinico Sant\u0026#39;Orsola (IRCCS) — BolognaITOspedale San Pietro Fatebenefratelli — RomeIT Radiation ~0.5–1 mSv Coverage 194 cm — whole body at once Self-pay ≈ €1,000Self-pay 2 Siemens Healthineers Biograph Vision QuadraLong-axial-FOV PET — 106 cm AI · OncoFreeze AI Inselspital Bern — BernCHSt Thomas\u0026#39; / King\u0026#39;s College London — LondonUKUniversity Hospital Tübingen — TübingenDEUMCG — GroningenNLNetherlands Cancer Institute (NKI-AVL) — AmsterdamNLAarhus University Hospital — AarhusDKRigshospitalet — CopenhagenDKMedUni Wien / AKH — ViennaAT ≈ €1,200 \u0026#43; €310 reportRoyal Infirmary of Edinburgh — EdinburghUKTurku PET Centre — TurkuFI Radiation ~2–4 mSv Coverage 106 cm — long axial field Self-pay ≈ €1,100–2,500 (varies by country)Self-pay 3 GE HealthCare Omni LegendExtended-FOV digital PET — 32 cm AI · Precision DL Anadolu Medical Center — GebzeTR Radiation ~4–7 mSv Coverage 32 cm — extended field Self-pay ≈ €1,250 (PET-CT)Self-pay 4 Siemens Healthineers Biograph Horizon 3RDigital PET — best time-of-flight in Romania AI · OncoFreeze AI SANADOR Oncology Center — BucharestRO Radiation ~7–10 mSv Coverage 22 cm ≈ 5,500 RON self-payFree (CAS, RO) 5 GE HealthCare Discovery IQ Gen 2 (digital SiPM)Digital SiPM PET Regina Maria — Pallady Oncology Hub — BucharestRO Radiation ~7–10 mSv Coverage ≈ 20 cm Self-pay (contact center)Self-pay 6 GE HealthCare Discovery MI Gen 2Digital SiPM PET AI · deep-learning recon Fundeni Oncology Institute (IOB) — BucharestRO Radiation ~7–10 mSv Coverage 20 cm Free (CAS, RO) 7 GE HealthCare Discovery MI-DRDigital PET, extended field Carol Davila University Emergency Hospital — BucharestRO Radiation ~7–10 mSv Coverage 25 cm Free (CAS, RO) 8 GE HealthCare Discovery IQ Gen 2Digital PET Neolife — IașiRO Radiation ~7–10 mSv Coverage 20 cm Free (CAS, RO) 9 GE HealthCare Discovery IQ (3-ring)Digital PET, narrow field Neolife Enayati Medical City — BucharestRO Radiation ~7–10 mSv Coverage 15.6 cm Free (CAS, RO) 10 GE HealthCare Discovery 610 HDOlder non-TOF PET Neolife — Bucharest (Băneasa)RO Radiation ~8–12 mSv Coverage 15.7 cm ≈ 5,100 RON self-payFree (CAS, RO) Also reported — scanner model not independently verified PET-CT (model not publicly disclosed) — Affidea Excellence Center, Fundeni, RO; Victor Babeș Hospital (new 2024), RO; Oncology Institute (IOCN), RO; Regional Oncology Institute (IRO), ROunverifiedPET-CT for specialised tracers (FAPI / research) — University Hospital Heidelberg, DE; University Hospital Essen (WTZ), DEunverified 1 Siemens Healthineers Biograph Horizon 3RDigital PET — best time-of-flight in Romania AI · OncoFreeze AI SANADOR Oncology Center — BucharestRO Radiation ~7–10 mSv Coverage 22 cm ≈ 5,500 RON self-payFree (CAS, RO) 2 GE HealthCare Discovery IQ Gen 2 (digital SiPM)Digital SiPM PET Regina Maria — Pallady Oncology Hub — BucharestRO Radiation ~7–10 mSv Coverage ≈ 20 cm Self-pay (contact center)Self-pay 3 GE HealthCare Discovery MI Gen 2Digital SiPM PET AI · deep-learning recon Fundeni Oncology Institute (IOB) — BucharestRO Radiation ~7–10 mSv Coverage 20 cm Free (CAS, RO) 4 GE HealthCare Discovery MI-DRDigital PET, extended field Carol Davila University Emergency Hospital — BucharestRO Radiation ~7–10 mSv Coverage 25 cm Free (CAS, RO) 5 GE HealthCare Discovery IQ Gen 2Digital PET Neolife — IașiRO Radiation ~7–10 mSv Coverage 20 cm Free (CAS, RO) 6 GE HealthCare Discovery IQ (3-ring)Digital PET, narrow field Neolife Enayati Medical City — BucharestRO Radiation ~7–10 mSv Coverage 15.6 cm Free (CAS, RO) 7 GE HealthCare Discovery 610 HDOlder non-TOF PET Neolife — Bucharest (Băneasa)RO Radiation ~8–12 mSv Coverage 15.7 cm ≈ 5,100 RON self-payFree (CAS, RO) Also reported — scanner model not independently verified PET-CT (model not publicly disclosed) — Affidea Excellence Center, Fundeni, RO; Victor Babeș Hospital (new 2024), RO; Oncology Institute (IOCN), RO; Regional Oncology Institute (IRO), ROunverified 1 United Imaging uEXPLORER (total-body PET-CT)Total-body PET — 194 cm AI · HYPER DLR Policlinico Sant\u0026#39;Orsola (IRCCS) — BolognaITOspedale San Pietro Fatebenefratelli — RomeIT Radiation ~0.5–1 mSv Coverage 194 cm — whole body at once Self-pay ≈ €1,000Self-pay 2 Siemens Healthineers Biograph Vision QuadraLong-axial-FOV PET — 106 cm AI · OncoFreeze AI Inselspital Bern — BernCHSt Thomas\u0026#39; / King\u0026#39;s College London — LondonUKUniversity Hospital Tübingen — TübingenDEUMCG — GroningenNLNetherlands Cancer Institute (NKI-AVL) — AmsterdamNLAarhus University Hospital — AarhusDKRigshospitalet — CopenhagenDKMedUni Wien / AKH — ViennaAT ≈ €1,200 \u0026#43; €310 reportRoyal Infirmary of Edinburgh — EdinburghUKTurku PET Centre — TurkuFI Radiation ~2–4 mSv Coverage 106 cm — long axial field Self-pay ≈ €1,100–2,500 (varies by country)Self-pay 3 GE HealthCare Omni LegendExtended-FOV digital PET — 32 cm AI · Precision DL Anadolu Medical Center — GebzeTR Radiation ~4–7 mSv Coverage 32 cm — extended field Self-pay ≈ €1,250 (PET-CT)Self-pay Also reported — scanner model not independently verified PET-CT for specialised tracers (FAPI / research) — University Hospital Heidelberg, DE; University Hospital Essen (WTZ), DEunverified What the top machine actually buys you. The #1, a \u0026ldquo;total-body\u0026rdquo; PET-CT (United Imaging uEXPLORER) has a 194 cm imaging window — it captures you from head to toe simultaneously. Because it collects on the order of 40 times more signal than a conventional scanner, it can use a tiny tracer injection (research protocols have reached sub-millisievert total doses by dropping the CT) or scan you in a few minutes. For someone scanned repeatedly, that is a dramatically lower lifetime radiation burden and the ability to detect very small lesions earlier (Spencer et al., J Nucl Med 2021 ; SNMMI ).\nThe next tier, a long-axial-FOV scanner (Siemens Biograph Vision Quadra, 106 cm), is close behind: ~10× the sensitivity of a conventional machine, which in practice halves the tracer dose (one 2025 dose-comparison study found the PET dose dropped from 6.2 to 2.9 mSv) while the CT dose stays the same and becomes the dominant part (dose comparison study, 2025 ).\nAnd the best in Romania? Romania\u0026rsquo;s strongest PET-CT — the Siemens Biograph Horizon 3R at the SANADOR Oncology Center in Bucharest, which has the country\u0026rsquo;s best time-of-flight — is an excellent, fully capable machine. But it sits at a standard ~22 cm coverage and a standard radiation tier, so it lands below the total-body, long-axial and extended-field scanners abroad — roughly the #4 spot on the combined list. It is very good for routine monitoring, but it is not the lowest-dose, highest-sensitivity option that exists. That gap is exactly what you weigh when you decide whether a particular scan is worth travelling for — a decision to make with your oncologist, since timing and your treatment stage matter as much as the machine.\nMRI — detail without any radiation Tip MRI uses no ionizing radiation at all. It images with magnetic fields and radio waves — not X-rays. For a cancer patient who is scanned often, that makes MRI the preferred tool wherever it can answer the question (brain, liver, spine, pelvis, soft tissue) (FDA — Benefits and Risks of MRI ). It has its own cautions — metal implants, some pacemakers, and the gadolinium contrast agent — but radiation is not one of them. For MRI, the headline quality metric is field strength, measured in tesla (T). Moving from 1.5T to 3T roughly doubles the signal, which means sharper images or faster scans. 7T machines exist but, for now, are cleared only for the brain and knee — not whole-body cancer staging. AI reconstruction (such as GE\u0026rsquo;s AIR Recon DL or Siemens\u0026rsquo; Deep Resolve) sharpens images and can cut scan time by half or more.\nThe combined ranking is topped by a 7T scanner on raw field strength — but it is approved only for brain and knee imaging. For body cancer staging, the machine to ask for is the best available 3T.\nCombinedRomaniaEurope \u0026#43; Turkey 1 Siemens Healthineers MAGNETOM Terra.X (7T)Clinical 7T — brain \u0026amp; knee only AI · Deep Resolve Otto-von-Guericke University — MagdeburgDEParis Brain Institute (ICM) — ParisFR Radiation None Field 7T (neuro / MSK only) Academic referralSelf-pay 2 Siemens Healthineers MAGNETOM Cima.X (3T)Highest-gradient clinical 3T AI · Deep Resolve University Medical Center Freiburg — FreiburgDE Radiation None Field 3T — record gradients Self-pay (contact center)Self-pay 3 GE HealthCare SIGNA Hero (3T)Newest 3T in Romania AI · AIR Recon DL Regional Oncology Institute (IRO) — IașiRO Radiation None Field 3T Free (CAS, RO) 4 Siemens Healthineers MAGNETOM Vida (3T)Premium 3T AI · Deep Resolve Provita Nord Imaging Center — BucharestRO Radiation None Field 3T Partly via CAS 5 Siemens Healthineers MAGNETOM Skyra (3T)Wide-bore 3T Provita Medical Group (Nord) — BucharestRO Radiation None Field 3T — 70 cm bore Partly via CAS 6 Siemens Healthineers MAGNETOM Altea (1.5T)Best 1.5T in Romania AI · Deep Resolve Affidea (Hiperdia) — Cluj-NapocaRO Radiation None Field 1.5T Free (CAS, RO) 7 GE HealthCare SIGNA Explorer (1.5T)Standard 1.5T AI · AIR Recon DL Neolife — Bucharest (Băneasa)RO Radiation None Field 1.5T Free (CAS, RO) Also reported — scanner model not independently verified Wide-bore 3T MRI (model not publicly disclosed) — Anadolu Medical Center, TRunverified 1 GE HealthCare SIGNA Hero (3T)Newest 3T in Romania AI · AIR Recon DL Regional Oncology Institute (IRO) — IașiRO Radiation None Field 3T Free (CAS, RO) 2 Siemens Healthineers MAGNETOM Vida (3T)Premium 3T AI · Deep Resolve Provita Nord Imaging Center — BucharestRO Radiation None Field 3T Partly via CAS 3 Siemens Healthineers MAGNETOM Skyra (3T)Wide-bore 3T Provita Medical Group (Nord) — BucharestRO Radiation None Field 3T — 70 cm bore Partly via CAS 4 Siemens Healthineers MAGNETOM Altea (1.5T)Best 1.5T in Romania AI · Deep Resolve Affidea (Hiperdia) — Cluj-NapocaRO Radiation None Field 1.5T Free (CAS, RO) 5 GE HealthCare SIGNA Explorer (1.5T)Standard 1.5T AI · AIR Recon DL Neolife — Bucharest (Băneasa)RO Radiation None Field 1.5T Free (CAS, RO) 1 Siemens Healthineers MAGNETOM Terra.X (7T)Clinical 7T — brain \u0026amp; knee only AI · Deep Resolve Otto-von-Guericke University — MagdeburgDEParis Brain Institute (ICM) — ParisFR Radiation None Field 7T (neuro / MSK only) Academic referralSelf-pay 2 Siemens Healthineers MAGNETOM Cima.X (3T)Highest-gradient clinical 3T AI · Deep Resolve University Medical Center Freiburg — FreiburgDE Radiation None Field 3T — record gradients Self-pay (contact center)Self-pay Also reported — scanner model not independently verified Wide-bore 3T MRI (model not publicly disclosed) — Anadolu Medical Center, TRunverified What the top machine buys you — and where Romania stands. Setting the brain/knee-only 7T aside, the meaningful tier for body cancer staging is a premium 3T with AI reconstruction — and here the news is good: Romania\u0026rsquo;s best MRI is a brand-new 3T with AI reconstruction, genuinely in the same class as the best 3T scanners across Europe. For routine cancer MRI you do not necessarily need to leave the country; you need to make sure you are booked on a 3T (not a 1.5T) machine, ideally one with AI reconstruction.\nCT — the workhorse, where dose discipline matters most A CT scan is fast, widely available, and the backbone of cancer follow-up. It is also pure X-ray radiation — so the generation of the detector matters a great deal for both image quality and dose.\nThe technology hierarchy, best to standard: photon-counting → spectral (dual-layer) → dual-source / dual-energy → conventional multi-slice. The newest photon-counting scanners deliver the sharpest images (down to ~0.2 mm), capture spectral (multi-energy) information on every scan with no extra dose, and typically lower the radiation dose — although the exact dose depends on the protocol (photon-counting CT review ; dose comparison ).\nStandard, spectral and dual-source CT scanners are widespread across European hospitals — too common to rank individually. So in the Europe + Turkey tab we list only the one genuinely new tier worth travelling for: photon-counting CT, the most advanced detector available.\nCombinedRomaniaEurope \u0026#43; Turkey 1 Siemens Healthineers NAEOTOM Alpha (photon-counting CT)Photon-counting — the newest CT detector Cardiomed Medical Center — Târgu MureșROUniversity Hospital Zürich (world-first, 2021) — ZürichCHErasmus MC — RotterdamNLUniversity Hospital Augsburg — AugsburgDECHU Lille — LilleFRRoyal Infirmary of Edinburgh — EdinburghUK Radiation ~1–4 mSv Detector Photon-counting Self-pay (varies by center) 2 Philips Spectral CT 7500Dual-layer spectral CT AI · Precise Image Carol Davila University Emergency Hospital — BucharestRO Radiation ~4–8 mSv Detector Spectral (dual-layer) Free (CAS, RO) 3 Siemens Healthineers SOMATOM ForceDual-source CT Ponderas Academic Hospital (Regina Maria) — BucharestRO Radiation ~3–6 mSv Detector Dual-source Partly via CAS 4 GE HealthCare Discovery 750 HDDual-energy CT Fundeni Oncology Institute (IOB) — BucharestRO Radiation ~5–8 mSv Detector Dual-energy (Gemstone) Free (CAS, RO) 5 Siemens Healthineers SOMATOM Perspective128-slice CT Provita Medical Group (Nord) — BucharestRO Radiation ~3–7 mSv Detector 128-slice Partly via CAS 6 GE HealthCare Revolution EVO64-slice CT AI · TrueFidelity DL Affidea (SEMA Parc) — BucharestRO Radiation ~4–8 mSv Detector 64-slice Partly via CAS Also reported — scanner model not independently verified CT built into the PET-CT (standalone model not disclosed) — Anadolu Medical Center, TRunverified 1 Siemens Healthineers NAEOTOM Alpha (photon-counting CT)Photon-counting — the newest CT detector Cardiomed Medical Center — Târgu MureșRO Radiation ~1–4 mSv Detector Photon-counting Self-pay (varies by center) 2 Philips Spectral CT 7500Dual-layer spectral CT AI · Precise Image Carol Davila University Emergency Hospital — BucharestRO Radiation ~4–8 mSv Detector Spectral (dual-layer) Free (CAS, RO) 3 Siemens Healthineers SOMATOM ForceDual-source CT Ponderas Academic Hospital (Regina Maria) — BucharestRO Radiation ~3–6 mSv Detector Dual-source Partly via CAS 4 GE HealthCare Discovery 750 HDDual-energy CT Fundeni Oncology Institute (IOB) — BucharestRO Radiation ~5–8 mSv Detector Dual-energy (Gemstone) Free (CAS, RO) 5 Siemens Healthineers SOMATOM Perspective128-slice CT Provita Medical Group (Nord) — BucharestRO Radiation ~3–7 mSv Detector 128-slice Partly via CAS 6 GE HealthCare Revolution EVO64-slice CT AI · TrueFidelity DL Affidea (SEMA Parc) — BucharestRO Radiation ~4–8 mSv Detector 64-slice Partly via CAS 1 Siemens Healthineers NAEOTOM Alpha (photon-counting CT)Photon-counting — the newest CT detector University Hospital Zürich (world-first, 2021) — ZürichCHErasmus MC — RotterdamNLUniversity Hospital Augsburg — AugsburgDECHU Lille — LilleFRRoyal Infirmary of Edinburgh — EdinburghUK Radiation ~1–4 mSv Detector Photon-counting Self-pay (varies by center) Also reported — scanner model not independently verified CT built into the PET-CT (standalone model not disclosed) — Anadolu Medical Center, TRunverified What the top machine buys you — and a Romanian surprise. The #1 is photon-counting CT (Siemens NAEOTOM Alpha), the first new CT detector design in decades — the highest resolution, spectral data on every scan, and lower dose. The next tier (dual-layer spectral CT) still gives spectral imaging with no extra dose; below that, dual-source and dual-energy scanners add useful capability over a conventional machine.\nNotably, the single best CT in this guide — photon-counting — is available in Romania: the Siemens NAEOTOM Alpha at the Cardiomed centre in Târgu Mureș, on the same platform as the world-first installation in Zürich. So for a patient who needs the most advanced, lowest-dose CT, the top tier is reachable inside the country — while the rest of Romania\u0026rsquo;s strong centres offer spectral, dual-source and dual-energy machines that are very capable for routine follow-up.\nA note on PET-MR A handful of academic centres in Europe run simultaneous PET/MR scanners, which capture PET and MRI at the same time. They are a niche tool — most useful for children (avoiding CT radiation), brain tumours, prostate cancer, and ambiguous soft-tissue findings — and they deliver less radiation than PET-CT because there is no CT component (EANM PET/MR survey 2023 ). For routine lung or whole-body staging they are not the standard choice, and there are none in Romania or Turkey today. You don\u0026rsquo;t need to seek one out — if simultaneous PET/MR could help in your specific case, your oncologist will raise it.\n1 Siemens Healthineers Biograph mMR (simultaneous PET/MR, 3T)Simultaneous PET \u0026#43; MRI University Hospital Essen (WTZ) — EssenDE Radiation ~3–6 mSv (no CT) Field 3T, simultaneous Academic / self-paySelf-pay What to ask before your next scan You don\u0026rsquo;t need to memorise scanner models. You need to ask four questions:\n\u0026ldquo;What machine will I be scanned on — make and model, and what year was it installed?\u0026rdquo; Newer is generally better. \u0026ldquo;For PET-CT: what is the tracer dose, and what is the CT dose?\u0026rdquo; Ask about both parts, not just one. \u0026ldquo;For MRI: is it a 3T or a 1.5T? Does it have AI reconstruction?\u0026rdquo; Prefer 3T for cancer staging. \u0026ldquo;For CT: is it photon-counting, spectral, or conventional?\u0026rdquo; And: \u0026ldquo;Is the dose optimised for someone who will be scanned repeatedly?\u0026rdquo; Tip In Romania, the key scans are covered by CAS (national insurance), with a referral (bilet de trimitere) from your doctor: PET-CT for cancer, MRI and CT are all reimbursable. Two things worth knowing:\nYou can ask for a referral to a specific, better-equipped centre — for example one with a 3T MRI or a newer PET-CT. This is your right; you do not have to accept the nearest machine by default. The most advanced options are self-pay. Total-body PET, and for now photon-counting CT, are not routinely reimbursed. Ask your oncologist whether the question you need answered actually justifies the cost or the trip — sometimes it clearly does; often the excellent covered option is enough. A word on travelling for a scan. Going abroad is not a small thing — the cost, the logistics, and your own energy all matter, and only you can weigh them. And your oncologist\u0026rsquo;s judgement comes first: if you are in the middle of chemotherapy, recovering from surgery, or simply unwell, the safest, soonest scan on a good local machine usually beats a better machine that means a hard journey. Use this guide to ask sharper questions — not to second-guess your team\u0026rsquo;s timing.\nFor how imaging fits into the bigger picture of getting a complete diagnosis, see our complete oncology diagnosis guide . For a worked example in one cancer subtype, see our guide to RET fusion-positive lung cancer .\nWhat to do now Before you book, ask which scanner you\u0026rsquo;ll be on — make, model, and install year. You are allowed to ask, and a good centre will tell you (call ahead or check their website). Match the machine to the question: for MRI insist on 3T; for CT ask whether photon-counting or spectral is available; for PET-CT ask about both the tracer dose and the CT dose. Use your CAS referral as leverage — you can request a centre with newer equipment, not just the nearest one. Decide any travel or self-pay together with your oncologist — weigh \u0026ldquo;best possible\u0026rdquo; against \u0026ldquo;best available to me\u0026rdquo;, and let your treatment timing lead. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/imaging/imaging-equipment-guide/","summary":"\u003cp\u003e\u003cstrong\u003eIf you have cancer, you will not have just one scan. You will have many — often every two to three months, for years.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThat is, in fact, a good sign: it means your team is watching closely. And there is \u003cstrong\u003egood news in this guide\u003c/strong\u003e — the best option near you may well be good enough, and where it isn\u0026rsquo;t, you have the right to ask for better. The goal is never \u0026ldquo;zero scans.\u0026rdquo; It is \u003cstrong\u003ethe right scan, on the best machine available to you.\u003c/strong\u003e\u003c/p\u003e","title":"Choosing the Right Scanner: How the Machine Changes Your Radiation and Your Diagnosis"},{"content":"You have just learned that you have RET fusion lung cancer. Or that someone you love has received this diagnosis.\nI know what you are going through. I have been there.\nThe first reaction is to feel like the world has stopped. Then comes the need to do something \u0026ndash; anything \u0026ndash; immediately. But here is what I have learned: the most important thing you can do right now is understand what you have, what options exist, and how to avoid the mistakes that can cost you.\nThis guide gives you everything you need to know \u0026ndash; from diagnosis to treatment, from side effects to emergencies, from what lies ahead to how you live day to day with this diagnosis. It is the map I wish I had.\nThe good news, before anything else: Your cancer has an approved, targeted treatment that works. You are not stuck with generic chemotherapy. Read on.\nWhat you have \u0026ndash; understanding the diagnosis You have a rare subtype of non-small cell lung cancer (NSCLC) driven by a RET gene fusion. Two genes in your tumor cells have joined together, creating an abnormal protein that tells cells to grow without stopping. The good news: this fusion is targetable \u0026ndash; there is a precision drug designed specifically for it.\nWhat RET fusion means Your cancer cells carry a specific genetic alteration: the RET gene has fused with another gene (most commonly KIF5B or CCDC6, though other partners exist). This fusion creates a signaling protein \u0026ldquo;stuck on\u0026rdquo; that drives cancer growth. Selpercatinib (Retevmo) directly blocks this abnormal RET protein.\nThe fusion partner matters:\nRET Partner What it means Clinical notes KIF5B-RET Most common (over 50% of cases) May show higher initial resistance; responds well to selective RET inhibitors CCDC6-RET Second most common Generally more responsive; excellent response to Selpercatinib Others (NCOA4, TRIM33 etc.) Rare variants All respond to RET-specific inhibitors Ask your doctor: \u0026ldquo;What RET fusion partner do I have?\u0026rdquo; The answer influences prognosis and treatment decisions if resistance develops.\nHow the diagnosis was confirmed The RET fusion was identified through molecular testing \u0026ndash; a genetic analysis of your tumor. Selpercatinib must be given only to patients with confirmed RET fusions.\nTesting method What it does Accuracy NGS (Next-Generation Sequencing) Reads the tumor DNA/RNA to find RET and other mutations simultaneously Over 95% \u0026ndash; gold standard FISH Uses fluorescent probes to visualize RET breakpoints 90-95% sensitivity, but lower specificity RT-PCR Detects RET fusion mRNA transcripts High for common partners Warning If you only had FISH, without NGS: Request confirmation by NGS. FISH can produce false-positive results and does not identify the exact fusion partner. NGS also detects co-mutations that influence prognosis. Who gets RET fusion lung cancer This type of cancer has a distinct patient profile:\nAge: Younger patients (median 55-62 years) Smoking: 55-70% are never-smokers or light smokers Sex: More common in women (60-70%) Histology: 99%+ are adenocarcinomas Important: RET fusions occur alone \u0026ndash; they do not usually coexist with EGFR, ALK, or ROS1 Your cancer is NOT caused by smoking. It is a spontaneous genetic accident in the tumor cells, not in your inherited genes. If you are at the beginning of your journey, also read the complete oncology diagnosis guide \u0026ndash; it covers the correct order of steps, from PET-CT to molecular testing.\nPrognosis: the real numbers Without RET-targeted therapy (older data): Median survival of 8-12 months with standard chemotherapy.\nWith Selpercatinib (current treatment):\nOverall response rate (ORR): 84% in patients who receive it as first-line treatment Progression-free survival (PFS): 24.8 months \u0026ndash; most patients remained stable on treatment for nearly two years Disease control rate: 88% Overall survival (OS): Not yet reached after 3.5+ years in first-line treated patients Brain metastases are common: 46% of RET fusion patients develop brain tumors during their lifetime. Regular brain MRI is essential.\nThe number that truly matters: Your individual prognosis depends on stage, fusion partner, co-mutations (such as TP53), and how your specific tumor responds to Selpercatinib. Ask your oncologist for YOUR NUMBERS.\nCo-mutations to check for Co-mutation Frequency Clinical impact TP53 ~45-50% Associated with worse prognosis and higher metastatic burden PIK3CA / PTEN loss ~25-30% May drive resistance; suggests need for combination therapies KRAS Under 10% Rare, as RET and KRAS are usually mutually exclusive Ask your doctor: \u0026ldquo;Does my tumor have co-mutations besides RET? Especially TP53 or PIK3CA?\u0026rdquo;\nThe best treatment right now Selpercatinib (Retevmo) \u0026ndash; the standard first-line treatment Selpercatinib is the preferred selective RET inhibitor for RET fusion lung cancer. Here is why:\nDoubles PFS compared to chemotherapy + pembrolizumab: 24.8 months vs. 11.2 months Superior response rate: 84% tumor reduction in first-line treated patients Brain penetration: 91% intracranial response rate in patients with brain metastases at baseline Selective for RET \u0026ndash; fewer side effects than older multi-kinase inhibitors Why immunotherapy does NOT work in RET-fused cancer Approach Response rate Selpercatinib alone 84% Chemotherapy + pembrolizumab 56% Immunotherapy alone in RET+ patients Poor Why? RET fusion-positive tumors have \u0026ldquo;cold\u0026rdquo; immune microenvironments with low PD-L1 expression. Immunotherapy targets the PD-1/PD-L1 axis \u0026ndash; your cancer does not depend on this checkpoint.\nLIBRETTO-431 explicitly showed: Pembrolizumab added to chemotherapy did not improve outcomes compared to chemotherapy alone in RET+ patients, and both were inferior to Selpercatinib.\nImportant Do NOT accept immunotherapy alone for RET-fused lung cancer. The international standard of care is Selpercatinib, not pembrolizumab or nivolumab. Selpercatinib vs. Pralsetinib (Gavreto) Factor Selpercatinib Pralsetinib ORR (first-line) 84% 61% PFS (first-line) 24.8 months 16.5-17 months Brain activity 91% intracranial response ~56% intracranial response Dosing 120-160 mg twice daily 400 mg once daily (on empty stomach) Guideline preference Preferred first-line Alternative Important for Romania and the EU: Pralsetinib (Gavreto) was withdrawn from the EU in October 2024 \u0026ndash; not for safety reasons, but through a commercial decision by the manufacturer. Selpercatinib is the only targeted RET inhibitor available in Europe.\nWhat NOT to do \u0026ndash; mistakes that can cost you If you are on Selpercatinib, the decisions you make outside the clinic matter just as much as those inside it. Some mistakes are easy to make \u0026ndash; a glass of juice, a vitamin, a supplement recommended by a neighbor. All of them can cost you.\nRead this section carefully. Print it. Show it to your family.\nMISTAKE 1: Grapefruit juice What happens: Grapefruit inhibits CYP3A4, the liver enzyme that breaks down Selpercatinib. When CYP3A4 is blocked, Selpercatinib accumulates in the blood at dangerously high concentrations. A single glass of grapefruit juice is enough to cause harm.\nInstead: Completely eliminate grapefruit, grapefruit juice, and products containing grapefruit for the entire duration of treatment. Oranges, apples, and lemons are safe.\nMISTAKE 2: St. John\u0026rsquo;s Wort What happens: St. John\u0026rsquo;s Wort does the opposite of grapefruit \u0026ndash; it speeds up CYP3A4, dramatically reducing the amount of drug in your blood. Less drug = treatment stops working. The tumor may progress silently.\nInstead: Do NOT take St. John\u0026rsquo;s Wort in any form during treatment. If you have depression or fatigue, tell your oncologist \u0026ndash; there are options that do not interact with your treatment.\nMISTAKE 3: Antibiotics without telling your oncologist What happens: Clarithromycin (Biaxin/Klacid) is a strong CYP3A4 inhibitor. Like grapefruit, it can make your Selpercatinib level rise dangerously in the blood.\nInstead: Tell every doctor who prescribes you anything: \u0026ldquo;I am on Selpercatinib \u0026ndash; a CYP3A4 substrate.\u0026rdquo; If you are prescribed clarithromycin, ask for alternatives (azithromycin, amoxicillin) \u0026ndash; discuss with your oncologist first.\nMISTAKE 4: High-dose antioxidant supplements What happens: Research shows that antioxidant supplements (vitamin A, C, E, coenzyme Q10) taken during treatment can protect cancer cells from the effects of therapy, reducing treatment effectiveness.\nInstead: Get nutrients from food, not from megadose pills. Bring a complete list of every supplement to every appointment. \u0026ldquo;Natural\u0026rdquo; does not mean safe during cancer treatment.\nMISTAKE 5: Stopping Selpercatinib because you feel better What happens: RET inhibitors are not cures \u0026ndash; they continuously suppress tumor growth. Stopping allows residual cancer cells to resume proliferating. Underdosing can allow resistant clones to emerge.\nInstead: Side effects, even severe ones, usually have manageable solutions. If they become unbearable, call your oncologist the same day \u0026ndash; do not stop treatment on your own.\nMISTAKE 6: Replacing treatment with alternative medicine What happens: RET fusion-positive lung cancer has a specific, targetable molecular driver. No alternative remedy targets RET fusions. Delaying effective therapy allows cancer to progress to a point where subsequent treatment becomes less effective or impossible.\nInstead: Complementary approaches (nutrition, exercise) can support treatment \u0026ndash; they do not replace it. If you are considering cannabis-based products, tell your oncologist \u0026ndash; some can interact with CYP3A4 pathways.\nMISTAKE 7: Ignoring new respiratory symptoms What happens: Selpercatinib can cause interstitial pneumonitis (severe lung inflammation) \u0026ndash; a serious, potentially life-threatening complication documented in RET+ lung cancer patients.\nInstead: Call your oncology team immediately if you experience: new or worsening shortness of breath, persistent dry cough, chest discomfort, fever with respiratory symptoms. Do NOT wait for your next appointment.\nMISTAKE 8: Assuming your psychiatrist or GP knows the interactions What happens: Selpercatinib is a moderate CYP3A4 inhibitor \u0026ndash; it can affect the metabolism of other medications (including psychiatric ones). The interaction goes both ways.\nInstead: Give every doctor, every dentist, and every pharmacist the complete list of your oncology medications. Do not assume specialists communicate with each other \u0026ndash; they often do not.\nQuick reference: substances to avoid on Selpercatinib Substance Risk Grapefruit / grapefruit juice CYP3A4 inhibition \u0026ndash; toxic accumulation St. John\u0026rsquo;s Wort CYP3A4 induction \u0026ndash; treatment fails Clarithromycin (Biaxin/Klacid) Strong CYP3A4 inhibitor \u0026ndash; toxic accumulation Kaletra (lopinavir/ritonavir) Strong CYP3A4 inhibitor High-dose antioxidants (A, C, E, CoQ10) May protect cancer cells High-dose vitamin B12 Associated with increased recurrence risk Any unreviewed supplement Unknown interactions \u0026ndash; treat as unsafe How to take your treatment correctly Selpercatinib (Retevmo) dosing Your weight Standard dose Under 50 kg 120 mg orally twice daily (every 12 hours) 50 kg or more 160 mg orally twice daily (every 12 hours) Take the pills at the same times every day. Set phone alarms \u0026ndash; consistency prevents drug level drops.\nCritical rules for stomach acid and food Selpercatinib has pH-dependent solubility: it dissolves well in acid and becomes practically insoluble at neutral pH. Anything that raises stomach pH reduces how much drug reaches the blood.\nYour situation What to do Why You take a PPI (omeprazole, lansoprazole, pantoprazole) You MUST take Selpercatinib WITH FOOD PPIs reduce absorption by -69% (total drug in blood) and -88% (peak level) when taken on an empty stomach You take an H2 blocker (famotidine/Pepcid) Take Selpercatinib 2 hours BEFORE or 10 hours AFTER the H2 blocker H2 blockers also raise pH You take antacids (Tums, Rennie, Maalox) Separate by at least 2 hours Same pH problem Dairy products (milk, yogurt, cheese) Avoid 2 hours before and 2 hours after Selpercatinib dose Calcium in dairy buffers stomach acid Water: Take Selpercatinib with ~200 ml (a small cup) of water. Avoid drinking a full glass (over 400 ml) at the same time \u0026ndash; large amounts of water dilute stomach acid.\nIf you missed a dose Remembered within a few hours? Take it immediately, then resume your normal schedule It is nearly time for the next dose? Skip the missed dose. Do NOT take a double dose Not sure? Call your pharmacist or oncology nurse If you vomited after a dose Do NOT retake the dose. Your stomach has already absorbed most of it. Resume your normal schedule at the next planned time.\nSide effects \u0026ndash; real probabilities This section shows you what actually happens to patients on Selpercatinib. Real numbers, not vague phrases.\nThe honest picture: In a real-world study of 243 patients, 86% had at least one adverse event and 48% had a severe one (Grade 3+). But this does NOT mean treatment is intolerable \u0026ndash; most patients report stable or improved quality of life.\nWhat will PROBABLY happen (over 50% of patients) Side effect How common What it means What to do Elevated liver enzymes (AST) 59% You feel nothing \u0026ndash; it shows up in blood tests. 3% have serious liver damage. Blood tests every 2 weeks x 3 months, then monthly Elevated blood sugar 53% You may not notice initially. 2.8% have severe elevation. Baseline glucose + periodic monitoring Edema (face/leg swelling) 49% Can limit daily function in severe cases Elevate limbs; diuretics if needed Fatigue 46% Not normal tiredness \u0026ndash; a profound exhaustion. The most impactful daily side effect. Aerobic exercise 3 times per week \u0026ndash; proven to help Dry mouth Very common Persistent. Affects eating, speaking. Frequent sips of water; sugar-free gum Common and manageable Side effect Frequency (Grade 3+) What to do Hypertension 19.7% Grade 3+ Check before starting and regularly. Manageable with medication Elevated ALT (liver enzyme) 11.8% Grade 3+ Blood tests every 2 weeks x 3 months, then monthly Hyponatremia (low sodium) 9.2% Grade 3+ Routine electrolyte panel Diarrhea / constipation Very common BRAT diet; loperamide; hydration Nausea Common Small frequent meals; anti-nausea medication available Skin rash Common Moisturizer; topical steroids Elevated creatinine ~18% Usually a false alarm called pseudo-AKI \u0026ndash; selpercatinib blocks MATE transporters in the kidney, artificially raising creatinine without actual damage. To distinguish real from false: ask for cystatin C and electrolytes (sodium, magnesium, calcium) at every blood draw. If creatinine is up but cystatin C is normal and electrolytes are stable: continue full dose. If cystatin C is also elevated or electrolytes are dropping: contact oncologist immediately Rarer but DANGEROUS \u0026ndash; attention saves lives here Side effect Frequency What to watch for What to do QTc prolongation (heart rhythm) 33% some degree; 5% life-threatening Chest pain, fainting, palpitations ECG before starting + regular monitoring Severe liver injury 3% Yellowing skin/eyes, dark urine, right upper abdominal pain Blood tests every 2 weeks x 3 months Pneumonitis (lung inflammation) 4% but can be fatal New/worsening shortness of breath, cough, chest discomfort Emergency IMMEDIATELY. No \u0026ldquo;wait and see\u0026rdquo; Severe hemorrhage 2.3% serious Unusual bleeding from anywhere Stop the drug; call emergency services if you have neurological symptoms or cough up blood Tumor lysis syndrome Early in treatment Severe fatigue, cramps, dark urine, nausea Emergency \u0026ndash; especially in the first weeks Hypersensitivity reaction 4.3% Fever + rash + joint pain + low platelets Stop Selpercatinib immediately Newly identified risks (real-world data, December 2024) Side effects not previously on the label, found through pharmacovigilance and real-world studies:\nDysphagia \u0026ndash; difficulty swallowing. Report to oncologist if new or worsening Pericardial effusion \u0026ndash; fluid around the heart (chest pressure, shortness of breath when lying down). Baseline echocardiogram recommended, repeat every 6 months or at symptom onset Hemiparesis \u0026ndash; weakness on one side of the body (stroke-like). Requires urgent brain MRI to differentiate from brain metastases Intestinal lymphangiectasia \u0026ndash; protein-losing enteropathy found in up to 29% of patients (TTLC 2026, MSKCC). Causes chronic diarrhea, malabsorption, and low albumin. Manageable with low-fat MCT diet and dose adjustment. Monitor albumin at every blood draw Thyroid function \u0026ndash; the forgotten check Selpercatinib inhibits DIO2, the enzyme that converts T4 (inactive thyroid hormone) to T3 (the active form). Approximately 13% of patients develop clinical hypothyroidism \u0026ndash; which causes fatigue, weight gain, and fluid retention that can be confused with other side effects.\nThe fix is simple: levothyroxine, a cheap medication with zero CYP3A4 interaction. But it only works if the problem is detected.\nAsk your oncologist to add TSH + free T4 to every blood draw. If TSH rises above 4.5 or free T4 drops below normal, levothyroxine should be started.\nHow side effects evolve over time The side effect profile of selpercatinib changes significantly over 6-24 months. What bothers you at month 2 is not the same as what bothers you at month 18:\nSide effect Early (months 1-6) Late (24+ months) Why it changes Edema 27.5% 63.2% Cumulative VEGFR inhibition impairs lymphatic drainage Diarrhea 30.5% 60.7% Intestinal lymphangiectasia develops gradually (median onset 15 months) Fatigue 36.6% 53.0% Multifactorial (metabolic, hypothyroidism, anemia) Liver enzymes (ALT) 30.5% 15.8% Liver adapts over time \u0026ndash; good news This is important to know because:\nIt is manageable \u0026ndash; only 2% of patients discontinue selpercatinib due to side effects Preparation helps \u0026ndash; compression stockings, loperamide supply, MCT diet knowledge, thyroid monitoring Dose adjustment works \u0026ndash; late side effects respond to dose reduction without necessarily losing efficacy Tip Proactive steps starting month 6: Begin wearing compression stockings for edema prevention. Ensure albumin is tested monthly to detect protein loss early. Have loperamide available. Continue TSH monitoring at every blood draw. Drug and food interactions Selpercatinib is primarily metabolized by CYP3A4 and CYP2C8 enzymes in the liver. Think of these enzymes as \u0026ldquo;chemical scissors.\u0026rdquo; If something blocks the scissors, the drug level rises. If something sharpens them, the drug level drops.\nSubstances that INCREASE Selpercatinib levels (DANGER) Substance Type What to do Grapefruit / Seville oranges Fruit AVOID COMPLETELY Itraconazole, ketoconazole, voriconazole Antifungals AVOID if possible. If necessary, Selpercatinib dose is reduced + more frequent ECGs Ritonavir, lopinavir HIV medications AVOID. Discuss alternatives Erythromycin, clarithromycin Macrolide antibiotics Ask for azithromycin instead Cyclosporine, tacrolimus Immunosuppressants Inform your transplant team If you MUST take a strong CYP3A4 inhibitor, your Selpercatinib dose may be reduced to 80 mg twice daily, with more frequent cardiac monitoring.\nSubstances that REDUCE effectiveness (treatment stops working) Substance Type What to do St. John\u0026rsquo;s Wort Herbal supplement DO NOT USE \u0026ndash; EVER Carbamazepine (Tegretol) Anticonvulsant CONTRAINDICATED Phenytoin (Dilantin) Anticonvulsant CONTRAINDICATED Rifampicin Antibiotic (TB) CONTRAINDICATED \u0026ndash; reduces Selpercatinib levels by half Other foods and substances that may affect Selpercatinib Food / substance Potential effect Action Black seed oil (Nigella sativa) May inhibit CYP3A4 and CYP2C8 \u0026ndash; risk of increased Selpercatinib levels Avoid during treatment Turmeric / curcumin in large doses CYP3A4 and CYP2C8 inhibitor Small amounts in food OK; concentrated supplements \u0026ndash; avoid Green tea (concentrated extract) May affect CYP450 enzymes Occasional tea OK; extract supplements \u0026ndash; discuss with oncologist Garlic (supplements or large amounts) May affect CYP3A4 metabolism Small amounts in cooking OK; garlic supplements \u0026ndash; avoid Red wine CYP3A4 effect + combined liver stress Avoid Alcohol Additional liver stress on a drug that affects the liver in 59% of patients Minimize or avoid completely Tip Check any food or supplement before consuming it. You can use an AI tool (such as ChatGPT, Claude, or Gemini) to quickly check the interaction between Selpercatinib and any ingredient or food. Ask: \u0026ldquo;Does [food/supplement name] interact with Selpercatinib (RET inhibitor, CYP3A4/CYP2C8 substrate)?\u0026rdquo; This does not replace medical advice, but can help you identify potential risks to discuss with your oncology team. Interaction checklist \u0026ndash; print and bring to every pharmacy Tell the pharmacist: \u0026ldquo;I am on Selpercatinib (RETEVMO) for lung cancer\u0026rdquo; Ask: \u0026ldquo;Does this new medication inhibit or induce CYP3A4?\u0026rdquo; Ask: \u0026ldquo;Does it interact with Selpercatinib?\u0026rdquo; Ask: \u0026ldquo;Can it affect heart rhythm or blood pressure?\u0026rdquo; What monitoring you need Monitoring is not optional \u0026ndash; it is an essential part of treatment that keeps you alive and catches problems early.\nBaseline tests BEFORE the first dose Test Why now Complete metabolic panel Kidneys, liver, electrolytes \u0026ndash; baseline Liver function (ALT, AST, bilirubin) Selpercatinib can affect the liver; you need a baseline ECG (12-lead) Selpercatinib prolongs QTc in ~33% of patients Blood pressure Selpercatinib causes hypertension in ~14-20% Fasting glucose or HbA1c 53% develop hyperglycemia TSH (thyroid hormone) Baseline for detecting future hypothyroidism Calcium and Vitamin D Essential, especially if you will be on Xgeva Pregnancy test (if applicable) Selpercatinib is teratogenic \u0026ndash; it causes birth defects Schedule: what tests, when Test Months 1-3 Month 4+ Liver function Every 2 weeks Monthly Blood pressure Week 1, then weekly x 8 weeks Monthly ECG Baseline, at 1-2 weeks and 4 weeks If palpitations, dizziness, new dose Electrolytes Every 2 weeks Monthly Kidney function Monthly Every 3 months Blood sugar Baseline done Every 3-6 months TSH Baseline done Every 6-12 months Imaging (CT chest/abdomen) Baseline; repeat at ~8 weeks Every 8-12 weeks Brain MRI \u0026ndash; do NOT wait for headaches 46% of RET fusion patients develop brain metastases. Many are asymptomatic initially.\nTiming Recommendation At diagnosis Brain MRI with contrast (standard of care) First year Every 8-12 weeks initially After stable response Every 3-6 months New neurological symptoms Urgent brain MRI, regardless of schedule If your doctor says \u0026ldquo;we will scan if you have symptoms,\u0026rdquo; push back \u0026ndash; surveillance scanning is the standard of care for RET fusion lung cancer.\nHow to interpret liver tests ALT elevation What it means Action Under 3x normal Mild; expected Continue Selpercatinib; repeat in one week 3-5x normal Moderate Reduce Selpercatinib dose or temporarily hold; repeat in 1 week Over 5x normal with symptoms Severe hepatotoxicity Stop Selpercatinib immediately. Contact your oncologist the same day When to go to the emergency room \u0026ndash; NOW PRINT THIS PAGE. PUT IT ON YOUR FRIDGE. CARRY IT IN YOUR WALLET. GIVE A COPY TO YOUR PARTNER/FAMILY.\nEMERGENCY CHECKLIST \u0026ndash; Go to the emergency room if you have any of these: Warning New or worsening shortness of breath + dry cough + fever \u0026ndash; Call emergency services / Go to the ER IMMEDIATELY. This triad is the warning sign for drug-induced pneumonitis. Do NOT take your next dose until a doctor evaluates you. Warning Coughing up blood OR unexplained bleeding that will not stop \u0026ndash; Call emergency services IMMEDIATELY. Hemorrhagic events are documented with Selpercatinib, including cerebral and respiratory bleeding. Warning Yellowing of skin/eyes + dark urine + right upper abdominal pain \u0026ndash; Go to the ER THE SAME DAY. Classic signs of severe hepatotoxicity. Stop Selpercatinib and go straight to the ER. Warning Chest pain + palpitations + fainting or near-fainting \u0026ndash; Call emergency services IMMEDIATELY. Selpercatinib causes QTc prolongation \u0026ndash; a dangerous change in heart rhythm. Tell the ER that you are on Selpercatinib \u0026ndash; they will do an ECG immediately. Warning Sudden weakness on one side of the body + severe headache + confusion \u0026ndash; Call emergency services IMMEDIATELY. Signs of cerebral hemorrhage or stroke. Warning Chest pressure + difficulty breathing when lying down \u0026ndash; Go to the ER THE SAME DAY. Suspect pericardial effusion (fluid around the heart). Warning Severe fatigue + muscle cramps + dark urine + nausea (especially in the first weeks) \u0026ndash; Go to the ER / Call the oncology hotline IMMEDIATELY. Suspect tumor lysis syndrome. Warning Fever above 38.5C + chills + rapid heart rate + no obvious cause \u0026ndash; Call the oncology hotline IMMEDIATELY. If no response within 15 minutes \u0026ndash; go to the ER. Fever in a cancer patient on targeted therapy is a medical emergency until proven otherwise. What to bring to the emergency room \u0026ndash; every time What Why Complete medication list (including dose and time) Selpercatinib has 664 documented interactions \u0026ndash; ER staff need to know before giving you anything Selpercatinib bottles Confirm the drug, dose, lot Latest blood test results Give the ER a comparison baseline Oncologist\u0026rsquo;s name and phone number The ER should contact them before major decisions This checklist So the ER staff understand you are on a RET inhibitor Do NOT take your next dose if you are in the ER for any of the situations above.\nSerious but NOT immediately life-threatening \u0026ndash; call your oncologist TODAY Blood pressure above 140/90 mmHg on two separate readings Unexplained weight gain of over 2 kg in 3 days (possible edema) Persistent nausea and vomiting preventing you from taking Selpercatinib New hyperglycemia symptoms (extreme thirst, frequent urination, blurred vision) Any new neurological symptoms Where it spreads and what to do Brain metastases \u0026ndash; complication number 1 Nearly 50% of RET fusion patients will develop brain metastases during their lifetime. This is not a rare event \u0026ndash; it is the most common complication.\nDoes Selpercatinib work in the brain? Yes. 82% brain response rate in the LIBRETTO-431 trial. Selpercatinib can also prevent the development of new brain metastases.\nIf brain metastases develop despite Selpercatinib:\nTreatment What it is When it is used Stereotactic radiosurgery (SRS) Focused radiation beam aimed at the brain tumor. 1-5 sessions. Outpatient. If you have 1-4 brain metastases. Can be combined with Selpercatinib. Continue Selpercatinib alone If lesions are small (under 5 mm) or asymptomatic Requires close follow-up imaging (at 4-6 weeks) Bone metastases Bone is a common site of metastasis. If you have unexplained bone pain, report it immediately \u0026ndash; do not assume it is arthritis or aging.\nBone pain: Radiation to the painful site + pain medication Fracture risk: Denosumab (Xgeva) or bisphosphonates to strengthen the bone Spinal metastases: If you develop back pain + weakness/numbness in the legs, go to the ER immediately \u0026ndash; risk of spinal cord compression Denosumab (Xgeva) protocol for bone metastases If you have bone metastases, Xgeva (denosumab) is recommended to prevent complications (fractures, spinal cord compression).\nAdministration: 120 mg subcutaneous injection every 28 days Vitamin D: Minimum 400 IU daily Calcium: Minimum 600 mg daily \u0026ndash; preferably calcium citrate (better absorption) CRITICAL: Take calcium supplements at least 2 hours BEFORE OR 2 hours AFTER Selpercatinib Practical example: Selpercatinib at 8:00 AM and 8:00 PM. Calcium + Vitamin D at noon Dental warning: Tell your dentist you are on Xgeva before any dental procedure Oligometastatic management \u0026ndash; the key concept If you have a limited number of metastases (1-5 sites), the most effective strategy may be local treatment of resistant lesions (radiation, ablation) while continuing Selpercatinib \u0026ndash; not changing the entire treatment plan.\nThe logic: if most of your cancer responds to Selpercatinib but 1-2 sites are growing, those sites may have local resistance. Destroying them eliminates the resistant cells while Selpercatinib continues to control the rest.\nAsk your oncologist: \u0026ldquo;Do I have oligometastatic disease? Would SBRT or ablation be appropriate for some lesions, while continuing Selpercatinib?\u0026rdquo;\nWhen treatment stops working The difficult truth: virtually every patient on Selpercatinib will eventually develop resistance. The question is not \u0026ldquo;if\u0026rdquo; \u0026ndash; but \u0026ldquo;when,\u0026rdquo; \u0026ldquo;how,\u0026rdquo; and \u0026ldquo;what do you do next.\u0026rdquo; You need a plan BEFORE you need it.\nTwo families of resistance Category What it means How common On-target (RET-dependent) The cancer mutates the RET gene itself (G810, V804M, Y806C mutations) ~12.4% of biopsies at progression Off-target (bypass) The cancer activates an entirely different survival pathway (MET amplification, KRAS, EGFR) The majority of resistance cases What to request at progression Do not accept \u0026ldquo;the cancer is growing\u0026rdquo; as a complete answer. Demand to know WHY.\nLiquid biopsy (ctDNA) \u0026ndash; a blood test that detects resistance mutations months before scans show tumor growth Tissue re-biopsy \u0026ndash; if liquid biopsy is negative but progression is clear Full NGS \u0026ndash; mandatory with every re-biopsy Your resistance strategy: three levels LEVEL 1 \u0026ndash; Options available NOW:\nStrategy When Continue Selpercatinib beyond progression (oligoprogression) If progression is limited to 1-3 sites. Add local treatment (SBRT). Additional median benefit: 9.8 months Pralsetinib (Gavreto) If resistance is off-target. Limited access in the EU after October 2024 withdrawal Chemotherapy (pemetrexed-based) Standard fallback. Often a bridge between first and next-generation RET inhibitors Selpercatinib rechallenge Documented in 2026: reintroduction after a chemotherapy interval produced near-complete brain remission LEVEL 2 \u0026ndash; Next-generation RET inhibitors (in clinical trials NOW):\nDrug What it does Status EP0031 (Lunbotinib) Selective RET inhibitor; broad activity vs. solvent front mutations Phase 1-2, ASCO 2025 data LOXO-260 Targets solvent front and gatekeeper mutations Phase 1; estimated completion June 2026. No expanded access program currently available Vepafestinib Selective RET; improved brain penetration Phase 1-2; MARGARET trial SY-5007 Selective RET inhibitor; 62% response rate Phase 2-3 (China) LEVEL 3 \u0026ndash; Targeted combinations (based on YOUR resistance mechanism):\nBypass identified Combination strategy MET amplification Selpercatinib + crizotinib (MET inhibitor) \u0026ndash; 4 documented cases with response EGFR/HER3 activation Discuss with oncologist \u0026ndash; preclinical data exists (afatinib) but clinical adoption is limited due to toxicity concerns BRAF fusion RET inhibitor + MEK inhibitor \u0026ndash; 1 documented case of success Expert centers that think ahead Center Why it matters Memorial Sloan Kettering (NYC) Alexander Drilon \u0026ndash; world\u0026rsquo;s number 1 for RET tumors. Serial liquid biopsies, resistance profiling, personalized combinations MD Anderson (Houston) Vivek Subbiah \u0026ndash; RET research, off-label combinations Gustave Roussy (Paris) Largest cancer center in Europe. Active clinical trials with next-generation RET inhibitors. The most accessible major EU center for Romanian patients IRCCS Milan Real-world experience with RET+ NSCLC in the European context Ask your oncologist: \u0026ldquo;Can you refer me to one of the centers above for a second opinion or trial enrollment?\u0026rdquo;\nWhat lies ahead \u0026ndash; pipeline and clinical trials Frontier technologies (2-5+ years away, but real science) Histotripsy \u0026ndash; Focused ultrasound waves destroy tumors without surgery, without radiation. FDA-approved for liver tumors (2023). Relevant if you develop liver metastases.\nLungVax vaccine (Oxford/UCL) \u0026ndash; The first preventive lung cancer vaccine. Trains the immune system to recognize \u0026ldquo;alarm signal\u0026rdquo; proteins on abnormal lung cells. Phase I from summer 2026. Relevant if you achieve remission and worry about recurrence.\nPROTACs \u0026ndash; Instead of blocking the RET protein (as Selpercatinib does), they destroy the RET protein completely through the cell\u0026rsquo;s own disposal system. You cannot develop binding-site resistance if the entire protein is destroyed. 3-5 years from patients.\nANKTIVA + Keytruda \u0026ndash; IL-15 grows new T cells and NK cells; Keytruda unblocks them. Conditional EU authorization (February 2026). Phase 3 trial for NSCLC (ResQ201A) currently enrolling.\nmRNA cancer vaccines \u0026ndash; BNT116 (BioNTech): FDA filing 2025 for NSCLC. Over 120 mRNA oncology vaccine clinical trials underway.\nHow to find and enroll in a clinical trial ClinicalTrials.gov \u0026ndash; search \u0026ldquo;RET fusion NSCLC\u0026rdquo; for open trials LUNGevity Foundation \u0026ndash; LungMATCH navigator The Happy Lungs Project (happylungsproject.org) \u0026ndash; tracks RET-specific trials RETpositive.org \u0026ndash; clinical trial database and community Compassionate / expanded access: ask your oncologist if LOXO-260 or other experimental drugs are available outside of trials In Romania/EU: cross-border enrollment in an EU clinical trial is possible Day-to-day life on Selpercatinib Realistic treatment timeline Weeks 1-2: Nausea, appetite loss, fatigue, dry mouth. Establish your dosing routine. Highest risk of tumor lysis syndrome.\nMonths 1-3: Side effects declare themselves. Fatigue may deepen. Blood pressure may start to rise. Highest risk of hepatotoxicity \u0026ndash; blood tests every 2 weeks. 31% of patients need a dose reduction.\nMonths 3-12: If you have tolerated it this far, acute risks decrease (but do not disappear). The first scans will likely show response. Exercise and nutrition become critical.\nYear 1-2: Most patients still respond (median PFS ~24.8 months). Start discussing with your doctor: what is the plan if resistance develops?\nYear 2+: Statistically, roughly half of patients will see progression. Some continue to respond much longer.\nExercise \u0026ndash; the most supported non-drug intervention What works: Aerobic + resistance training combined.\nHow often: 3 times per week. Programs under 12 weeks show the strongest fatigue reduction.\nStart with: Walking. Even 10-15 minutes. Increase gradually.\nThe trap: Fatigue makes you want to rest. Resting makes fatigue worse. Movement breaks the cycle.\nStrategy How often Aerobic exercise 3-5 days/week, 30-45 min Resistance training 2-3 days/week, light weights Protein intake 1.2-1.5 g/kg body weight daily Anti-inflammatory diet Daily: vegetables, fish, olive oil Hydration 2-3 liters/day minimum Eating during treatment Small, frequent meals \u0026ndash; 5-6 per day instead of 3.\nProtein-rich foods \u0026ndash; protect against muscle wasting.\nFruits and vegetables: 5-6 servings per day. Antioxidants from food are OK; antioxidant supplements are NOT.\nWhen food tastes wrong: Cold foods (less smell), experiment with seasonings.\nRequest a referral to an oncology dietitian \u0026ndash; this is treatment support, not wellness advice.\nMental health Anxiety, depression, and adjustment disorders are common and predictable responses to diagnosis and ongoing treatment. This is not weakness.\nSeek psychological support proactively \u0026ndash; do not wait until you are in crisis:\nCounseling or therapy (individual, group, or couples) Support groups for lung cancer patients Financial counseling if treatment costs are a burden Fertility Selpercatinib is teratogenic (causes birth defects). Women must use effective contraception during treatment and for 1 week after stopping.\nIf you want children, discuss fertility preservation BEFORE continuing treatment. Freezing eggs or sperm before starting is an option.\nSurgery and travel Stop Selpercatinib at least 7 days before ANY surgery, including dental Travel: Carry Selpercatinib in the original bottles in your carry-on luggage. Carry a letter from your oncologist confirming the prescription Treatment access Romania \u0026ndash; FREE, but requires a legal procedure for first-line access Context: Selpercatinib was initially approved as a second-line treatment (after chemotherapy failure). In 2022 (FDA) and 2023 (EMA), it was updated to first-line treatment based on the LIBRETTO-431 results. Both ESMO and NCCN now recommend Selpercatinib as Category 1 first-line monotherapy.\nThe problem in Romania: CNAS (the national health insurance authority) has not updated its reimbursement guidelines. Selpercatinib is covered through standard channels only as a second-line treatment. Romanian patients are forced to undergo inferior chemotherapy first \u0026ndash; contradicting international guidelines \u0026ndash; unless they use the legal pathway below.\nHow to get free access to Selpercatinib in Romania Contact a lawyer experienced in medical law (a patient advocacy organization can recommend one) The lawyer files an \u0026ldquo;Ordonanta Presedintiala\u0026rdquo; (emergency court order) against CNAS The court file must include: A letter from your oncologist specifying Selpercatinib (Retevmo) as the recommended first-line treatment ESMO Clinical Practice Guidelines for metastatic NSCLC EMA Marketing Authorization for Retevmo Timeline: The court typically grants the order within 3-4 weeks Once approved, CNAS covers the full cost \u0026ndash; treatment is free for the patient Important Do NOT wait for CNAS to add Selpercatinib to the standard reimbursement list \u0026ndash; it could take years. The Ordonanta Presedintiala pathway is the established route that Romanian patients use for rare disease drugs not yet on the list. After the court approves your request Choose a pharmacy where you will pick up the medication from now on Your oncologist must write simple prescriptions (like antibiotic prescriptions) \u0026ndash; NOT electronic prescriptions with QR codes. QR prescriptions go through the standard CNAS system that does not cover first-line Selpercatinib. A simple prescription, backed by the court order, bypasses this limitation Contact the pharmacy at least 1 week before picking up the medication \u0026ndash; Selpercatinib is not routinely stocked and the pharmacy needs time to order it Keep copies of the court order with you at all times. The pharmacy will need to see it Be prepared: Even with the court order and full coverage, access can be unpredictable. The pharmacy may have supply delays, the prescription format may cause confusion for staff unfamiliar with the procedure. Patience and persistence are unfortunately part of treatment in Romania.\nAccess in other European countries Country Status France Approved and reimbursed; zero patient co-pay Germany Covered through statutory health insurance (GKV); positive G-BA assessment Italy Covered + mandatory RETSEVMO registry enrollment Spain Covered from April 2023 (after 840 days of waiting post-EMA approval) Poland Approved with restrictions; OncoMap precision medicine program underway UK Approved (restricted) through the Cancer Drugs Fund Manufacturer assistance programs (Eli Lilly) If you are uninsured or have high co-pays:\nContact: 1-844-RETEVMO (US) or the Eli Lilly support line in your country Offers: compassionate access, co-pay assistance, expanded access programs Processing in 2-3 weeks You are not alone RET-specific communities Resource What it offers RETpositive.org Private Facebook groups, clinical trial tracking, quality of life registries, patient stories The Happy Lungs Project RET-specific research updates, stories, webinars RET Renegades (Facebook) Support group co-founded by an 18+ year RET+ NSCLC survivor LUNGevity Foundation RET-specific support communities, LungMATCH navigator Cancer GRACE Forum for RET-fusion patients, treatment discussions Inspire Lung cancer survivor community and peer support forums HealthUnlocked GO2 for Lung Cancer community \u0026ndash; patient discussions and support Support for caregivers Your family members are affected too. Do not ask them to navigate this alone.\nLUNGevity Caregiver Support Groups \u0026ndash; online forums for families CancerCare Support Groups \u0026ndash; free support group for caregivers My Cancer Circle \u0026ndash; free online tool for organizing the care network American Lung Association Survivor Network \u0026ndash; peer support and shared experiences What to do now Print the \u0026ldquo;When to go to the emergency room\u0026rdquo; section and put it on your fridge and in your wallet Print the drug interaction list and show it to every doctor and pharmacist Ask your oncologist about the RET fusion partner, co-mutations, and brain MRI schedule \u0026ndash; also see the diagnosis guide for the correct order of investigations In Romania: Contact a lawyer for an Ordonanta Presedintiala if you need first-line access to Selpercatinib Sign up at RETpositive.org and The Happy Lungs Project \u0026ndash; find your community Discuss with your oncologist the action plan if resistance develops \u0026ndash; before you need it Request a liquid biopsy (ctDNA) for monitoring \u0026ndash; it can detect resistance months before scans show it Ready for more? Read Beyond Standard Treatment: A Proactive Strategy for RET Fusion Lung Cancer \u0026ndash; vaccines, cryoablation, ctDNA monitoring, and drug repurposing options The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/cancer-types/lung-ret-fusion/","summary":"\u003cp\u003e\u003cstrong\u003eYou have just learned that you have RET fusion lung cancer. Or that someone you love has received this diagnosis.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eI know what you are going through. I have been there.\u003c/p\u003e\n\u003cp\u003eThe first reaction is to feel like the world has stopped. Then comes the need to do something \u0026ndash; anything \u0026ndash; immediately. But here is what I have learned: \u003cstrong\u003ethe most important thing you can do right now is understand what you have, what options exist, and how to avoid the mistakes that can cost you.\u003c/strong\u003e\u003c/p\u003e","title":"RET Fusion Lung Cancer: The Complete Patient Guide"},{"content":"You just found out you have cancer. Or that there is a serious suspicion. The world has stopped.\nI know what you are going through. I have been there.\nIn moments like these, the instinct is to do anything \u0026ndash;immediately. To accept the first plan someone proposes. To rush into treatment. But here is what I learned the hard way: the most important thing you can do right now is to reach a complete and accurate diagnosis before making any treatment decision.\nThis guide shows you exactly what steps to follow, in what order, and \u0026ndash;just as importantly \u0026ndash;what to avoid. It is the roadmap I wish I had.\nWhy the order of steps matters An oncology diagnosis is not a single test. It is a protocol \u0026ndash;a series of investigations that, done in the correct order, give you the full picture of your disease. Each step depends on the one before it.\nIn a specialized oncology center, this protocol can take 10 days. In a fragmented system, without coordination, it can take 8 weeks or more \u0026ndash;not because the tests themselves take longer, but because nobody is coordinating them efficiently.\nThe difference is not just about comfort. The difference can be between an optimal treatment and a suboptimal one. An incomplete diagnosis leads to incomplete decisions.\nStep 1: Whole-body PET-CT \u0026ndash;see the full picture FIRST The correct first step is to see the full extent of the disease. Not a simple CT, not an ultrasound. A whole-body PET-CT (from head to knee or below).\nWhat is PET-CT? PET-CT combines two technologies: PET (Positron Emission Tomography) shows metabolic activity \u0026ndash;meaning where cells are consuming energy more than normal (the sign of an active tumor). CT (Computed Tomography) shows anatomy \u0026ndash;the shape, size, and exact location.\nTogether, PET-CT shows you what is there and how active it is, across your entire body, in a single investigation.\nWhy PET-CT BEFORE biopsy? It shows whether the disease is localized or has spread (metastases) It guides the biopsy \u0026ndash; the doctor knows exactly where to sample, from the area with the strongest tumor activity. Without PET-CT, you risk the biopsy being taken from an inactive zone, and the result being inconclusive or inaccurate. It can completely change the approach: if metastases are present, the treatment plan is different PET-CT changes staging in 19-35% of cases compared to simple CT Warning DO NOT accept a biopsy without PET-CT. You need to know the extent of the disease before deciding where and how the biopsy is performed. In a specialized center, PET-CT is the first step. If your doctor suggests a biopsy without complete imaging, ask why. Equipment quality matters Not all PET-CTs are equal. State-of-the-art machines offer:\nLower radiation doses (important, especially if you will need multiple scans) Higher resolution \u0026ndash;detecting smaller lesions AI-assisted interpretation in some centers Ask what PET-CT model the center uses and when it was installed. Newer, latest-generation machines make a difference.\nStep 2: Biopsy \u0026ndash;the material everything is built on A biopsy is the procedure through which a piece of the tumor is collected to be analyzed under a microscope. Without a biopsy, there is no definitive diagnosis.\nTypes of biopsy Fine needle aspiration (FNA): Fast, minimally invasive. Used for thyroid, superficial lymph nodes. But it may collect too little material. Core needle biopsy: Collects a cylinder of tissue. Preferred for most solid tumors. Sensitivity 85-100%. CT-guided or ultrasound-guided biopsy: The needle is guided by imaging to the tumor. Essential for deep tumors (lung, liver, bone). Surgical biopsy: When other methods are not possible or sufficient. How long do results take? Basic histopathology report: 3-7 business days in a good center With immunohistochemistry (IHC): another 1-2 days In a specialized oncology center, the biopsy result can come in 3 days Ideally, choose a center that can guarantee fast turnaround times. If you are told the result takes 2-3 weeks, ask whether faster options exist \u0026ndash; including sending the sample to another lab or having it evaluated at a specialized center.\nWarning Insist on enough tissue. Tell the doctor performing the biopsy that you will need molecular/genetic testing (NGS). If too little material is collected, you may need to repeat the biopsy \u0026ndash;which means lost time and an additional procedure. Tip When scheduling your biopsy, ask: \u0026ldquo;Will enough material be collected for NGS molecular testing?\u0026rdquo; This needs to be planned from the start, not discovered later. Request fresh frozen tissue \u0026ndash;not just FFPE By default, your biopsy tissue will be preserved in formaldehyde and embedded in paraffin (called FFPE). This is standard and sufficient for most tests. But some advanced options \u0026ndash; cancer vaccines, organoid drug testing, high-quality RNA sequencing \u0026ndash; require fresh frozen tissue stored at -80 degrees Celsius.\nYou cannot go back and freeze tissue after it has already been fixed in formaldehyde. The decision must be made before the biopsy, not after.\nAsk the interventional radiologist or surgeon: \u0026ldquo;Can you also store some tissue cores fresh frozen at -80 degrees for future research and advanced testing?\u0026rdquo; If the center cannot do this, ask whether they can send cores to a biobank that can.\nIdeally, request 4-8 biopsy cores distributed between:\nPathology (diagnosis \u0026ndash; mandatory, always done) Molecular testing (NGS, WES, RNA-seq) Fresh frozen biobank at -80 degrees (for future options: vaccines, organoids, retesting) This one request, made at the right moment, can open treatment doors that do not yet exist today.\nTip Want the full checklist? We have republished the complete guide \u0026ldquo;Preserving your tumor tissue\u0026rdquo; (from Future of Cancer Care Today) \u0026ndash; what to ask, which tests it keeps open, and what to do if tissue was already collected. Step 3: Molecular and genetic testing \u0026ndash;the most overlooked step This is probably the most important step that nobody talks about enough. Molecular tests analyze the DNA of your tumor and identify the specific mutations driving it. These mutations determine which treatment works and which does not.\nWhy does it change everything? Modern oncology has evolved enormously. Today there are targeted therapies \u0026ndash; drugs designed to specifically attack certain genetic mutations in your tumor. These treatments are often more effective and better tolerated than traditional chemotherapy.\nBut to receive the right treatment, you need to know what mutation you have.\nTwo patients with \u0026ldquo;lung cancer\u0026rdquo; can have completely different diseases at the molecular level. One has an EGFR mutation \u0026ndash; and there is a targeted drug that works remarkably well. The other has a KRAS G12C mutation \u0026ndash; and a different drug works. Without molecular testing, the doctor does not know which treatment is right for YOU.\nNot just for lung cancer This is a common misconception. Molecular testing is the standard of care (meaning mandatory according to international guidelines) for most advanced cancers:\nCancer type Mandatory tests (examples) Why it matters Lung (NSCLC) EGFR, ALK, ROS1, KRAS G12C, PD-L1 + others Over 10 targeted therapies available Breast ER, PR, HER2, BRCA1/2, PIK3CA Determines whether you receive hormonal therapy, anti-HER2 or PARP Colorectal KRAS/NRAS, BRAF, MSI/MMR Anti-EGFR is contraindicated in RAS-mutant Melanoma BRAF V600E, PD-L1 BRAF/MEK combination available only with BRAF mutation Ovarian BRCA1/2, HRD PARP inhibitors available for BRCA-mutant Prostate (metastatic) BRCA, HRR genes, MSI/MMR PARP inhibitors, immunotherapy Gastric HER2, PD-L1, MSI/MMR Trastuzumab, immunotherapy For a concrete example, read our complete guide to RET fusion-positive lung cancer \u0026ndash; a molecular subtype with a highly effective targeted treatment.\n\u0026ldquo;Agnostic\u0026rdquo; biomarkers \u0026ndash;valid for ANY cancer Regardless of your cancer type, there are biomarkers that can unlock treatment options for any solid tumor:\nMSI-H/dMMR \u0026ndash;responds to immunotherapy (pembrolizumab) NTRK fusions \u0026ndash;responds to larotrectinib or entrectinib TMB-H (high tumor mutational burden) \u0026ndash;responds to immunotherapy BRAF V600E \u0026ndash;combination dabrafenib + trametinib These should be tested regardless of what cancer you have.\nTwo types of tests: somatic and germline Somatic testing (of the tumor): Analyzes mutations acquired by your tumor. Done from biopsy tissue or from blood (liquid biopsy). Guides treatment. Germline testing (hereditary): Analyzes inherited mutations, present since birth. Done from a blood sample. Important for you AND for your family (cancer risk in relatives). They are not interchangeable. You may need both.\nHow long do they take? Rapid panel (subset of mutations): 3 days in specialized centers Full NGS panel: 7-14 days in a good lab Outsourced: can take 2-4 weeks Warning DO NOT start treatment without molecular testing results. A treatment chosen without this information may be ineffective or even counterproductive. The exception: medical emergencies where delaying treatment puts your life at risk. Warning DO NOT accept 21+ days of waiting for molecular testing without asking what faster options exist. Specialized centers get results in 3-10 days. If the local lab cannot deliver, ask about sending the sample to a faster lab or about liquid biopsy (from blood) as an alternative. Beyond standard panels: WES, WGS and RNA-seq A standard NGS panel tests 50-500 genes. This is usually sufficient \u0026ndash; but not always. For rare cancers, unusual molecular subtypes, or when the standard panel finds nothing actionable, more comprehensive options exist:\nWhole Exome Sequencing (WES): Tests all protein-coding genes (~20,000). Identifies co-mutations, neoantigen candidates for vaccines, and DNA repair defects (BRCA, FANCL, ATM) Whole Genome Sequencing (WGS): Tests the entire genome, including non-coding regions. The most comprehensive option \u0026ndash; 73-89% of patients receive actionable findings. Non-profit and academic programs exist in some EU countries: Hartwig Medical Foundation OncoAct (Netherlands, NSCLC explicitly covered) and NCT MASTER (Heidelberg, Germany \u0026ndash; WGS + RNA-seq + methylome). Access depends on your country \u0026ndash; these programs are typically reimbursed for patients in their home country\u0026rsquo;s healthcare system, but international patients usually need a cross-border referral, an S2 form (EU Cross-Border Healthcare Directive), or private payment. Ask your oncologist whether your country has a pathway to these programs or whether they accept international referrals RNA-seq: Shows which genes are actually active in your tumor. Can detect gene fusions, bypass resistance mechanisms, and transcriptional changes invisible to DNA-only testing These advanced tests are not always reimbursed by standard health insurance. Ask your oncologist whether they are covered or whether academic programs (often free) accept your case.\nStep 3b: AI-assisted pathology \u0026ndash;preserving precious tissue A new generation of AI tools can predict biomarkers directly from standard biopsy slides (H\u0026amp;E staining), before cutting additional tissue for immunohistochemistry. This matters because biopsy tissue is limited \u0026ndash; every additional test consumes irreplaceable material.\nValidated platforms:\nHEX (Stanford, Nature Medicine 2026) \u0026ndash; predicts 40 proteins and immune phenotype from standard H\u0026amp;E slides. Open-source and free Paige Predict (Tempus, commercial since January 2026) \u0026ndash; predicts 123+ biomarkers from H\u0026amp;E Not all centers have adopted these tools yet. But if your biopsy is small and tissue is limited, ask: \u0026ldquo;Can AI-assisted pathology help prioritize which additional tests to run, to conserve tissue?\u0026rdquo;\nStep 3c: Liquid biopsy \u0026ndash;diagnosis and monitoring from blood A liquid biopsy (ctDNA test) detects tumor DNA fragments circulating in your blood. It requires only a blood draw \u0026ndash; no needle in the tumor.\nWhen it helps at diagnosis:\nWhen the tumor is in a location difficult to biopsy (deep lung, brain, bone) When the biopsy yielded insufficient tissue for molecular testing As a complement to tissue biopsy \u0026ndash; liquid biopsy can detect mutations the tissue sample missed, and vice versa When it helps during treatment:\nDetects resistance mutations 3-6 months before imaging shows progression Confirms treatment response at the molecular level (ctDNA clearance at week 8 is the strongest predictor of outcome) Monitors for minimal residual disease after local treatment (surgery, radiation, ablation) Available platforms: FoundationOne Liquid CDx (300+ genes, available through partner labs in many countries including Romania), Guardant360 CDx (74 genes), and ultra-sensitive personalized platforms like Signatera and Haystack MRD for ongoing monitoring.\nTip Liquid biopsy does not replace tissue biopsy \u0026ndash; the two are complementary. Tissue provides histology (what the cancer looks like under the microscope) and enough material for comprehensive testing. Liquid biopsy provides real-time molecular monitoring and catches what tissue may miss. Step 4: Complete staging \u0026ndash;leave nothing to chance In addition to the initial PET-CT, some cancers require additional staging investigations:\nBrain MRI Mandatory for:\nLung cancer \u0026ndash;high risk of brain metastases Melanoma \u0026ndash;high risk of brain metastases HER2+ breast cancer \u0026ndash;increased risk PET-CT does not \u0026ldquo;see\u0026rdquo; the brain well because of its naturally high metabolic activity. Brain MRI is the correct investigation.\nOther staging investigations Bone scintigraphy: for prostate cancer, breast cancer (when bone metastases are suspected) Pelvic MRI: for pelvic cancers (rectal, cervical, prostate) Ask your oncologist: \u0026ldquo;Is the staging complete? Do I also need a brain MRI?\u0026rdquo;\nStep 5: Tumor board \u0026ndash;doctors who talk to each other The tumor board (also called a multidisciplinary team meeting) is the session where all involved specialists review your case and jointly decide the treatment plan.\nWho participates? Medical oncologist \u0026ndash;the specialist in systemic treatments (chemotherapy, targeted therapy, immunotherapy) Surgical oncologist \u0026ndash;evaluates whether and when surgery is indicated Radiation oncologist \u0026ndash;evaluates whether radiation therapy is indicated Pathologist \u0026ndash;the one who read the biopsy, can review the diagnosis Radiologist \u0026ndash;reviews the imaging live Clinical trials coordinator \u0026ndash;checks whether you are eligible for clinical studies Plus: geneticist, nutritionist, palliative care specialist, psychologist, as needed Why does it matter so much? The numbers speak for themselves:\n40% of cases presented at tumor board have the treatment plan modified 29-45% of cases have diagnostic changes (the pathologist or radiologist discovers something new) In neuro-oncology: 59% of cases have clinical management changes Studies show significant reductions in mortality risk for patients discussed at tumor board Not all tumor boards are equal Daily: top specialized oncology centers have daily tumor boards. Your case is discussed quickly, without weeks of delay. Weekly: many large hospitals have tumor board once a week. Acceptable, but can add days of waiting. Nonexistent or superficial: some centers do not have a real tumor board. The decision is made by a single doctor. This is a red flag. Integrated information system In a good center, all doctors on the board have access to a single digital record \u0026ndash;imaging, pathology, lab results, everything. There is no more \u0026ldquo;I have not seen the colleague\u0026rsquo;s result\u0026rdquo; or \u0026ldquo;you need to bring the file from another hospital.\u0026rdquo;\nWarning DO NOT accept a treatment plan decided by a single doctor. Ask: \u0026ldquo;Will my case be presented at the tumor board? When? Can I find out what was decided?\u0026rdquo; If there is no tumor board, take that into consideration when choosing where to be treated. Step 5b: Free AI tools for genomic interpretation When your molecular testing results arrive, several free, clinically validated platforms can help you and your oncologist interpret them:\nOncoKB (Memorial Sloan Kettering) \u0026ndash; 8,000+ alterations classified by actionability level (FDA-approved, clinical evidence, investigational). Free for clinical use CIViC (Washington University) \u0026ndash; crowd-curated clinical evidence database linking mutations to treatments. Open access ClinicalTrials.gov \u0026ndash; search your specific mutations to find open clinical trials worldwide These tools do not replace your oncologist\u0026rsquo;s judgment. They complement it by ensuring no actionable finding is overlooked \u0026ndash; especially for rare mutations where even experienced oncologists may not be aware of every option.\nTip On the day you receive molecular results: Enter each identified mutation into OncoKB. If any mutation shows \u0026ldquo;Level 1\u0026rdquo; or \u0026ldquo;Level 2\u0026rdquo; evidence for a treatment you are not receiving, bring this to your next oncology appointment. Step 6: Second opinion \u0026ndash;it is not optional, it is responsible Asking for a second medical opinion is not an insult to your doctor. It is a responsible step that any good doctor respects.\nWhen is it necessary? Always for rare cancers or unusual molecular subtypes When the proposed treatment plan does not seem clearly explained to you When you did not have a tumor board When something feels off \u0026ndash;trust your instincts How to ask without feeling awkward? Simply say: \u0026ldquo;I want to make sure we are doing the best possible thing. I would like a second opinion at another center.\u0026rdquo; A good doctor will not be offended. If they are offended, that is itself a signal.\nTip Prepare a complete file before the second opinion: imaging on CD/DVD or link, histopathology report, molecular testing results, all blood tests. The more complete the file, the more valuable the opinion will be. Where it matters to go: specialized oncology centers Not all hospitals are equal when it comes to oncology diagnosis. A specialized oncology center makes the difference through: state-of-the-art equipment, daily tumor board, rapid molecular testing, and an integrated system where all doctors see all the information.\nReal-world experience: Anadolu Medical Center, Istanbul A patient with lung cancer had the following experience at Anadolu Medical Center:\nPET-CT as the first step \u0026ndash; done immediately, with state-of-the-art equipment (low doses, high resolution, results in 24 hours) CT-guided biopsy \u0026ndash; from the area with the highest tumor activity, identified on PET-CT Rapid molecular testing \u0026ndash; subset in 3 days, full NGS panel in 10 days Daily tumor board \u0026ndash; the case discussed by all specialists together, not passed from one doctor to another Single information system \u0026ndash; all doctors have access to all information, zero fragmentation Complete diagnosis + first treatment (CyberKnife) in 10 days What made the difference: Anadolu is a specialized oncology center \u0026ndash; this is what they do continuously. They have concentrated experience, high case volumes, and optimized protocols. It is not a general hospital that \u0026ldquo;also does oncology.\u0026rdquo;\nTip This is not an advertisement for a specific center. It is an example of how any serious oncology center should operate. Use these benchmarks as a standard when evaluating where to be treated. Leading oncology centers in Europe and Turkey If you are evaluating options for diagnosis or second opinion, here are renowned centers with internationally recognized oncology expertise:\nTurkey:\nAnadolu Medical Center, Istanbul \u0026ndash; specialized oncology center, academic partner of Johns Hopkins (USA). Daily tumor board, AI PET-CT, rapid molecular testing. France:\nGustave Roussy, Paris \u0026ndash; one of the largest oncology centers in Europe. Pioneer of rapid diagnosis (one-day breast diagnosis, since 2004). Institut Curie, Paris \u0026ndash; excellence in oncology research and treatment Germany:\nCharite Comprehensive Cancer Center, Berlin \u0026ndash; top university center Heidelberg University Hospital \u0026ndash; leader in oncology research University Hospital Munich (LMU) \u0026ndash; comprehensive cancer center Other European centers:\nNetherlands Cancer Institute (NKI), Amsterdam \u0026ndash; cutting-edge research and treatment Karolinska University Hospital, Stockholm \u0026ndash; excellence in oncology When evaluating a center, ask: Do they have a tumor board dedicated to my cancer type? How long do molecular tests take? What generation of PET-CT do they have? Do they have an integrated information system? Also check ClinicalTrials.gov for active clinical trials in your area.\nWhat NOT to do \u0026ndash; summary Here are the most common and costly mistakes you can avoid:\nDO NOT accept a biopsy without PET-CT \u0026ndash; you need to know the extent of the disease first DO NOT start treatment without molecular testing \u0026ndash; you may miss the treatment that suits you best DO NOT accept a plan from a single doctor \u0026ndash; ask for a tumor board DO NOT settle for 21+ day wait times for tests \u0026ndash; faster options exist DO NOT make major decisions in the first 48 hours \u0026ndash; emotions are at their peak, information is at its minimum DO NOT search Google randomly \u0026ndash; unverified information increases panic without real benefit DO NOT assume your doctor does everything automatically \u0026ndash; be your own advocate, ask, verify, request Timeline: what is normal vs cause for concern Stage Specialized center Fragmented pathway Red flag PET-CT + result 1-2 days 1-2 weeks \u0026gt; 3 weeks Biopsy + pathology result 3-7 days 1-3 weeks \u0026gt; 3 weeks Molecular testing 3-10 days 2-4 weeks \u0026gt; 4 weeks Tumor board Daily Weekly Does not exist Total: suspicion to treatment plan ~10 days 4-8 weeks \u0026gt; 8 weeks If your complete diagnosis takes longer than 8 weeks, actively ask what is causing the delay and whether faster options exist \u0026ndash;including at another center.\nUse AI tools as an ally in your journey Artificial intelligence tools (ChatGPT, Claude, Gemini, and others) can be a valuable ally in your diagnostic journey. They do not replace your doctor, but they can help you:\nUnderstand medical terms \u0026ndash; copy a paragraph from your pathology or imaging report and ask for an explanation in plain language Prepare questions for your doctor \u0026ndash; describe your situation and ask for a list of relevant questions to bring to your next appointment Verify information \u0026ndash; if you read something online and are not sure whether it is correct, ask the AI to check against NCCN or ESMO guidelines Understand treatment options \u0026ndash; ask for explanations about the difference between two proposed treatments, side effects, relevant clinical trials Translate medical documents \u0026ndash; if you have reports in another language, AI can translate and explain simultaneously Compare treatment options \u0026ndash; check our molecular subtype guides for detailed information, then discuss with your doctor Tip When using AI for medical information, be specific: include your cancer type, stage, mutations (if you know them), and what treatment you are on. The more context you provide, the more relevant the answer will be. Always verify the information with your medical team. What to do now Ask for a whole-body PET-CT as the first step, before biopsy Tell the doctor performing the biopsy that you need enough material for NGS molecular testing Ask explicitly about molecular testing \u0026ndash;what is being tested, when will results come, is there a rapid panel? Request presentation at the tumor board \u0026ndash;ask when it will be and what was decided Prepare your file for a second opinion \u0026ndash;imaging, pathology, molecular tests, lab results The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/diagnosis/complete-diagnosis-guide/","summary":"\u003cp\u003e\u003cstrong\u003eYou just found out you have cancer. Or that there is a serious suspicion. The world has stopped.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eI know what you are going through. I have been there.\u003c/p\u003e\n\u003cp\u003eIn moments like these, the instinct is to do anything \u0026ndash;immediately. To accept the first plan someone proposes. To rush into treatment. But here is what I learned the hard way: \u003cstrong\u003ethe most important thing you can do right now is to reach a complete and accurate diagnosis before making any treatment decision.\u003c/strong\u003e\u003c/p\u003e","title":"The Complete Oncology Diagnosis Guide: Step by Step"},{"content":" Important This is an OncoGuide reproduction of \u0026ldquo;Preserving Your Tumor Tissue\u0026rdquo;, published by Future of Cancer Care Today (FCCT) , an initiative of the Sijbrandij Foundation. We republish it with attribution so patients in every language can use it. The medical content is unchanged. Read the original English PDF . This guide is a companion to our complete diagnosis guide . It explains one decision that is easy to miss and impossible to undo later: what happens to your tumor tissue.\nWarning An OncoGuide note, added to the FCCT guide below — the one thing we most wish we had understood at the first biopsy. Tissue is finite, it is not renewable, and — this is the part that surprises people — a good response to treatment can quietly close the door on ever getting more. Plan for the whole journey, not just the first diagnosis.\nOver the course of treatment, one small biopsy may be asked to serve several separate needs, each of which consumes material:\nthe first molecular test (comprehensive DNA/RNA sequencing, \u0026ldquo;NGS\u0026rdquo;) that chooses your first-line therapy; often a second molecular test at resistance, if the cancer changes and a new driver has to be found — that is at least two full sequencing runs before anything else; a tumor-informed blood test for recurrence (MRD), built from a one-time tumor sequencing; and, if you ever pursue one, a personalized (neoantigen) cancer vaccine — which typically needs substantially more material than a routine panel, because it may require whole-exome and whole-transcriptome sequencing, and several centers strongly prefer fresh-frozen tissue over paraffin. A standard core biopsy is often just enough for the first diagnosis and little more. So at the first procedure — while there is still tumor to sample — it is worth asking, in writing, for extra cores, asking whether a portion can be kept fresh-frozen (not only fixed in paraffin), and making sure the diagnostic block is not completely used up by the first test.\nWhy the timing is unforgiving: if treatment works very well, there may later be no biopsiable tumor left — nothing active or large enough to sample safely. That is a good problem to have. But it means the tissue you banked early may be the only tissue you will ever have — and a paraffin block that seemed adequate can turn out to hold less than a millimetre of usable tumour when a vaccine lab finally measures it. Ask for a written inventory of what remains after each test, so you are never surprised late.\nIf a vaccine is on your mind, we wrote a companion piece on exactly this: Personalized cancer vaccines, part 2 — the tissue you need, and why to secure it early .\nWhy this matters Tumor tissue is one of the most valuable clinical resources in cancer care. It can be used for diagnosis, molecular testing, treatment planning, clinical trial matching, and, in some cases, more advanced personalized approaches.\nTissue is usually collected during a biopsy or surgery, usually for diagnostic purposes. But by the time you later need additional testing, drug-response work, immune profiling, or future re-analysis, the best opportunity to preserve tissue may have passed.\nThe landscape of cancer diagnostics is evolving rapidly. Current applications for tumor tissue include comprehensive DNA and RNA sequencing, protein staining, immune profiling, spatial biology, and drug-response testing. Preserved tissue allows for future re-analysis as new biomarkers, therapies, and testing methods emerge.\nPursuing high-quality preservation does not mean you need to commit to a specific treatment path. It simply keeps more clinical options open for the future.\nWhat tumor tissue can be used for A single well-preserved sample can support many different tests:\nMolecular profiling: DNA and RNA sequencing to identify mutations, gene expression patterns, and potentially actionable biomarkers. Pathology staining: Protein and biomarker testing used to classify tumors and guide therapy selection. Drug response testing: Testing live tumor cells against therapies in a laboratory setting. This requires fresh tissue processed quickly after collection. Immune profiling: Characterizing immune cells within the tumor microenvironment to inform immunotherapy approaches. Personalized therapy development: Supporting neoantigen vaccine design, engineered cell therapies, and other individualized approaches. What happens to tissue by default When tissue is removed during a biopsy or surgery, it goes to the hospital\u0026rsquo;s pathology department. Part is used for diagnosis, and the remainder is typically chemically fixed, embedded in paraffin wax, and archived for future clinical use.\nThis standard process works well for diagnosis and later sequencing, but it has limitations:\nFixed tissue cannot be used for tests that need living cells. Storage policies vary, though institutions commonly retain blocks under College of American Pathologists (CAP) and other regulatory standards. Tissue stays at the institution that collected it, and sending it elsewhere later can take time. Before a biopsy or surgery Raise it early As soon as a procedure is scheduled, tell your care team you would like to talk about tissue preservation.\nAsk about extra tissue Sometimes the team can collect more than the minimum needed for diagnosis. It depends on the procedure and should be discussed with your surgeon and pathologist.\nAsk about fresh or frozen tissue Some downstream applications, such as drug-response testing or immune analyses, require a portion to be preserved fresh or frozen rather than only fixed in chemicals. This has to be arranged in advance.\nConsider a tissue preservation service Several organizations specialize in preserving a patient\u0026rsquo;s tumor at the time of biopsy or surgery, including living tissue for future use. They coordinate with the hospital and store the tissue under your control. Arranging this takes lead time.\nImportant Time-sensitive. Fresh tissue preservation, additional collection, and third-party storage arrangements all need to be set up before the procedure. If a biopsy or surgery is coming up, now is the time to ask. If tissue has already been collected If a procedure has already happened, options are more limited, but several steps are still useful:\nFind out what exists: Ask where the tissue is stored, in what form, how much remains, and how long it will be retained. Request your blocks or slides if needed: Pathology materials can often be transferred to another institution or testing laboratory, though the process may take time. Use archived tissue for additional testing: Existing samples can often be used for additional sequencing or biomarker analysis. Plan for future procedures: If another biopsy or surgery is likely, use it as an opportunity for more comprehensive preservation. One important point: a tumor removed years ago may be genetically different from the cancer as it exists today, especially after treatment. While studies suggest most of the genetic alterations are similar between primary and recurrent cancers, a fresh sample is sometimes valuable even when older tissue is available. Whether you need new tissue is a question for your care team.\nQuestions to ask your care team Pick the questions most relevant to your situation, and use these as conversation starters.\nWhat happens to my tissue after this procedure? Can additional tissue be collected beyond what is needed for diagnosis? Can a portion be preserved fresh or frozen, not only fixed in chemicals? How much tissue is likely to remain after diagnosis, and how long will it be stored? If I want to use a tissue preservation service, can the team coordinate with them? Given my diagnosis, what tests might this tissue be useful for, now or later? Final note Preserving tumor tissue allows for the ability to pursue future molecular analysis, research participation, or emerging therapeutic approaches as cancer care continues to evolve. External storage or vendor services are often an out-of-pocket cost and may not be insurance-covered.\nThe most important step is to start the conversation early. Ask your care team what tissue will be collected, how it will be preserved, where it will be stored, and how long it will remain available. Having that information can help keep future diagnostic, research, and treatment options open as cancer care and testing technologies continue to evolve.\nTip Different cancers need different tests. For what matters most in your specific situation, see our master guides by molecular subtype . What to do now If a biopsy or surgery is scheduled, raise tissue preservation now \u0026ndash; before the procedure, not after. Ask whether extra tissue can be collected beyond what diagnosis needs, and whether a portion can be kept fresh or frozen. Ask where your tissue will be stored and for how long. If a procedure already happened, ask what tissue still exists and whether it can be used or transferred to another lab. Read the original FCCT guide and bring the questions above to your care team. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/diagnosis/preserving-tumor-tissue/","summary":"\u003cdiv class=\"onco-callout onco-callout--important\" role=\"note\"\u003e\n  \u003cdiv class=\"onco-callout-title\"\u003eImportant\u003c/div\u003e\n  This is an OncoGuide reproduction of \u003cstrong\u003e\u0026ldquo;Preserving Your Tumor Tissue\u0026rdquo;\u003c/strong\u003e, published by \u003ca href=\"https://sijbrandijfoundation.org/FCCT\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eFuture of Cancer Care Today (FCCT)\u003c/a\u003e\n, an initiative of the Sijbrandij Foundation. We republish it with attribution so patients in every language can use it. The medical content is unchanged. Read the \u003ca href=\"https://static1.squarespace.com/static/6306491067d7c950dcc669fe/t/6a332e97f2d57e6ef8d94fd5/1781739159729/FCCT_Tissue_Preservation_Playbook.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eoriginal English PDF\u003c/a\u003e\n.\n\u003c/div\u003e\n\n\u003cp\u003eThis guide is a companion to our \u003ca href=\"/en/diagnosis/complete-diagnosis-guide/\"\u003ecomplete diagnosis guide\u003c/a\u003e\n. It explains one decision that is easy to miss and impossible to undo later: what happens to your tumor tissue.\u003c/p\u003e","title":"Preserving your tumor tissue: a guide for patients and families"},{"content":"If you are reading this, it means you have made it through the first few months. You have the diagnosis, you have the treatment, you understand the basics. Selpercatinib is working \u0026ndash; the tumor has probably shrunk, you probably feel better than you expected.\nAnd yet, the question that never goes away: how long will it last?\nThis guide is for you. Not to scare you, but to show you that there are options your oncologist does not always mention \u0026ndash; not because they are irrelevant, but because they are new, specialized, and not (yet) part of standard protocols. Your oncologist remains the central piece of your treatment. This guide gives you the tools to have a more informed conversation with them.\nIf you are just starting out, first read the complete guide for newly diagnosed patients . This article picks up where that one ends.\nIf you are a physician: this article is designed as a complement to clinical practice \u0026ndash; a structured inventory of emerging options for RET+ lung cancer, with references. The goal is to facilitate the physician-patient dialogue, not to replace it.\nThe problem with \u0026ldquo;wait and see\u0026rdquo; The current standard of care for RET fusion lung cancer looks like this:\nDiagnose the RET fusion through molecular testing (NGS) Start Selpercatinib (RETSEVMO) Monitor with CT every 2-3 months When the tumor progresses, switch treatment This protocol works. Selpercatinib offers an 84% response rate as first line, and the median progression-free survival is nearly 25 months. Compared to traditional chemotherapy, that is an enormous difference.\nBut \u0026ldquo;median\u0026rdquo; means half of patients progress before 25 months. Some resistance mechanisms appear early: solvent front mutations (G810) can be detected on ctDNA at just 3-4 months, and MET amplification \u0026ndash; the most common bypass mechanism \u0026ndash; appears on average at 8 months. Other patients remain stable well past 3 years. Every case is different.\nBut the strategy remains passive. You wait for the disease to return, then react.\nWhat \u0026ldquo;standard of care\u0026rdquo; means and why it matters:\n\u0026ldquo;Standard of care\u0026rdquo; is the treatment that hospitals and clinics routinely apply. For a new treatment to reach this level, it must go through rigorous clinical trials \u0026ndash; Phase 1 (safety), Phase 2 (efficacy), Phase 3 (direct comparison with existing treatment). This process has traditionally taken many years, but the pace is accelerating. Selpercatinib, for example, received accelerated FDA approval just 3 years after the first patient was treated, and programs like \u0026ldquo;breakthrough therapy\u0026rdquo; and \u0026ldquo;expanded access\u0026rdquo; are constantly shortening the path from discovery to patient.\nNevertheless, many of the options described in this article have not yet gone through all stages \u0026ndash; not because they do not work, but because the process, although increasingly faster, requires time and validation across hundreds or thousands of patients. Your oncologist follows validated protocols \u0026ndash; and is right to do so. This guide does not contradict their protocol, but shows you what complementary options exist beyond it, with what level of evidence, and how you can discuss them in an informed way.\nThe fundamental problem remains: at stage IV, nearly every patient will develop resistance at some point. The question is not \u0026ldquo;if\u0026rdquo; but \u0026ldquo;when\u0026rdquo; \u0026ndash; and \u0026ldquo;what have you prepared for that moment.\u0026rdquo;\nThe good news: technology has advanced enough that proactive action is now possible. We are not talking about baseless experimental treatments. We are talking about options with clinical trials, published data, and solid biological rationale \u0026ndash; available now or within the next 1-3 years.\nThe window of opportunity is now, while treatment is working. Your immune system and treatment response are at their best. Once resistance sets in, options narrow.\nAdvanced molecular profiling \u0026ndash; know your enemy The NGS test that confirmed the RET fusion was just the beginning. There are much deeper layers of molecular information that directly influence what options you have.\nBeyond NGS: complete sequencing Whole Exome Sequencing (WES) analyzes all genes in your tumor, not just a panel of 50-500. Why it matters:\nIdentifies co-mutations that influence prognosis (TP53, PIK3CA, KEAP1) Finds tumor neoantigens \u0026ndash; protein fragments unique to your tumor that the immune system can recognize. They are the basis of personalized vaccines Detects DNA repair defects (FANCL, BRCA, ATM) that can open additional therapeutic options, such as PARP inhibitors RNA-seq goes even further: it shows which genes are actually active in your tumor, not just present. It can confirm the RET fusion partner (KIF5B, CCDC6, etc.) with certainty and detect resistance mechanisms that do not appear at the DNA level.\nWhy the fusion partner is worth confirming: RET rarely acts alone \u0026ndash; it almost always fuses with a second gene (most often KIF5B or CCDC6), and that pairing is called your fusion partner. Knowing which partner you have is no longer just a vaccine-design detail. Data presented at ASCO 2026 suggest the partner gene influences how durable the response to a RET inhibitor is (for example, CCDC6-RET has been associated with a longer duration of response than KIF5B-RET in some analyses \u0026ndash; though the difference is modest and not seen consistently across all studies, so no single partner is a verdict). It helps your oncologist anticipate prognosis and plan the next line of treatment \u0026ndash; so it is worth confirming early, not only if a vaccine is on the table.\nTip In practice \u0026ndash; ask for one comprehensive bundle, not scattered tests. Rather than chasing several separate tests at different academic centers, ask your oncologist whether a single comprehensive genomic profiling (CGP) bundle can be run on your existing tumor block (FFPE). A good bundle, available from GDPR-compliant laboratories across Europe, combines in one shipment:\nA broad DNA panel (500-1000+ genes) \u0026ndash; co-mutations, DNA-repair defects, MTAP/RB1 status RNA-seq with fusion-partner resolution \u0026ndash; confirms KIF5B vs CCDC6 vs another partner, not just \u0026ldquo;RET-positive\u0026rdquo; Targeted IHC markers \u0026ndash; c-MET, MTAP, HER3, TROP2 (these gate access to specific drugs and antibody-drug conjugates discussed later) A ctDNA baseline from a blood draw taken around the same time (this part is a blood test, not from the tissue block) Most of this works on a stored paraffin block (FFPE) \u0026ndash; no new biopsy needed. Important: these tests are not always covered by public health insurance; ask whether they are reimbursed or require private payment (a combined bundle is often far cheaper than the separate tests it replaces). Some European academic programs also offer sequencing for eligible patients, though cross-border access typically requires a referral or an S2 form.\nSpecific biomarkers that open trial options Beyond general sequencing, a few specific biomarkers are worth explicitly testing because they gate access to emerging treatment classes:\nMTAP loss (methylthioadenosine phosphorylase) \u0026ndash; A peer-reviewed 2026 study (Aldea et al., Annals of Oncology, March 2026) documented MTAP loss in 18-35% of RET fusion-positive NSCLC patients \u0026ndash; a high prevalence that opens eligibility for PRMT5 inhibitors, a new class of targeted therapies currently in phase 2-3 trials. MTAP status is best confirmed by IHC on tumor tissue (not by liquid biopsy, which cannot reliably detect MTAP deletions). If you have a stored FFPE biopsy, MTAP IHC can be added at marginal additional cost. RB1 status (tumor suppressor gene) \u0026ndash; Relevant for understanding lineage plasticity risk (see the resistance section below). Usually reported as part of a standard NGS panel; worth confirming it is included. Ask your oncologist whether these markers are part of the panel already run. If not, they can often be added to the existing tissue sample at marginal additional cost.\nGenetic testing: not just the tumor, but also you Three genetic tests that matter beyond the tumor:\n1. Germline (hereditary) testing\nThe tumor has acquired mutations, but some may be inherited. For example, mutations in the FANCL or BRCA genes may indicate a vulnerability in DNA repair \u0026ndash; which opens therapeutic options (PARP inhibitors) and has implications for blood relatives.\n2. HLA typing\nHLA genes determine which protein fragments your immune system can \u0026ldquo;see.\u0026rdquo; They are essential for:\nEligibility for anti-cancer vaccines (some require specific HLA types) Design of personalized vaccines (neoantigens are filtered through your HLA type) Immunotherapy planning A simple blood test, performed once.\n3. Pharmacogenomics\nHow your body metabolizes medications. Selpercatinib is processed by the CYP3A4 and CYP2C8 enzymes. Genetic variants in these enzymes can explain why some patients have more side effects than others at the same dose.\nImportant Ask your oncologist: \u0026ldquo;Have I been tested for germline mutations? Do we know if I have inherited mutations in DNA repair genes?\u0026rdquo; If the answer is no, request a referral. ctDNA \u0026ndash; real-time disease monitoring Imaging (CT, PET-CT) shows what the tumor looked like weeks ago. Circulating tumor DNA (ctDNA) shows what the tumor is doing today.\nWhat is ctDNA Tumor cells release DNA fragments into the bloodstream. These can be detected through a simple blood draw \u0026ndash; no biopsy, no anesthesia. It is called a liquid biopsy.\nWhy it matters ctDNA can detect disease progression 3-6 months before it becomes visible on imaging. In practice, this means:\nYou detect resistance early, when intervention options are at their maximum You can identify the mechanism of resistance (RET mutation, MET amplification, KRAS activation) directly from blood You can monitor treatment response without additional radiation After local treatment (radiotherapy, cryoablation), undetectable ctDNA is a strong indicator of complete response Available platforms There are multiple ctDNA monitoring platforms, with different levels of sensitivity:\nNote: Sensitivity is measured in VAF (Variant Allele Frequency) \u0026ndash; the minimum percentage of mutant DNA out of total circulating DNA that the test can detect. The smaller the number, the finer the traces of disease the test can pick up.\nPlatform What it measures Sensitivity Availability Guardant360 74 genes, fixed panel 0.1% VAF Europe (through partner laboratories) FoundationOne Liquid CDx 300+ genes, fixed panel 0.1-0.5% VAF Europe and USA Signatera (Natera) 16 personalized variants from your tumor (fixed from initial biopsy) 0.01% VAF EU (CE-IVD marked) NeXT Personal (Personalis) Tumor-informed hybrid-capture, can track emergent resistance variants during treatment 1.7 ppm (0.00017%) US + EU via partner laboratories Haystack MRD (HPH Hamburg) 50 variants from tumor WGS 0.0006% Germany, accessible EU-wide The difference between fixed panels and personalized monitoring is enormous. A fixed panel like Guardant360 detects known mutations at a relatively high level. A personalized platform (Signatera, NeXT Personal, Haystack) detects traces of disease 100-1000 times smaller \u0026ndash; essential for confirming whether the disease has been completely eliminated.\nA further distinction matters for patients already on treatment months in: most personalized platforms (Signatera, Haystack) track a fixed set of variants selected from your initial tumor biopsy. If new resistance mutations emerge during treatment, those fixed panels may not see them. NeXT Personal (Personalis) launched in January 2026 a \u0026ldquo;Real-Time Variant Tracker\u0026rdquo; capability (clinical data presented at AACR 2026) that uses hybrid-capture to detect new mutations as they appear during therapy \u0026ndash; useful for early detection of emerging resistance. Ask your lab which approach they use and whether emergent-mutation tracking is available.\nWarning A blood test can be falsely reassuring. When your medication is controlling the disease well, the tumor sheds very little of its DNA into the blood \u0026ndash; which is itself a good sign, but it also means a blood test has very little to find. In that situation the most important resistance mechanism \u0026ndash; MET amplification \u0026ndash; is caught far more reliably in tissue than in blood (in one published comparison, roughly 38% of cases were picked up from tissue versus only 7% from blood). The practical takeaway: an \u0026ldquo;undetectable ctDNA\u0026rdquo; result is excellent news, but it does not replace a tissue rebiopsy if your imaging or symptoms suggest progression. Ask your oncologist when a repeat tissue sample is worth doing. When to test Timepoint Why At diagnosis (before treatment) Baseline reference At 8-12 weeks of treatment Confirmation of molecular response Before local therapy (SBRT/cryo) Quantification of residual disease At 4-6 weeks after local therapy Response confirmation \u0026ndash; undetectable ctDNA = excellent prognosis Every 3 months thereafter Continuous molecular surveillance Tip ctDNA monitoring is not (yet) standard of care in most countries. But it is available, clinically validated, and provides information that imaging cannot. Discuss with your oncologist about integrating it into your monitoring plan. Practical access in Romania and the EU FoundationOne Liquid CDx (Roche/Foundation Medicine) is the most widely used broad-panel liquid biopsy test (300+ genes) and is available in Romania through partner laboratories, including the Regina Maria network and other molecular oncology centers. The test requires only a blood draw and provides results in 2-3 weeks.\nGuardant360 CDx is accessible in the EU through partner laboratories in Germany (TherapySelect) or the UK.\nSignatera (Natera) \u0026ndash; the personalized MRD (minimal residual disease) monitoring platform \u0026ndash; has CE-IVD marking and is available in the EU through Oncompass Medicine (Hungary/Switzerland).\nHaystack MRD (HPH Hamburg) \u0026ndash; the most sensitive platform available in Europe \u0026ndash; accepts samples from across the EU.\nFor personalized platforms (Signatera, Haystack), the first step is sending the tumor NGS result (from biopsy) to the laboratory, which creates a personalized monitoring profile. Afterward, each test requires only a blood draw.\nImportant Ask your oncologist: \u0026ldquo;Can we add ctDNA monitoring to my plan? Which partner laboratory do you recommend?\u0026rdquo; If your oncologist is not familiar with these tests, you can contact the laboratories mentioned above directly \u0026ndash; all of them accept samples sent by patients through their treating physician. Consolidative local therapy \u0026ndash; treat what remains If treatment is working and you have a small number of residual lesions (1-5 sites), you do not have to wait for progression. You can actively treat what remains, while Selpercatinib controls the rest of the disease.\nThis concept is called consolidative local therapy (CLT) and has solid evidence from randomized trials.\nWhy it works The logic is simple: if 90% of the disease responds to Selpercatinib, but a few lesions have cells that could develop resistance, destroying them now eliminates the source of future problems.\nThe evidence is strong:\nSINDAS (randomized trial, Phase III): SBRT + TKI vs TKI alone \u0026ndash; median survival +8 months (25.5 vs 17.4 months) SABR-COMET (8-year follow-up): 21% of patients progression-free at 8 years \u0026ndash; a cure signal in 1 out of 5 oligometastatic patients LIBRETTO-001 (RET-specific data): Continuing selpercatinib + SBRT at oligoprogression adds +9.8 months of progression-free survival The optimal window for CLT: months 4-6 from starting treatment, when response is maximal but residual lesions are still visible on imaging.\nLocal treatment options SBRT (stereotactic body radiation therapy) A focused radiation beam destroys the tumor with millimeter precision, in 1-5 sessions. It is the most studied form of CLT.\nAdvantages:\nLocal control \u0026gt;95% at 1 year Outpatient, no anesthesia Low risk of pneumothorax Covered by insurance in many countries Limitations:\nCumulative doses limit repeatability At standard ablative doses, tumor antigens can be denatured by radiation \u0026ndash; systemic immune activation is often modest Two dosing philosophies:\nSBRT can be delivered with two different intents, and the correct choice depends on the clinical objective:\nIntent Typical dose What it does Local control Immune activation Ablative (tumor destruction) BED \u0026gt; 100 (e.g., 54 Gy/3 fx or 50 Gy/5 fx) Completely destroys tumor tissue \u0026gt;95% at 1 year Moderate (antigens partially denatured by high-dose radiation) Immunogenic (immune activation) Lower BED (e.g., 8 Gy x 3 fx) Fragments tumor while keeping antigens more intact Inferior Superior (stays below the Trex1 enzyme threshold, which degrades cytoplasmic DNA) The PEMBRO-RT trial used the immunogenic dose (8 Gy x 3) combined with pembrolizumab and achieved 41.7% abscopal response even in \u0026ldquo;cold\u0026rdquo; tumors. But local control of the irradiated lesion is lower than with ablative doses.\nIn practice, the radiation oncologist may choose an intermediate or ablative dose for the primary lesion (local control priority) and an immunogenic dose for a secondary lesion (immune activation priority). The decision belongs strictly to the radiation oncologist, depending on tumor location, the priority goal for each lesion, and the overall treatment strategy.\nCryoablation \u0026ndash; the \u0026ldquo;in-situ vaccine\u0026rdquo; Cryoablation destroys the tumor through repeated freeze/thaw cycles, using a CT-guided probe inserted percutaneously.\nWhat makes it special: Unlike heat or radiation, cryoablation preserves tumor antigens intact \u0026ndash; the tumor proteins remain recognizable to the immune system. The result:\nSTING pathway activation (immune signaling pathway) without PD-L1 overexpression NK cell and CD8+ lymphocyte expansion Potential abscopal effect \u0026ndash; untreated distant tumors shrink Clinical evidence:\nBOOSTER (randomized trial): Cryo + immunotherapy vs immunotherapy alone \u0026ndash; progression-free survival 26.7 vs 11.7 months (HR 0.213). The strongest clinical effect demonstrated for cryoablation ECLIPSE (Gustave Roussy, 5 years): Local control 79.2% at 5 years \u0026ndash; the longest follow-up for pulmonary cryoablation in the world JVIR 2026 meta-analysis (786 patients): Local control at 1 year 90.5%. For tumors under 2 cm, 3-year control reaches 96-100% SOLSTICE (128 patients, 7 centers): Local control after re-cryoablation rises to 91.1% \u0026ndash; cryoablation is repeatable without limit, with no cumulative dose Robotic vs manual cryoablation:\nRobotic platforms (Perfint MAXIO, Quantum Epione) offer precision of 1.7-6.1 mm, major complications of only 3%, and over 80% reduction in radiation exposure for the patient. They are available at a few reference centers in Europe, but do not yet have long-term data (the technology is 3-5 years old). Manual CT-guided cryoablation has two decades of experience and proven results.\nLimitations:\nRisk of pneumothorax (15-25% for tumors under 2 cm; 75% resolve spontaneously) Does not produce tumor tissue for analysis \u0026ndash; cryoablation destroys in-situ. If you need tissue for molecular testing or vaccines, a separate biopsy during the same session is required Important European reference centers for pulmonary cryoablation:\nGustave Roussy (Paris) \u0026ndash; the largest global experience (~600+ patients), ECLIPSE/SOLSTICE programs, robotic capability (Quantum Epione) + conventional, integration with MATCH-R for molecular profiling Royal Marsden (London) \u0026ndash; published data with robotic cryoablation (97% local control at 12 months on 37 pulmonary lesions), shortest TKI pause protocol (24-48h) IEO Milan \u0026ndash; vast experience in general ablation (6000+ procedures), IceCure ProSense platform (liquid nitrogen, -196C) Surgery Rarely indicated at stage IV, but may be considered if:\nThe residual lesion is solitary and completely resectable There is a need for fresh tumor tissue for functional testing or vaccines Other local options are not anatomically feasible What to choose: SBRT, cryo, or surgery? Criterion SBRT Cryoablation Surgery 1-year local control 95%+ 90.5% 95%+ Immune activation Moderate Superior Minimal Repeatability Limited Unlimited Limited Tissue for analysis No No (requires separate biopsy) Yes Pneumothorax risk \u0026lt;1% 15-25% Variable Recovery time Days Days Weeks Selpercatinib pause 3-7 days 1-3 days 7+ days The optimal approach may combine methods: for example, cryoablation on the primary tumor (for immune activation) and SBRT on the bone metastasis (for maximum local control).\nTip Ask your oncologist: \u0026ldquo;Do I have oligometastatic disease? Would stereotactic radiotherapy or cryoablation be appropriate for the residual lesions, while continuing Selpercatinib in parallel?\u0026rdquo; Anti-cancer vaccines \u0026ndash; train your immune system Therapeutic anti-cancer vaccines do not prevent cancer. They train the immune system to recognize and attack existing tumor cells. And RET fusion cancer has a unique advantage in this space.\nWhy the RET fusion is an ideal vaccine target The RET fusion occurs when two genes (for example, KIF5B and RET) join abnormally. At the junction point, a protein sequence that does not exist anywhere in the normal body is formed \u0026ndash; a perfect tumor neoantigen.\nThis means:\nZero risk of autoimmunity \u0026ndash; the vaccine targets something only the tumor has The tumor cannot escape without losing the mutation it depends on for survival A single design covers all patients with the same fusion type (e.g., KIF5B-RET) Unlike other cancers where each patient must be sequenced individually, the RET fusion offers a shared, clonal, and specific target.\nTypes of vaccines 1. Peptide vaccines (protein-based) The simplest concept: a synthetic protein fragment (peptide) from the fusion junction, injected with an adjuvant that stimulates the immune response.\nFusionVAC (University of Tubingen, Germany):\nProven platform on other cancers with genetic fusions \u0026ndash; in the Phase 1 trial on the DNAJB1-PRKACA fusion (Nature Medicine 2025 ): 75% disease control (9 out of 12 patients), 3 patients with no detectable disease, one patient on compassionate use cancer-free for over 4 years. Note: these results are from a different cancer type (fibrolamellar carcinoma), not RET+ lung cancer. The platform is modular \u0026ndash; it adapts to any fusion, but RET-specific clinical data do not exist yet The 22-amino acid peptide covers 93-96% of the European population, without requiring specific HLA typing The XS15 adjuvant is specifically designed for immunocompromised patients (relevant, since 52% of selpercatinib patients develop lymphopenia) Requires fresh frozen tumor tissue (-80C) for feasibility assessment and vaccine design. Paraffin blocks (FFPE) are not sufficient. This is the single biggest practical barrier: if you are in a deep response with no lesion that can safely be biopsied, you cannot currently produce the tissue this vaccine needs. In practice, FusionVAC therefore becomes realistic at a future oligo-progression, when a biopsy can both identify the resistance mechanism and bank fresh-frozen cores. The lesson for now: at any future intervention (biopsy, cryoablation), explicitly request that extra cores be cryopreserved at -80C Estimated production time of a few weeks at the GMP facility in Tubingen (peptide synthesis, not cell culture) Access: Through the German \u0026ldquo;individual use\u0026rdquo; procedure (Individueller Heilversuch). There is no open RET+ lung-cancer trial for it \u0026ndash; the published trial (NCT05937295) is for a different cancer (fibrolamellar liver carcinoma); for RET+ NSCLC the route is this individualized academic pathway, not trial enrollment. Treat any \u0026ldquo;free / fully covered\u0026rdquo; claim with caution \u0026ndash; the cost of an individualized Heilversuch is not publicly fixed; confirm directly with the center Important For the FusionVAC vaccine, the RET fusion partner must be confirmed (KIF5B vs CCDC6 vs other). Each fusion partner creates a different junction and requires a different peptide design. Confirmation is done through extended tumor genetic sequencing (WES or RNA-seq, described above). Validated KIF5B-RET neopeptides:\nNNDVKEDPK \u0026ndash; strongest HLA-C*07:02 binder, immune response experimentally confirmed (Gunaratne, Frontiers in Immunology 2025) KEDPKWEFP \u0026ndash; second immunogenic hit 15 TCR clonotypes identified, 5 with high activation markers The FusionNeoAntigen database (Oxford) maps KIF5B-RET to 92 HLA-I alleles, covering approximately 94% of the global population 2. mRNA vaccines The same technology from the COVID vaccines, adapted for oncology. A messenger RNA encodes the tumor antigens, and the body\u0026rsquo;s cells produce and present them to the immune system.\nBNT116 (BioNTech) + Cemiplimab:\nEncodes 6 common tumor antigens (not RET fusion-specific) Phase 1/2 ongoing: 45% response rate, 80% disease control in NSCLC Active clinical trial at multiple European centers (including Turkey) Limitation: Most protocols exclude patients with driver mutations (EGFR, ALK, RET) \u0026ndash; eligibility verification is essential V940/mRNA-4157 (Moderna + Merck):\nPersonalized vaccine: encodes up to 34 unique neoantigens from your tumor Combined with pembrolizumab (Keytruda) Results in melanoma: 44% reduction in recurrence Phase 3 for NSCLC (INTerpath-002) \u0026ndash; actively recruiting, estimated results ~2030+ mRNA-4359 (Moderna, Mobilize Trial):\nExplicitly accepts patients with driver mutations (including post-TKI) Personalized vaccine with up to 34 neoantigens Combined with pembrolizumab 3. Dendritic cell vaccines Dendritic cells are the \u0026ldquo;teachers\u0026rdquo; of the immune system \u0026ndash; they present tumor antigens directly to T lymphocytes, activating a targeted immune response.\nIOZK (Cologne, Germany) \u0026ndash; IO-VAC:\nAutologous dendritic cells (from the patient\u0026rsquo;s blood), loaded with tumor antigens Combined with oncolytic Newcastle Disease Virus (NDV) and hyperthermia 350+ patients treated annually No restrictions related to standard immune markers (PD-L1, TMB \u0026ndash; tumor mutational burden) or driver mutations Important limitation: Requires fresh or frozen tumor tissue (FFPE does not work). Also has limited data in lung cancer, with zero RET+-specific data PDC*lung01:\nAllogeneic dendritic cells (pre-manufactured, standardized) \u0026ndash; does not require the patient\u0026rsquo;s own tumor tissue Phase 1/2: 51-55% response rate in combination with immunotherapy Limitation: Requires HLA-A*02:01 (present in approximately 40% of Europeans) CeGaT CancerNeo (Tubingen, Germany):\nComplete pipeline: tumor sequencing, AI neoantigen prediction, GMP synthesis, administration 90% immune response rate (87 out of 97 patients) Median survival of 53 months in responders, compared to 27 without response Accepts FFPE (important advantage if you already have a stored biopsy) Production time: approximately 2 months 4. Personalized neoantigen vaccines The most advanced concept: complete sequencing of your tumor, identification of all unique neoantigens, and creation of a vaccine targeting all of them.\nAdvantages: Broad coverage (the tumor cannot escape by losing a single antigen). Disadvantages: Higher cost, longer production time (2-5 months).\nActive companies and programs:\nCeGaT CancerNeo (Tubingen, Germany) \u0026ndash; described above, complete pipeline from sequencing to administration. Accepts FFPE Jaime Leandro Foundation (USA) \u0026ndash; personalized neoantigen peptide vaccine. Explicitly accepts lung cancer. 48 patients treated (August 2025). Access through FDA Expanded Access (Form 3926, approval rate \u0026gt;99%). Production: 4-5 months BioNTech Individualized Neoantigen Therapy (iNeST/BNT122) \u0026ndash; personalized mRNA platform (autogene cevumeran). Phase 2 in pancreatic cancer and melanoma, with significant reduction in recurrence. Extension to NSCLC is anticipated Moderna mRNA-4157/V940 \u0026ndash; described above under mRNA vaccines. Up to 34 personalized neoantigens per patient Gritstone Bio (GRANITE/SLATE) \u0026ndash; combined platform: adenoviral vector (prime) + self-amplifying mRNA (boost). Phase 2 in MSI-stable solid tumors (direct relevance for RET+, which is MSI-stable) Most of these programs are accessible through clinical trials or compassionate use. CeGaT is the only one with direct commercial access in Europe.\nTip FusionVAC and CeGaT CancerNeo \u0026ndash; complementary, not competing\nBoth programs are in Tubingen, but are independent entities: FusionVAC is a research program of the University Hospital (Prof. Walz), and CeGaT is a private company with a commercial service. The essential difference:\nFusionVAC = a precise bullet targeting the RET fusion junction (a single antigen, the most important one) CeGaT CancerNeo = broad coverage of all unique mutations in your tumor (dozens of antigens) Theoretically, they can be combined: FusionVAC for the primary target (the fusion) + CeGaT for broader coverage. FusionVAC requires fresh frozen tissue, CeGaT accepts FFPE too \u0026ndash; so they can work from different tissue sources.\n5. Vaccinating against resistance \u0026ndash; before it appears A newer idea, and one especially suited to patients who are doing well on treatment: instead of waiting for a resistance mutation to emerge and then reacting, you vaccinate against the resistance mutations the tumor is most likely to develop \u0026ndash; while you are still on your TKI and in deep response.\nThe proof of concept comes from ALK-positive lung cancer (a close molecular cousin of RET+). At ASCO 2026, the ARCHER trial (Phase 1b, Johns Hopkins, Dr. Vincent Lam) tested a peptide vaccine targeting anticipated ALK resistance mutations, given alongside the patient\u0026rsquo;s ongoing TKI:\n14 of 15 patients (93%) mounted a T-cell response against at least one targeted mutation 93% disease control while continuing TKI therapy No serious side effects (no grade 3+ toxicity, no cytokine release syndrome reported) Why this matters for RET+: in principle the same approach can target RET\u0026rsquo;s known resistance mutations (the G810 \u0026ldquo;solvent-front\u0026rdquo; family). Crucially, it needs neither fresh-frozen tissue nor measurable disease \u0026ndash; exactly the situation of someone in a deep response, for whom the fresh-tissue vaccines above are out of reach. A RET-specific version does not exist yet, and ALK is not RET \u0026ndash; but ARCHER shows the strategy is safe and immunologically active. What you can do now: at your next appointment, ask whether any trial is studying on-TKI resistance-mutation vaccines for RET+ lung cancer, and whether your center can flag you if one opens.\nVaccines: matching the option to your situation Availability is only half the question. What usually decides which vaccine you can actually pursue is what each one requires from you \u0026ndash; the type of tissue you have, whether you have a biopsy-able lesion, or whether a trial is open. This is where many patients lose months. Match your situation to the realistic options:\nIf your situation is\u0026hellip; Options that actually fit Only a stored FFPE block, in deep response, no lesion safe to biopsy FFPE-compatible neoantigen vaccines (CeGaT CancerNeo); some clinical trials \u0026ndash; but check eligibility carefully, as several (e.g. BNT116) exclude driver mutations like RET Fresh-frozen tissue available, or a planned biopsy that can bank some FusionVAC (Tubingen) \u0026ndash; fresh-frozen mandatory, FFPE not accepted Doing well, want to act against resistance pre-emptively Resistance-mutation vaccines (ARCHER paradigm, above) \u0026ndash; no fresh tissue or measurable disease needed; RET-specific version not yet available At progression, evidence-based options exhausted Dendritic-cell vaccines with limited lung data (IOZK IO-VAC) \u0026ndash; a reserve, not a first choice Active clinical trials: BNT116, mRNA-4359/Mobilize, PDC*lung01, V940 \u0026ndash; note that compassionate-use access outside a trial is often closed, so the route is enrollment at a participating center. On the horizon (1-3 years): personalized mRNA vaccines specific to RET, KAIST B-cell AI vaccines. Further out (3-5+ years): anti-RET PROTACs, next-gen lipid mRNA.\nThe combination that amplifies efficacy Vaccines work best when combined with other treatments that amplify the immune response. The optimal evidence-based sequence:\nImmune activation (ANKTIVA/IL-15 \u0026ndash; see next section) \u0026ndash; restores lymphocytes before vaccination Vaccination (FusionVAC or another platform) \u0026ndash; trains the immune system Cryoablation \u0026ndash; releases tumor antigens in-situ, amplifying the vaccine\u0026rsquo;s effect Vaccine booster at 6-12 weeks after cryoablation \u0026ndash; within the window of maximum immune activation Continuing Selpercatinib throughout \u0026ndash; tyrosine kinase inhibitors (TKIs, the class to which Selpercatinib belongs) upregulate HLA class I on tumors, making them more visible to vaccine-trained T cells Warning No anti-cancer vaccine has yet cured RET fusion lung cancer. The evidence is strong from other cancer types with fusions, and the biological rationale is solid, but RET-specific clinical data are in early stages. These options are complementary to standard treatment, not a replacement. Immune system activation RET fusion cancer has an unfortunate characteristic: the tumor is immunologically \u0026ldquo;cold\u0026rdquo; \u0026ndash; few lymphocytes infiltrate it, PD-L1 expression is low. That is why classical immunotherapy (pembrolizumab, nivolumab) works poorly.\nBut that does not mean the immune system cannot be activated. It just requires different tools.\nANKTIVA (N-803) \u0026ndash; IL-15 superagonist ANKTIVA is a biologic drug that activates NK cells (natural killers) and CD8+ T lymphocytes without expanding regulatory T cells (which would suppress the immune response).\nWhy it matters for RET+:\nWorks independently of PD-L1 \u0026ndash; it does not matter that your tumor is \u0026ldquo;cold\u0026rdquo; Reverses lymphopenia (low lymphocyte counts) \u0026ndash; 80% of patients in trials achieved lymphocytes \u0026gt;1200/uL In the QUILT-3.055 trial (86 refractory NSCLC patients), PD-L1 negative patients had superior median survival compared to PD-L1 positive (15.4 vs 13.8 months) \u0026ndash; cold tumors benefited more Status:\nFDA approved (2024, full approval) and EC conditionally approved (February 2026) for bladder cancer (BCG-unresponsive non-muscle-invasive bladder cancer) Approved in Saudi Arabia (January 2026) for metastatic NSCLC after standard therapy \u0026ndash; the first approval worldwide for lung cancer (note: this is for NSCLC broadly, regardless of mutation \u0026ndash; it is not RET-specific) Phase 3 trial (ResQ201A) actively recruiting in checkpoint-inhibitor-relapsed NSCLC \u0026ndash; relevant for RET+ patients, whose tumors tend to be immunologically \u0026ldquo;cold,\u0026rdquo; although the trial is not limited to RET Access in the EU:\nOff-label (EC-approved drug, use outside indication) Named patient programs (Everyone.org or Accord Healthcare, EU distributor) Clinical trial (ResQ201A \u0026ndash; requires progression after immunotherapy) Pembrolizumab (Keytruda) \u0026ndash; limited role, but not zero The LIBRETTO-431 trial clearly demonstrated: Selpercatinib alone is superior to chemotherapy + pembrolizumab as first line (84% vs 56% response rate). Pembrolizumab alone has a response rate of only 6-10% in RET+.\nWhen it could still help:\nAfter cryoablation: Tissue destruction + immune activation + systemic pembrolizumab \u0026ndash; the abscopal effect (PEMBRO-RT: 41.7% abscopal response even in cold tumors, with SBRT 8 Gy x 3 + pembrolizumab within 7 days) Combined with vaccines: Vaccines + checkpoint inhibitors \u0026gt; vaccine alone With ANKTIVA: IL-15 activates T lymphocytes, pembrolizumab \u0026ldquo;unblocks\u0026rdquo; them Warning Important risk: Patients who have received immunotherapy (pembrolizumab, nivolumab) have a 13.9% risk of hypersensitivity reaction upon reintroduction of selpercatinib (compared to 3.1% without prior immunotherapy). Treatment sequencing must be carefully planned. The abscopal effect \u0026ndash; treat one lesion, benefit all When you destroy a tumor (through cryoablation, SBRT, or even a vaccine), it releases antigens and danger signals. If the immune system is already activated (through ANKTIVA, vaccine, or checkpoint inhibitor), it can attack distant tumors you did not directly treat.\nThe combination that maximizes the abscopal effect: cryoablation (intact antigen release) + vaccine (specific training) + ANKTIVA (immune amplification).\nOn the horizon: cellular cancer therapies Beyond activating existing NK and T cells in the body, research is advancing toward adoptive cell therapies \u0026ndash; immune cells harvested, genetically modified in the laboratory, and reinfused into the patient.\nCAR-NK (chimeric antigen receptor NK cells): \u0026ldquo;Off-the-shelf\u0026rdquo; NK cells (from donors, not the patient) modified to recognize tumor markers. Advantage: does not require HLA matching, low risk of graft-versus-host disease. Multiple active clinical trials in NSCLC, but none specifically for RET+ TCR-T anti-RET: The only program in the world developing T cells genetically modified to specifically recognize peptides derived from the RET protein. Led by Dr. Alexandre Reuben at MD Anderson (Houston). Preclinical stage \u0026ndash; estimated 3-5 years until clinical trial These therapies are not available now, but represent an important direction for patients who exhaust current options. ANKTIVA remains the nearest available NK activation option today.\nDrug repurposing \u0026ndash; existing medications with anti-cancer potential Some medications approved for decades for other conditions have demonstrated anti-cancer properties in clinical or preclinical studies. They are inexpensive, available, and have well-known safety profiles.\nThe basic principle: As long as Selpercatinib is working, you do not want to add significant toxicity. Drug repurposing focuses on options with low risk and potential supplementary benefit.\nCandidates with evidence Aspirin (in studies, the dose of 100 mg/day with enteric coating was used)\nMechanism: Inhibits TXA2, which forms a \u0026ldquo;platelet shield\u0026rdquo; around circulating tumor cells, protecting them from the immune system. Aspirin removes this shield.\nEvidence: Retrospective study in NSCLC (Chen, Lung Cancer 2020 ): 21% reduction in death risk. Nature 2025 : TXA2/Treg mechanism confirmed.\nWarning Caution: Selpercatinib has a documented 2.3% risk of severe hemorrhage. Aspirin additionally increases bleeding risk. Do not start aspirin without your oncologist\u0026rsquo;s explicit approval, who will evaluate the benefit/risk ratio in your specific case. Propranolol (in studies, 10-20 mg twice daily was used)\nMechanism: Non-selective beta-blocker that reduces adrenergic signaling \u0026ndash; chronic stress stimulates metastasis through beta-adrenergic receptors.\nEvidence: 2025 meta-analysis in lung cancer : distant metastasis-free survival HR 0.67, overall survival HR 0.78.\nPrecaution: Requires prior cardiology evaluation, especially in patients with low resting heart rate.\nRosuvastatin (in studies, doses of 10-20 mg/day were used)\nMechanism: HMG-CoA inhibitor \u0026ndash; blocks the mevalonate pathway, with anti-angiogenic effects and suppression of mutant p53 function. Important: not atorvastatin, simvastatin, or lovastatin, which are processed by CYP3A4 (the same enzyme as selpercatinib \u0026ndash; risk of toxic interaction).\nEvidence: 41% mortality reduction in combination with immunotherapy (JCI Insight 2022 ).\nVitamin D3 (in studies, doses of 4000-5000 IU/day were used)\nEvidence: DKFZ 2025 meta-analysis (14 randomized trials, \u0026gt;100,000 patients): -12% all-cause cancer mortality. Target in studies: 60-80 ng/mL in blood. Optimal dose should be determined by your physician based on your current level.\nMetformin (if indicated for diabetes or pre-diabetes)\nThe strongest level of evidence among all: a randomized trial (JAMA Oncology Japan ) shows progression-free survival 13.1 vs 9.9 months and overall survival 31.7 vs 17.5 months in patients with driver mutations (EGFR+). The benefit is dependent on body mass index \u0026ndash; stronger in overweight patients. It is not prescribed off-label solely for the anti-cancer effect without a metabolic indication.\nWhat to avoid Substance Why Fenbendazole The case study was retracted (January 2026). Risk of hepatotoxicity. The Joe Tippens case was actually enrolled in a pembrolizumab trial (confounding factor) Ivermectin Zero evidence in NSCLC. Interaction with selpercatinib through P-gp Itraconazole Absolutely contraindicated \u0026ndash; strong CYP3A4 inhibitor, increases selpercatinib levels by 2.3x Atorvastatin CYP3A4 substrate \u0026ndash; use rosuvastatin instead High-dose antioxidant supplements May protect tumor cells from treatment effects Important None of these options replace Selpercatinib. They are complementary to standard treatment, with varying levels of evidence. Discuss with your oncologist before adding any medication, including seemingly harmless ones. Your role is not to prescribe, but to come prepared with informed questions. Next-gen RET inhibitors and ADCs \u0026ndash; your backup plan If Selpercatinib is working, why do you need a Plan B? Because resistance will appear at some point \u0026ndash; and when it does, you want to act fast, not search for options.\nWhy resistance occurs Two main mechanisms:\n1. On-target RET mutations (14%): The tumor modifies the RET protein itself, so selpercatinib can no longer bind. Most common: G810R/S/C (solvent front mutations).\n2. Bypass (off-target, 86%): The tumor activates another survival pathway, completely bypassing RET. Most common:\nMET amplification (18.2% \u0026ndash; most frequent and most aggressive, appears on average at 8.4 months) KRAS activation (7.1%) YAP/HER3/EGFR bypass (adaptive, appears early) MAPK reactivation (30% of cases) 3. Lineage plasticity \u0026ndash; the tumor changes identity\nA third, less-known mechanism: under sustained targeted therapy, some adenocarcinomas can transition toward a neuroendocrine phenotype \u0026ndash; the tumor changes what it is, not just how it responds. This was a major theme at AACR 2026 (MSK opening plenary by Charles Sawyers), documented across EGFR, ALK, and other targeted therapy classes. It is driver-agnostic, including RET.\nRB1 gene loss is the strongest predisposing biomarker. Patients with RB1 loss at baseline \u0026ndash; or acquired during treatment \u0026ndash; face a higher risk of this transition. Preclinical data (mostly from prostate cancer, cross-domain) suggests FGFR and JAK inhibitors may reverse lineage plasticity in RB1-deficient tumors, but this is not yet validated in NSCLC.\nClinical implication: If RB1 loss is detected on your NGS or ctDNA (now or later), a rebiopsy at progression becomes essential \u0026ndash; not just switching to a next-generation TKI. Neuroendocrine-phenotype disease responds to different drugs (platinum/etoposide-based regimens, not RET TKIs). Acting on imaging progression without re-confirming tumor biology risks choosing the wrong next treatment. If a transformed tumor expresses the marker DLL3 (common in neuroendocrine disease), a targeted option now exists: tarlatamab (Imdelltra), a DLL3-directed immunotherapy that received full FDA approval in November 2025 for small-cell lung cancer and is being studied specifically in neuroendocrine-transformed NSCLC (trial NCT06788938). This is another reason the rebiopsy matters \u0026ndash; it can reveal a target that changes the whole treatment plan.\nNext-generation RET inhibitors These agents are designed to work where selpercatinib fails \u0026ndash; including solvent front mutations.\nA practical note first: the other approved RET inhibitor, pralsetinib, shares selpercatinib\u0026rsquo;s main resistance mutations \u0026ndash; so simply switching between the two at progression usually does not help. The next-generation agents below are designed specifically for that setting.\nAgent Response rate (ORR) Mutation coverage Brain penetration Status EP0031 (Lunbotinib) 87.1% (pre-treated, ASCO 2026) G810R/S/C Yes Phase 2 pivotal data; NDA filed (China) Vepafestinib 30% (disease control: 80%) G810 + V804 Best in class Phase 1/2 (MARGARET) SY-5007 69.4% G810 Yes Phase 3 (the only one with Phase 3 data) APS03118 Preclinical G810 + V804 + L730 + Y806 Yes Broadest spectrum, Phase 1 EP0031 (Lunbotinib) is currently the most clinically advanced. Pivotal Phase 2 data presented at ASCO 2026 showed, in patients who had already progressed on a first RET inhibitor, an 87% response rate, median progression-free survival of 27.5 months, and no treatment-related deaths (virtually no one had to stop the drug because of side effects \u0026ndash; just 1.2%); it was also active in the brain (intracranial complete response ~30%). An application for approval has been filed in China, and trials are open at European centers (VHIO Barcelona, Gemelli Rome, Christie Manchester, Sarah Cannon London). This is the strongest second-line RET data reported to date.\nADCs (Antibody-Drug Conjugates) A new class of drugs: antibodies that deliver a chemotherapy payload directly to tumor cells, reducing systemic toxicity.\nRelevant for RET+ at progression:\nTelisotuzumab Vedotin (Emrelis) \u0026ndash; targets MET (the most common bypass mechanism). FDA approved 2025. Response rate 35% as monotherapy, 50% in combination. Available in Turkey Datopotamab Deruxtecan (Dato-DXd) \u0026ndash; targets TROP2. FDA approved 2025. Response rate 35.8% in driver-mutated cancers HER3-DXd (Patritumab Deruxtecan) \u0026ndash; targets HER3. Phase 2. Excellent results in brain and leptomeningeal metastases PROTACs \u0026ndash; the future of protein destruction PROTACs do not block the RET protein \u0026ndash; they completely destroy it through the cell\u0026rsquo;s recycling system (the proteasome). If the protein no longer exists, resistance mutations at the binding site become irrelevant.\nQZ2135 (Peking University): active on G810 variants RD-23: independent validation Estimate: 2028+ for clinical trial entry Combinations at progression If resistance appears, drug combination based on the identified mechanism is critical:\nIdentified mechanism Combination MET amplification Selpercatinib + capmatinib (documented CR) or crizotinib (4/4 responded) EGFR/HER3 activation Selpercatinib + afatinib BRAF fusion RET inhibitor + trametinib (near-complete response documented) KRAS mutation Selpercatinib + adagrasib/sotorasib NTRK fusion Selpercatinib + larotrectinib The golden rule: At progression, never stop selpercatinib without an alternative. Continue + add.\nTip Prepare now: Discuss with your oncologist about pre-screening for trials with EP0031 or vepafestinib. You do not have to be eligible today \u0026ndash; but when the time comes, you want to have the relationship established and documentation ready. The path to NED \u0026ndash; eradication strategy NED means No Evidence of Disease \u0026ndash; no evidence of disease. Not a cure (we cannot guarantee that), but the absence of any detectable sign of cancer.\nWhat NED means in practice Both criteria must be met simultaneously and sustained (minimum 6 months):\nNegative PET-CT at all known sites Undetectable ctDNA (\u0026lt;1 copy/mL) on an ultrasensitive platform Is it realistic? Yes. It is not guaranteed, but the data support it:\nSABR-COMET (8 years): 21% progression-free at 8 years \u0026ndash; a cure signal in 1 out of 5 oligometastatic patients LIBRETTO-432: Selpercatinib has curative potential in early stages CML (chronic myeloid leukemia) analogy: 40-60% of patients on imatinib (another TKI) achieve treatment-free remission \u0026ndash; they stop the medication and remain disease-free. RET fusion cancer is not CML, but the model is relevant What an integrated strategy (TKI + local therapy + vaccines + immune support) might realistically achieve. These are not slices of a single pie \u0026ndash; they are different ways of looking at the odds, and they overlap:\n10-20% chance of sustained functional NED (5+ years with no detectable disease) 40-50% chance of long-term control (3-4+ years with minimal disease) In 30-50% of people, the added immune therapies may not produce a measurable immune response \u0026ndash; they still have the TKI working underneath Under 5% net added risk \u0026ndash; the safety profile of these vaccines is excellent Why some disease can survive even when the scans look clean Here is the hard truth behind \u0026ldquo;clean scans are not the same as cured\u0026rdquo;: a small number of cancer cells can survive treatment not by mutating, but by going to sleep. They stop dividing and lie low \u0026ndash; so a TKI (which works best on dividing cells) barely touches them, and the immune system sees almost nothing to attack. Researchers call these drug-tolerant persister (DTP) cells, and they are a likely source of relapse years later.\nUnderneath, these dormant cells switch on DNA-repair and survival programs (and often switch off a gene called RB1). This is increasingly seen as a third front in an eradication strategy \u0026ndash; separate from shrinking the tumor (TKI + local therapy) and from training the immune system (vaccines).\nThis is not yet proven, everyday practice \u0026ndash; it is an active area of research. The emerging idea, highlighted at AACR 2025 (Memorial Sloan Kettering), is to add a drug that specifically hits these sleeping cells during the window just after the best response, when their numbers are lowest. PARP inhibitors and other DNA-repair-targeting drugs are the leading candidates being studied (and connect back to any DNA-repair findings, such as FANCL or BRCA, on your sequencing). For now the practical message is simpler: it explains why staying on monitoring \u0026ndash; the Phase 4 plan below \u0026ndash; matters even when everything looks clear.\nThe 4 phases of the eradication strategy Phase 1: Response and optimization (months 1-3)\nSelpercatinib as main line Complete molecular profiling (WES + RNA-seq + ctDNA baseline) Low-risk drug repurposing (aspirin, rosuvastatin, vitamin D) ctDNA monitoring at 8-12 weeks Phase 2: Consolidation + local therapy (months 4-6)\nPET-CT for re-evaluation Cryoablation/SBRT on residual lesions Biopsy for fresh tumor tissue (vaccines, functional testing) ctDNA pre and post intervention Phase 3: Immune activation (months 7-12)\nImmune activation (ANKTIVA \u0026ndash; lymphocyte recovery) Vaccination (FusionVAC or alternative) with booster at 6-12 weeks Cryoablation provides an immune amplification window ctDNA every 3 months Assessment of specific immune response (ELISpot anti-fusion T cells) Phase 4: TFR evaluation (from month 24)\nIf sustained negative ctDNA + negative PET-CT \u0026gt;12 months Discussion with oncologist about reducing or stopping TKI Intensive monitoring protocol: ctDNA every 3 months If disease returns: resume Selpercatinib (in CML, 96% re-response rate) The \u0026ldquo;Stay Paranoid\u0026rdquo; principle: Even at NED, never stop monitoring Real-world example: Sid Sijbrandij Sid Sijbrandij, co-founder of GitLab, publicly documented his strategy against cancer (osteosarcoma). When doctors told him he had exhausted the standard of care and there were no clinical trials for his situation, he went into \u0026ldquo;Founder Mode\u0026rdquo; \u0026ndash; he assembled a team of physicians and researchers, used AI to analyze medical data, and systematically explored every diagnostic and treatment option beyond standard protocols. The full story is on his blog and at sytse.com/cancer . It is not RET cancer, but it demonstrates that a proactive, informationally aggressive strategy is possible and can generate results beyond average statistics.\nBiobanking \u0026ndash; protect your future options At every biopsy or surgical intervention, explicitly request that a portion of tissue be properly preserved. This simple step can open options that do not exist today.\nWhy it matters Personalized vaccines require tumor tissue (either fresh or frozen) Functional testing (organoids, drug sensitivity) requires living tissue Complete molecular profiling works best on fresh frozen tissue (not just FFPE) If the tumor changes under treatment (and it will change), tissue from each biopsy is a \u0026ldquo;snapshot\u0026rdquo; of disease evolution What to request At every biopsy or intervention:\nFFPE (formaldehyde + paraffin) \u0026ndash; standard, sufficient for most molecular tests. This is done routinely anyway Cryopreservation at -80C \u0026ndash; essential for organoids, dendritic cell vaccines, and high-quality RNA sequencing. Must be explicitly requested Sufficient samples \u0026ndash; not a single fragment. Request 4-8 biopsy cores if possible, distributed between: Pathology (diagnosis, mandatory) Molecular sequencing (WES + RNA-seq) Biobank (-80C, for the future) Vaccine/functional testing (if already planned) Important You cannot do biobanking retroactively. Once tissue has been processed as FFPE only or discarded, the option disappears. Discuss before the intervention, not after. Ask your oncologist or surgeon: \u0026ldquo;Can you also preserve frozen tissue at -80C for future research?\u0026rdquo; ROSE evaluation ROSE (Rapid On-Site Evaluation) means that a pathologist verifies during the procedure whether the biopsy fragments contain viable tumor cells. Without ROSE, you risk freezing tissue that does not contain tumor.\nNot all centers offer ROSE. Ask specifically whether it is available.\nHow to access these options Many of the options described in this article are not available through the standard pathway (oncologist prescription, pharmacy). But that does not mean they are inaccessible. Specific legal mechanisms exist.\nClinical trials The most direct access to new treatments. Treatment is free, monitoring is intensive, and you contribute to advancing knowledge.\nWhere to search:\nClinicalTrials.gov \u0026ndash; search \u0026ldquo;RET fusion NSCLC\u0026rdquo; EU Clinical Trials Register LUNGevity Foundation \u0026ndash; LungMATCH navigator RETpositive.org \u0026ndash; RET-specific database Practical tip: You can be pre-screened for a trial without being eligible today. The relationship with the research center is established before you need it.\nCompassionate use / expanded access New medications that are not yet approved can be accessed for individual patients:\nExpanded Access (USA): FDA Form 3926, approval rate \u0026gt;99%, processing in 48h Heilversuch (Germany): Individual compassionate use procedure, legal basis Sec. 34 StGB. Covers vaccines, experimental drugs, and off-label combinations Named Patient Programs (EU): Through platforms like everyone.org (11,000+ patients served, 100% confirmed delivery) S2 form (EU Cross-Border Healthcare Directive) If you are insured in the EU, you can receive medical treatment in another member state with health insurance authorization. The S2 form (or E112) covers:\nConsultations and second opinions Procedures (cryoablation, biopsy) at specialized centers Treatment that is not available or has excessive waiting times in your country The process: Your oncologist completes the medical justification -\u0026gt; the health insurance body approves -\u0026gt; the external center bills the insurance body, not the patient.\nOff-label (outside indication) Medications approved for another indication, used based on scientific evidence for your situation. Examples: ANKTIVA (EC approved for bladder cancer, used off-label for NSCLC).\nRequires a prescription from the oncologist + documented medical justification.\nTimeline: what is available and when Available NOW 1-2 years 3-5 years Selpercatinib (standard) EP0031 (anticipated approval) Anti-RET PROTACs SBRT / Cryoablation Personalized RET-specific mRNA vaccines Molecular glues targeting fusions ctDNA monitoring (Signatera, Haystack) SY-5007 (anticipated approval) 3rd generation immunotherapies Drug repurposing (aspirin, statins) New ADCs (BL-B01D1, HER3-DXd) Vaccines targeting B cells + T cells FusionVAC (needs fresh-frozen tissue) APS03118 (broad spectrum) Anti-RET cellular therapy (TCR-T) CeGaT CancerNeo (FFPE-compatible) ANKTIVA + vaccine combo trials ANKTIVA (off-label EU) Tedopi/OSE2101 (after approval) IOZK IO-VAC (commercial) Organoids / functional testing BNT116, V940 (clinical trials) Resources RET-specific communities RETpositive.org \u0026ndash; patient community, clinical trials, registries The Happy Lungs Project \u0026ndash; research updates, webinars RET Renegades (Facebook) \u0026ndash; support group LUNGevity Foundation \u0026ndash; LungMATCH navigator, communities Cancer GRACE \u0026ndash; forum for RET+ patients Clinical trial databases ClinicalTrials.gov \u0026ndash; global database EU Clinical Trials Register \u0026ndash; European trials Reference centers for RET+ NSCLC Memorial Sloan Kettering (New York) \u0026ndash; Dr. Alexander Drilon, the world\u0026rsquo;s largest RET registry Gustave Roussy (Paris) \u0026ndash; the largest oncology center in Europe, active RET research programs MD Anderson (Houston) \u0026ndash; Dr. Vivek Subbiah, RET combination research IEO Milan \u0026ndash; real-world experience with RET+ in a European context What to do now Request complete molecular profiling (WES + RNA-seq) if you have not already been tested beyond the standard NGS panel Discuss ctDNA monitoring with your oncologist \u0026ndash; integrate it into the surveillance plan Ask about consolidative local therapy (SBRT/cryoablation) if you have residual lesions Explore eligibility for clinical trials with vaccines or next-generation RET inhibitors At every future biopsy, request biobanking \u0026ndash; frozen tissue at -80C in addition to standard FFPE Prepare your backup plan \u0026ndash; discuss pre-screening for trials with EP0031 or vepafestinib Discuss these options with your oncologist \u0026ndash; come prepared with specific questions for your next consultation The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/cancer-types/lung-ret-fusion-proactive-strategy/","summary":"\u003cp\u003e\u003cstrong\u003eIf you are reading this, it means you have made it through the first few months.\u003c/strong\u003e You have the diagnosis, you have the treatment, you understand the basics. Selpercatinib is working \u0026ndash; the tumor has probably shrunk, you probably feel better than you expected.\u003c/p\u003e\n\u003cp\u003eAnd yet, the question that never goes away: \u003cstrong\u003ehow long will it last?\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis guide is for you. Not to scare you, but to show you that there are options your oncologist does not always mention \u0026ndash; not because they are irrelevant, but because they are new, specialized, and not (yet) part of standard protocols. Your oncologist remains the central piece of your treatment. This guide gives you the tools to have a more informed conversation with them.\u003c/p\u003e","title":"RET Fusion Lung Cancer: Proactive Strategy -- Beyond Standard Treatment"},{"content":"In short: I am the patient behind this blog. In this first story I tell you how I went, in a few weeks, from back pain to a complete diagnosis of stage IV lung cancer \u0026ndash; and what I learned along the way, so it can be a little easier for you.\nWho I am I\u0026rsquo;m not going to use my name here. Not because I\u0026rsquo;m ashamed, but because this blog is about you, the reader, not about me. The message matters, not the messenger.\nI\u0026rsquo;m 42 years old, I\u0026rsquo;m from Romania, from Bucharest, and I work as a software engineer. I have never smoked. I don\u0026rsquo;t drink. I eat healthy, I\u0026rsquo;ve always been in good physical shape and lived a normal, balanced life.\nI say this not to brag, but because that is exactly what made the diagnosis so hard to accept. Cancer, in all of our minds, happens to other people. Not to a young, healthy person with no classic risk factor at all.\nAnd yet.\nIt started with back pain Around September 2025 I started having back pain, in the lower-back area. Nothing dramatic at first \u0026ndash; the kind of pain anyone would put down to bad posture or stress.\nI had a lumbar MRI at a private clinic. The official result spoke only of degenerative disc problems. Nothing worrying. On the basis of that result I went through weeks of physiotherapy, kinesiotherapy, massage, TENS.\nBut the pain wasn\u0026rsquo;t going away. On the contrary, it was getting worse.\nMuch later I understood how much a second opinion on the images matters when a pain won\u0026rsquo;t go away. It\u0026rsquo;s a lesson that still hurts \u0026ndash; I wish I\u0026rsquo;d known it sooner: a \u0026ldquo;clean\u0026rdquo; result shouldn\u0026rsquo;t be the last word when your symptoms say otherwise.\nImportant If you have pain that won\u0026rsquo;t go away or that gets worse despite treatment, insist. Ask for a second opinion on the images. A \u0026ldquo;clean\u0026rdquo; report doesn\u0026rsquo;t always mean everything is fine. January 2026: the MRI that changed everything Because the pain was getting worse, in January 2026 I went to another clinic. This time they recommended an MRI of the entire spine, not just the lower-back area.\nThat\u0026rsquo;s how it showed up. At the level of the T11 vertebra, a tumor that took up almost one and a half vertebrae, that pushed into the canal between the vertebrae and pressed on the nerves.\nIt was a shock. For me, for my wife, for the whole family. I was young, a non-smoker, with no vices, with a healthy lifestyle. And yet, all of a sudden, we were talking about cancer.\nThe first void: I knew absolutely nothing At that moment I knew nothing about cancer. Nothing.\nYou search the internet and you run into dozens, hundreds of variants, options and scenarios, each one more frightening than the last. But without knowing exactly what you have, none of it helps you. The first thing you\u0026rsquo;re missing, and the most important, is a precise diagnosis.\nThat was our first lesson: until you have a complete diagnosis \u0026ndash; including at the molecular level \u0026ndash; you can\u0026rsquo;t make any good decision. Everything else is noise.\nThe Romanian medical system: my experience Here I have to be honest, because the purpose of this blog is to be useful, not to be polite. I encountered, sometimes on the same day and in the same building, both the warmest people and the most painful lack of empathy.\nWith the MRI referral and the CD in hand, after several pieces of advice from family, I ended up at the emergency room at Floreasca Hospital. There, a man at the emergency desk came down on me pretty hard: what was I doing there with back pain, since he too has back pain and doesn\u0026rsquo;t come to the emergency room for that.\nAt my insistence, he did eventually agree to call a neurosurgeon. The neurosurgeon took my CD, looked at the images and confirmed what I feared: it was cancer. The spinal lesion looked like a metastasis \u0026ndash; a sign that there was a primary tumor somewhere else.\nFloreasca doesn\u0026rsquo;t have an oncology department, so I was referred to a hospital that does \u0026ndash; the University Hospital or Elias.\nI went to Elias. At the emergency room they told me, correctly, that this wasn\u0026rsquo;t an emergency matter and that I needed an oncologist to characterize the tumor. But just as I was leaving, someone told me that oncology was open and that I could ask there too.\nI waited in a small queue. Inside there were two people who turned out to be incredibly empathetic. They called the oncologist, got me a referral through the Romanian national health insurance (CAS) for a CT scan, and found a slot the very next day, at a partner clinic. In that moment \u0026ndash; and now, looking back \u0026ndash; it seemed incredible to me.\nThat was the moment that opened my path to living with cancer. Because, as I quickly learned, it isn\u0026rsquo;t a fight \u0026ndash; it\u0026rsquo;s a coexistence.\nThe next day\u0026rsquo;s CT showed the full picture: I had lesions in the lungs, in the spine and in the lymph nodes.\nIn the following days, my wife and family mobilized \u0026ndash; dozens of phone calls, looking for options, appointments, MRIs with contrast of the entire spine and of the head. I needed someone to give me the referral slips.\nI made an expensive appointment with oncology at Sanador, but there they told me they couldn\u0026rsquo;t give me the referrals, because it wasn\u0026rsquo;t yet a confirmed case.\nSo I went back to Elias, where the evening before I had found those wonderful people, hoping to get the referrals too. Unfortunately, someone else was on duty. They almost scolded me for daring to bother them without an appointment, two days in a row \u0026ndash; something \u0026ldquo;unacceptable\u0026rdquo; for their hospital.\nIt was very ugly. Something I wouldn\u0026rsquo;t wish on anyone, especially on the second day after finding out you have cancer. I insisted and, in the end, I got those referral slips.\nLooking back, those investigations would have cost me a few hundred euros anyway if I\u0026rsquo;d done them on my own. Now, after tens of thousands of euros in expenses have piled up, I understand that every penny saved counts. Those people didn\u0026rsquo;t know that. And, unfortunately, they didn\u0026rsquo;t even stop to consider it.\nThe turning point: Anadolu, Istanbul A few days before the day scheduled for the lymph node biopsy, someone sent me a link about the Anadolu hospital in Turkey.\nI called them on a Saturday night, late. A warm and helpful person answered, and explained their protocol: before anything else, you do a PET-CT, so you enter their workflow of investigations. This was something no one had told me in Romania, even though I was heading toward a biopsy.\nTip Why does a PET-CT before a biopsy matter? A PET-CT shows you exactly where the cancer is active. That way, the biopsy can be taken from a place where the disease is definitely active, not from a place where the result might come back inconclusive \u0026ndash; and you\u0026rsquo;d wait ten days for nothing, at a stage where progression is exponential. And the speed was unimaginable. The people at Anadolu told me they had a free slot for a PET-CT on Wednesday. I told them I could come on Sunday evening. I arrived in Istanbul on Sunday evening, on Monday morning they called me that a slot had opened up, on Monday I had the PET-CT, and by Tuesday I already had the results.\nFor comparison: for some MRIs done in Romania, the official interpretations came after a week and a half, even two weeks. The lucky thing was that the people in Istanbul are extremely professional. You go with the CD and they do their own interpretation on the spot, for a reasonable sum (around 150 euros per CD). These are people who do only oncology, so they read the images with the eye of someone who has seen hundreds of cases like yours. It\u0026rsquo;s money worth investing.\nThe biopsy and the molecular tests The decision about how to do the biopsy wasn\u0026rsquo;t made by a single doctor. At Anadolu, a tumor board takes place every day \u0026ndash; a meeting where doctors from different specialties (radiologist, interventional radiologist, radiation oncologist, oncologist, neurosurgeon, neurologist) discuss, one by one, each individual case. Not just mine \u0026ndash; that\u0026rsquo;s how they work with every patient. For my case, the conclusion was that the simplest option was a CT-guided needle biopsy, directly into the lung.\nThe procedure itself took a few minutes. I didn\u0026rsquo;t even realize when it happened; the preparation took longer than the biopsy itself.\nThen I was offered two molecular testing options: a smaller panel, with a result in three days, and a larger, complete one, in ten days. Because I\u0026rsquo;m a non-smoker, there was a high chance I\u0026rsquo;d fall into one of the mutations covered by the small panel, so I chose the fast option.\nIn three days I had the answer: lung cancer of the adenocarcinoma type, RET fusion-positive, confirmed by two different methods. By the end of five days I already had the complete diagnosis, including the molecular one. Unbelievable.\nWarning A lesson I learned too late: ask, if possible, to have part of the biopsy tissue preserved frozen (\u0026ldquo;fresh-frozen\u0026rdquo;), not only in paraffin. Living tissue, properly preserved, can open the door to future treatments. I didn\u0026rsquo;t know this at the time and didn\u0026rsquo;t ask. For me it\u0026rsquo;s too late, but for you it could matter enormously. Radiotherapy to the spine Because the tumor at T11 took up almost one and a half vertebrae, there was a real risk that the vertebra would collapse or press even harder on the nerves. At Anadolu I had targeted radiotherapy to the spine, with a CyberKnife machine that we don\u0026rsquo;t have back home \u0026ndash; three sessions, over three consecutive days.\nIt was one of the best decisions. I did it right at the beginning, before any treatment with pills, in exactly the right window. After the radiotherapy, the back pain disappeared.\nOne moment has stayed with me. The tumor was very close to the spinal cord, and the radiation oncologist had to decide on the dose. He left the room, went to his colleague the interventional radiologist, and they looked at the images together, to make sure they could irradiate without affecting the spinal cord. He came back, confirmed it, and everything was fine.\nThat level of collaboration between doctors, in real time, was something I hadn\u0026rsquo;t seen in Romania, even though unfortunately I had interacted with quite a few doctors. And everything lives in a shared data system: anyone who opens your file sees your current condition and the entire history written by the others.\nThe treatment: a smart pill Until you know exactly what you have, you don\u0026rsquo;t know how it\u0026rsquo;s treated either. And we had just found out: RET fusion-positive.\nThe oncologist told me it was very good news \u0026ndash; there\u0026rsquo;s a targeted treatment, a smart pill from the class of TKI inhibitors (in my case, selpercatinib / Retsevmo). \u0026ldquo;Unfortunately,\u0026rdquo; he added, \u0026ldquo;it\u0026rsquo;s a bit more expensive.\u0026rdquo;\nI left the office and we quickly looked online to see how much it costs. I was expecting 1,000, 2,000, maybe 3,000 euros. As we searched, somehow, with the help of artificial intelligence, a figure appeared: 10,000 euros a month. I froze. (The amounts I give here are from my experience, approximate.)\nThe next day, before we left for home, we wanted to order the first month of treatment, so we\u0026rsquo;d have something to start with. They made a few phone calls and it turned out it cost 5,100 euros there. It seemed fantastic to us \u0026ndash; we were already relieved to be paying almost half of the figure from the internet.\nBack home, within two days, I registered with an oncologist in Bucharest. He gave me news that seemed wonderful: the pills had been approved in Romania as reimbursed. He immediately submitted the request to CAS, electronically.\nExcept the news wasn\u0026rsquo;t quite like that. Two weeks later, when he was supposed to give me the referral, he saw that the request had been rejected. The reason: in Romania, the medication was approved only for second line of treatment, and I was on first line.\nSo I had to buy the second month on my own as well. In Romania it cost 3,400 euros \u0026ndash; even less than in Turkey.\nThe absurd part is that it\u0026rsquo;s exactly for first line that it\u0026rsquo;s now officially recommended, both by the manufacturer and at the European level, because the results are far better, scientifically proven. It\u0026rsquo;s just that the internal procedure in Romania hadn\u0026rsquo;t been updated yet.\nThat\u0026rsquo;s when I found out there\u0026rsquo;s a legal route. A colleague put me in touch with some lawyers, who immediately understood what it was about: an emergency court order (a presidential-ordinance procedure) \u0026ndash; a legal route to access a drug already approved at the European Union level but not yet reimbursed locally. In two to three weeks I had the result \u0026ndash; I had won. The whole process cost me around 2,000 euros.\nSince then, through this route, I receive the treatment for free every month. Practically, I paid out of pocket only for the first two months.\nImportant If a treatment is approved and recommended at the European Union level, but is not yet approved locally in Romania, you can use the emergency court order mechanism (the presidential-ordinance procedure). It\u0026rsquo;s not a medical problem \u0026ndash; it\u0026rsquo;s only a matter of updating the local recommendations. And a patient should not have to put their life at risk because of the system\u0026rsquo;s slowness. The first results Here\u0026rsquo;s the part I wish I could have read myself back then: real, honest numbers.\nI had a PET-CT at diagnosis, in January, and again at three months, in April. The comparison between the two:\nThe lung tumor: the metabolic activity (SUVmax) dropped from 19.2 to 2.0 \u0026ndash; that is, almost completely, down to close to the level of healthy tissue. The spinal tumor (T11): from 20.3 to 2.8, after radiotherapy and treatment. The lymph nodes: from a large mass, the largest one dropped to under 10 mm, and their activity decreased a lot. The pelvic lesion (iliac crest): showed no metabolic activity at all anymore. The official conclusion was \u0026ldquo;marked response to treatment\u0026rdquo;. It doesn\u0026rsquo;t mean I\u0026rsquo;ve beaten the disease \u0026ndash; at stage IV we\u0026rsquo;re talking about control, careful monitoring and steps forward. But after months of fear, to see those numbers dropping is a form of hope that I can\u0026rsquo;t describe in words.\nWhy I write I write because, when I needed it most, I was missing exactly this kind of information: clear, honest, from someone who had been through it.\nI\u0026rsquo;d like this blog to become, over time, a place where you can find not only my story, but also comparative data from other patients, told honestly and transparently. If you are a patient or a caregiver and want to share your experience, write to us. Together we can make the road a little easier for those who come after us.\nThat\u0026rsquo;s enough for a first article. I\u0026rsquo;ll come back with others, more practical, about each step in turn.\nWhat to do now Ask, as early as possible, for complete molecular testing (NGS). For many types of cancer, the mutation that\u0026rsquo;s found completely changes the treatment. Ask about a PET-CT before the biopsy, so the sample is taken from a place that\u0026rsquo;s definitely active. Ask whether frozen (\u0026ldquo;fresh-frozen\u0026rdquo;) tissue from the biopsy can be preserved \u0026ndash; it may open the door to future treatments. Ask for a second opinion, ideally at a center specialized only in oncology, with a tumor board. Check your reimbursement rights and don\u0026rsquo;t accept a bureaucratic refusal as the final answer. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/blog/my-story/","summary":"\u003cp\u003e\u003cstrong\u003eIn short:\u003c/strong\u003e I am the patient behind this blog. In this first story I tell you how I went, in a few weeks, from back pain to a complete diagnosis of stage IV lung cancer \u0026ndash; and what I learned along the way, so it can be a little easier for you.\u003c/p\u003e\n\u003chr\u003e\n\u003ch2 id=\"who-i-am\"\u003eWho I am\u003c/h2\u003e\n\u003cp\u003eI\u0026rsquo;m not going to use my name here. Not because I\u0026rsquo;m ashamed, but because this blog is about you, the reader, not about me. The message matters, not the messenger.\u003c/p\u003e","title":"My story: from back pain to a complete cancer diagnosis in ten days"},{"content":"If your cancer has spread to your bones, you probably already know denosumab by its steady monthly rhythm, or by its brand name, Xgeva. It\u0026rsquo;s a small injection that quietly protects your skeleton, and for many people it becomes part of life for a long time.\nThat is exactly why the details are worth understanding: what it actually does, the blood tests needed before every injection, the welcome shift from a monthly injection to one every three months, the step-down ladder your doctors may follow, and the safety rules that protect you. In this guide we added two things many materials leave out: who the \u0026ldquo;rebound\u0026rdquo; risk on stopping actually applies to (it is not the same for everyone) and how that risk can be tracked through blood tests. None of this replaces your oncology team, who decide your dosing schedule; the information is here so you can follow what\u0026rsquo;s happening and ask sharper questions.\nWhat denosumab is Denosumab is a monoclonal antibody, a lab-made protein, that blocks a body signal called RANKL. RANKL switches on osteoclasts, the cells that dissolve bone. When cancer reaches bone, it hijacks this signal to eat away at the skeleton. By switching RANKL off, denosumab calms that bone destruction. It is given as an injection under the skin (120 mg), and it works the same way no matter which cancer has spread to the bone.\nTip The same drug also exists in a lower dose (Prolia, 60 mg) for osteoporosis. This guide is about the cancer dose, Xgeva 120 mg, which is stronger and given more often. Keep the difference in mind when you read about denosumab: much of the research on stopping comes from the osteoporosis world, with the low dose, in a different population (see below). When it\u0026rsquo;s used In cancer, denosumab is used when there are bone metastases from a solid tumour, to prevent skeletal-related events, the serious bone complications:\nfractures from little or no injury, compression of the spinal cord, needing radiotherapy or surgery to a bone, dangerously high blood calcium (hypercalcaemia). The main alternative is a bisphosphonate such as zoledronic acid (Zometa). Both protect bone well. They differ in a few trade-offs: denosumab is more potent and needs no kidney dose-adjustment, but its effect is reversible (which matters hugely if it is ever stopped, see the safety section); zoledronic acid does not cause a rebound when stopped, but is limited in poor kidney function.\nThe blood tests before every injection Denosumab pulls calcium into bone, so it can push your blood calcium down, sometimes dangerously far. That is why you should be topped up on calcium and vitamin D and have a few values checked before each dose:\nBlood test Why it matters Calcium (blood level) Denosumab can cause low calcium; it must be in range before each injection Vitamin D (25-OH-D) Low vitamin D makes low calcium worse; it should be sufficient (about ≥30 ng/mL) Magnesium If magnesium is low, calcium is very hard to correct PTH (parathyroid hormone) Helps your team understand how your body is handling calcium Kidney function (creatinine / eGFR) Severe low calcium is more likely when kidneys work poorly. Note: some cancer medicines make the usual creatinine estimate read falsely low; ask whether a cystatin C based estimate is more accurate for you. Important Take your calcium + vitamin D every day throughout treatment, unless your doctor says otherwise. This is not optional; it is exactly what keeps the injection safe. After your first doses, calcium is often re-checked around day 7-14. Report any tingling, numbness, muscle cramps or spasms the same day. (Lab reports show calcium in a few ways; ask your team which value they track for you: total, ionised, or \u0026ldquo;corrected\u0026rdquo;.) From every 4 weeks to every 12 weeks For years, denosumab was given every 4 weeks. We now have strong evidence that, after an initial loading phase of about 4 monthly doses, switching to every 12 weeks protects bone just as well, with fewer side effects and far fewer injections.\nThe pivotal trial, REDUSE (SAKK 96/12), a phase 3 randomised trial in about 1,380 patients with bone metastases from breast or prostate cancer, found every-12-weeks non-inferior to every-4-weeks for symptomatic skeletal events (hazard ratio 1.04, 90% CI 0.91-1.20), while side effects dropped (REDUSE, Journal of Clinical Oncology 2026 ):\nEvery 4 weeks Every 12 weeks Bone protection reference just as good (HR 1.04) Low calcium (any grade) ~46% ~30% Jaw osteonecrosis (ONJ) ~8.5% ~6.9% Injections per year ~13 ~4 What this means for you: the same injection, same dose, just less often. Fewer clinic visits, a lower risk of low calcium and jaw problems, and far fewer injections over the years (which matters, because some risks add up dose by dose). The switch is not automatic everywhere; after your loading doses, ask your oncologist whether you qualify to move to every 12 weeks.\nTip REDUSE studied breast and prostate cancer. Because denosumab works the same way in every cancer, many oncologists apply the every-12-weeks approach to other solid tumours (such as lung) too, even though formal guidelines are still catching up. Keep one important difference in mind: REDUSE showed you can space out the injections, not that you can stop them completely. Those are two different questions. The Cheung de-escalation ladder Beyond the move to every 12 weeks, some patients whose bone disease is well-controlled may step down further over time. This idea is informed by the framework of Cheung and colleagues (The Oncologist, 2022 ), who set out how denosumab might be de-escalated or stopped in cancer. One of their core principles: once you have had more than a couple of doses, doctors try hard to avoid simply stopping, because of the rebound risk described below. The rungs below combine that thinking with the REDUSE schedule.\nThink of them as rungs you step down only as long as your disease stays controlled, always under your oncologist\u0026rsquo;s direction:\nLoading, every 4 weeks (about 4 doses). Monthly injections to fully \u0026ldquo;switch off\u0026rdquo; bone breakdown. Maintenance, every 12 weeks. The main, evidence-based step-down (REDUSE). Same dose, given every 3 months. Extension, about every 16 weeks. In selected, very stable patients, the gap may be stretched a little further, with closer monitoring. This is at the edge of the evidence; no completed trial has confirmed this step. Conditional stop, with a bisphosphonate \u0026ldquo;bridge.\u0026rdquo; Only in selected patients, with durably controlled disease, and never alone: when stopping, your team schedules a dose of zoledronic acid about 6 months after the last denosumab injection, plus blood monitoring (see below), to prevent rebound. Surveillance only. Off denosumab, with continued scans and blood tests; treatment restarts immediately if any sign of bone activity returns. Rungs 3-5 involve careful criteria and judgement; they are clinician decisions, made for each person individually. The ladder can also be stepped back up at any time if the disease reactivates.\nWho the rebound risk actually applies to The most important thing to understand about stopping denosumab is the rebound phenomenon: because the drug\u0026rsquo;s effect is reversible, if it is stopped without a plan, bone breakdown can come back with force after a few months and can lead to spontaneous spine fractures. But this risk is not the same for everyone, and many materials present it as if it were. Here is what the evidence shows about who is at highest risk:\nThe rebound risk is HIGHER if you:\nhave already had a vertebral (spine) fracture (by far the strongest predictor), have osteoporosis or low bone density at the start of treatment, have received denosumab for many years (a large \u0026ldquo;suppression\u0026rdquo; reserve that unloads on stopping), are postmenopausal or on a treatment that lowers hormones (anti-hormonal therapy for breast or prostate cancer). The risk tends to be LOWER (but never zero) if you have none of the above factors: no prior vertebral fractures, normal bone density, short exposure, no hormonal deprivation.\nWarning You can\u0026rsquo;t assess your own risk. Only your team can weigh the factors that truly matter: whether you have had vertebral fractures (sometimes \u0026ldquo;silent\u0026rdquo;, found only on imaging), your bone density (a DXA test measures it), and how long you have been on denosumab. Two honest warnings, true regardless of your profile: the studies linking \u0026ldquo;few doses\u0026rdquo; to lower risk come from osteoporosis, and in a recent cancer study patients with fewer doses paradoxically had more bone events after stopping (probably because they had stopped before the disease was controlled). And a bone that has been irradiated (for example a vertebra treated with radiotherapy) is a local weak link that blood tests cannot \u0026ldquo;see\u0026rdquo;. It can be tracked through blood tests The good news, and the answer to a question many patients ask: rebound usually does not come like a bolt from the blue. It is preceded by a signal we can measure in the blood.\nThere are two bone turnover markers that show how fast bone is being \u0026ldquo;resorbed\u0026rdquo; and rebuilt:\nCTX (or beta-CrossLaps): how fast bone is dissolving, P1NP: how fast bone is being rebuilt. After denosumab is stopped, these markers don\u0026rsquo;t simply return to normal: they jump above the starting value (an \u0026ldquo;overshoot\u0026rdquo;), which begins at around 3 months and peaks at about 6 months. Rebound fractures, when they occur, cluster later, at 8-16 months from the last dose. In other words, if you track CTX every few months after stopping, you often get a warning window before the fracture window, time in which your team can step in with a bisphosphonate dose (zoledronic acid).\nImportant Monitoring helps, but it is not perfect, and it is fair to know the limits: in some people the marker can stay almost normal at first, and a few fractures may appear before the CTX peak. And, as we said, blood tests do not \u0026ldquo;see\u0026rdquo; a local weak point (for example an irradiated vertebra). That is why the golden rule, if denosumab has been stopped, is: any new or severe back pain = urgent imaging check (MRI), without waiting for the blood tests. The markers are an extra warning system, not a guarantee. Safety, the rules that matter Warning Stopping denosumab is your team\u0026rsquo;s decision, never one made on your own. And pausing a dose for a safety reason (such as low calcium) is not the same as stopping. Unlike bisphosphonates, denosumab\u0026rsquo;s effect is reversible: stopped without a plan, it can trigger a rebound of bone breakdown after 6-9 months and spontaneous spine fractures, sometimes in people who felt perfectly well. Stopping can be considered in selected patients, with favourable features (oligometastatic disease, a deep and durable response to treatment), usually after a period of sustained control, per ESMO guidance . But even then it is done in a planned way: with a bisphosphonate bridge (zoledronic acid) about 6 months after the last dose, and with bone marker monitoring (bridging protocol, ECTS ). Rebound is well documented, including in cancer patients (case report ). The jaw (osteonecrosis of the jaw, ONJ, the localised death of jawbone): see a dentist first. Have a dental check-up and any needed dental work done before starting, keep up good oral hygiene, and tell every dentist that you are on denosumab. Plan non-urgent extractions carefully. The risk rises with the number of doses, another reason the every-12-weeks schedule helps.\nLow calcium. Keep taking your calcium + vitamin D, and report any tingling or cramps (see the blood-test section above).\nKidneys. Kidney function is checked before dosing; very poor kidney function raises the low-calcium risk.\nVascular safety, calcium and vitamin D over the long haul Because denosumab makes daily calcium and vitamin D essential, people who take it for years reasonably ask: could all that calcium harm my heart or arteries?\nThe evidence-based answer is reassuring: in generally healthy adults, calcium from food and supplements, kept within the recommended daily upper limit (about 2,000-2,500 mg/day in total), has no proven link to heart or blood-vessel disease (National Osteoporosis Foundation \u0026amp; American Society for Preventive Cardiology guideline, Annals of Internal Medicine 2016 ). The practical takeaways:\nGet calcium from food first, and use supplements to reach, not exceed, your target. Don\u0026rsquo;t mega-dose. More is not better; stay under the upper limit. Keep vitamin D sufficient; it helps your body use calcium properly. Set your calcium target with your team, especially if you have kidney or heart conditions. Tip Some clinicians also discuss vitamin K2, on the idea that it helps direct calcium into bone rather than into arteries. The evidence for this is not established; don\u0026rsquo;t add it on your own, raise it with your team if you\u0026rsquo;re interested. Questions worth asking your oncologist After my loading doses, can I move to every 12 weeks? Often, yes. After about four monthly loading doses, the REDUSE trial showed that every-12-weeks protects bone just as well as every-4-weeks, with fewer side effects. It does not happen automatically everywhere, so ask your oncologist whether you qualify once your loading doses are done.\nWhat is my personal rebound risk, if we ever consider stopping? It depends on your profile, not on a universal number. Ask your team whether you have had any vertebral fracture (even a \u0026ldquo;silent\u0026rdquo; one), how your bone density looks (a DXA test shows it), and how long you have been on denosumab. These things matter far more than age or sex. The answers decide whether stopping is a reasonable option for you, and how close the monitoring needs to be.\nAre my calcium and vitamin D checked before each injection, and am I on the right supplements? They should be. Because denosumab can lower blood calcium, your team should confirm your calcium (and ideally vitamin D, magnesium and kidney function) are in range before each dose, and you should take daily calcium + vitamin D throughout treatment. If you are unsure, ask what your last levels were and exactly which supplements and doses you should be taking.\nHave I had a dental check before starting, and is dental work planned safely? A dental check-up and any needed dental work should ideally be done before your first dose, because denosumab slightly raises the risk of osteonecrosis of the jaw. Keep good oral hygiene, tell every dentist that you are on denosumab, and plan any non-urgent extractions together with your oncology and dental teams.\nIf we ever consider stopping, what is the plan to protect my spine (the bridge and the monitoring)? Denosumab should never be stopped abruptly and alone; stopping without a plan can trigger rebound spine fractures about 6-9 months later. If stopping ever becomes appropriate, ask what the concrete plan is: the bisphosphonate bridge (zoledronic acid) about 6 months after the last dose, bone marker monitoring (CTX, P1NP) after stopping, and the rule that any new back pain means an urgent imaging check.\nAm I taking the right amount of calcium, enough for safety, but within the recommended limit? The aim is enough calcium and vitamin D to keep the injection safe, without exceeding the recommended daily upper limit (about 2,000-2,500 mg/day in total, from food plus supplements), an amount considered safe for your heart and blood vessels. Favour food sources, use supplements to reach (not exceed) your target, and let your team set the right amount for you.\nWhat to do now Take your calcium + vitamin D every day, throughout treatment. This is what keeps the injection safe. Before every dose, make sure your calcium has been checked (ideally also vitamin D, magnesium, kidney function). Report tingling, numbness or cramps the same day. Have a dental check-up before starting, and tell every dentist that you are on denosumab. After your loading doses, ask about moving to every 12 weeks (just as effective, with fewer side effects). Never stop denosumab on your own. If stopping is discussed, ask about the plan to protect your spine: the bisphosphonate bridge at ~6 months plus bone marker monitoring (CTX/P1NP), and remember the rule \u0026ldquo;new back pain = urgent MRI\u0026rdquo;. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/treatment/denosumab/","summary":"\u003cp\u003e\u003cstrong\u003eIf your cancer has spread to your bones, you probably already know denosumab by its steady monthly rhythm, or by its brand name, Xgeva.\u003c/strong\u003e It\u0026rsquo;s a small injection that quietly protects your skeleton, and for many people it becomes part of life for a long time.\u003c/p\u003e\n\u003cp\u003eThat is exactly why the details are worth understanding: what it actually does, the \u003cstrong\u003eblood tests needed before every injection\u003c/strong\u003e, the welcome shift from a \u003cstrong\u003emonthly\u003c/strong\u003e injection to one \u003cstrong\u003eevery three months\u003c/strong\u003e, the step-down ladder your doctors may follow, and the safety rules that protect you. In this guide we added two things many materials leave out: \u003cstrong\u003ewho the \u0026ldquo;rebound\u0026rdquo; risk on stopping actually applies to\u003c/strong\u003e (it is not the same for everyone) and \u003cstrong\u003ehow that risk can be tracked through blood tests.\u003c/strong\u003e None of this replaces your oncology team, who decide your dosing schedule; the information is here so you can follow what\u0026rsquo;s happening and ask sharper questions.\u003c/p\u003e","title":"Denosumab: From Monthly to Every 3 Months, and How to Stop It Safely"},{"content":"In short: I\u0026rsquo;m the patient behind this blog. Five months after diagnosis, my treatment is going well \u0026ndash; and that\u0026rsquo;s exactly why I found myself asking a question I didn\u0026rsquo;t expect: what do you do with good news, when you know it won\u0026rsquo;t last forever? This article is about what I\u0026rsquo;ve understood, from the inside, about the difference between \u0026ldquo;standard treatment\u0026rdquo; and personalized medicine \u0026ndash; and about the options I\u0026rsquo;m exploring now, while I have a good window.\nWhere I am now I have stage IV lung cancer, with a genetic particularity called a RET fusion. Since February 2026 I\u0026rsquo;ve been taking a targeted pill \u0026ndash; an inhibitor from the TKI class (in my case, selpercatinib) \u0026ndash; and, after the first few months, the response has been very good. (You can read how it all began here .)\nThe main tumor in my lung has almost disappeared in terms of activity, the lesion on my spine \u0026ndash; treated early on with targeted radiotherapy \u0026ndash; has quieted down, and one of the metastases is no longer visible. One residual area has remained \u0026ndash; a lymph node that has shrunk a lot, but not completely.\nIt\u0026rsquo;s not a cure. In stage IV we don\u0026rsquo;t say \u0026ldquo;I won.\u0026rdquo; We say the disease is, for now, under control. And this is where the part I want to write about begins.\n\u0026ldquo;Standard of care\u0026rdquo;: the treatment that works now There\u0026rsquo;s a term I heard a lot after diagnosis: standard of care. It means, simply put, the treatment officially recommended for your type of cancer, the proven and approved one, the one any oncologist will offer you.\nFor me, the targeted pill is standard of care. And it\u0026rsquo;s a good standard: for RET fusions, these pills have completely changed the prognosis compared to classical chemotherapy.\nBut standard of care comes with a truth that\u0026rsquo;s better understood early than late.\nIn advanced cancer, at best, the standard treatment is something that works now. Not for life. In the long run \u0026ndash; and often sooner than we\u0026rsquo;d like \u0026ndash; the cancer finds a way around the pill. What\u0026rsquo;s called resistance appears, and after it, progression. The question isn\u0026rsquo;t whether, but when.\nAnd progression can come in several forms: gentler, more aggressive, or much more aggressive. There\u0026rsquo;s no way to know in advance which one it will be.\nThis isn\u0026rsquo;t pessimism. It\u0026rsquo;s just the correct map of the terrain. And precisely because I see it this way, I try to understand what I might do with the time I have now. I don\u0026rsquo;t have any certainty \u0026ndash; I ask myself questions and see where they lead.\nPersonalized care, personalized medicine: they\u0026rsquo;re not the same thing Here I needed some time to understand a few nuances that, at first, got jumbled together in my head.\nStandard of care is the protocol: what is normally done for your cancer.\nPersonalized care is something else. It means the way you, together with your doctor, understand your exact situation \u0026ndash; your risks, your values, what you\u0026rsquo;re willing to try \u0026ndash; and make the decisions together, not on autopilot. It\u0026rsquo;s more an attitude than a technology.\nPersonalized medicine is the actual technology: treatments chosen based on the exact biology of your tumor. The molecular tests that find the mutation, the targeted pill that hits exactly that mutation, and \u0026ndash; increasingly \u0026ndash; therapies built almost to your measure: genetic, molecular, immunological.\nIn recent years, this field has evolved enormously. Ten years ago, a diagnosis like mine meant, broadly, chemotherapy for everyone. Today, the fact that my tumor has a certain genetic fusion gives me a pill that targets exactly that defect. That\u0026rsquo;s personalized medicine \u0026ndash; and it has already given me months \u0026ndash; potentially, years \u0026ndash; of good life.\nThe important part: personalized medicine doesn\u0026rsquo;t stop at the pill I take now.\nWhy it matters, especially in stage IV I\u0026rsquo;m not writing this to give advice \u0026ndash; I\u0026rsquo;m in no position to lecture anyone. I\u0026rsquo;m writing it because I\u0026rsquo;m sharing it with you, the way I would have wished someone had shared it with me when I needed it.\nEvery patient is different. For many people, the best choice is to trust their doctor and follow the standard treatment, without burdening their mind with everything that might come next. It\u0026rsquo;s a perfectly legitimate choice, and sometimes the most peaceful one.\nFor me, though, it mattered to try to understand the risks and to be an active part in the decisions. Not out of distrust in doctors, but because I feel that, in stage IV, time matters and I want to know the terrain as well as I can. I suspect \u0026ndash; without being able to prove it \u0026ndash; that, for some of us, understanding early what might come and what questions to ask really does matter.\nImportant Standard treatment solves your present. The future is something you prepare yourself, together with your doctor, while you have a good window. In advanced cancer, these two things don\u0026rsquo;t exclude each other \u0026ndash; they happen in parallel. The window That moment of breathing room is exactly what I have now. In the literature it\u0026rsquo;s called the \u0026ldquo;window of good response\u0026rdquo; \u0026ndash; the period during which the treatment works deeply and the disease is at its lowest level.\nIt\u0026rsquo;s tempting to settle quietly into this window and just be glad it\u0026rsquo;s working. And, in a way, that\u0026rsquo;s exactly what I\u0026rsquo;m doing: I\u0026rsquo;m not changing anything that works. The pill is too good to disturb.\nAnd, at the same time, I look from the present toward the future \u0026ndash; without today\u0026rsquo;s certainty, because the future doesn\u0026rsquo;t have it \u0026ndash; and I try to understand: could I use this window to push progression as far away as possible, or even to target the residual disease that\u0026rsquo;s left?\nThe logic is simple. The fewest cancer cells I will ever have are the ones I have now, while the pill keeps the disease on the ground. If there\u0026rsquo;s any chance to hit what\u0026rsquo;s left \u0026ndash; or to delay the moment when the cancer learns to resist \u0026ndash; now is the moment with the best cards in hand, not later.\nSo my strategy, for now, has two layers: I keep the standard treatment that works, and at the same time I investigate, without rushing, personalized medicine options that could either extend the window or directly attack the residual disease.\nThe hard part: on the frontier you\u0026rsquo;re more alone And here I reach the most delicate part, which I want to say carefully.\nAs long as you\u0026rsquo;re on standard of care, you\u0026rsquo;re not alone. There are protocols, guidelines, doctors who know them, a well-trodden path. The oncologists do exactly what they should, and they do it well.\nBut the moment you start looking beyond the standard \u0026ndash; toward experimental treatments, toward cutting-edge personalized medicine \u0026ndash; you enter terrain where the map is no longer drawn. And there, honestly, you\u0026rsquo;re more alone.\nNot because anyone is making a mistake, but because these options are so new that, across the entire world, very few people have real experience with them. Especially for a rare cancer like mine, where the data is scarce.\nThis isn\u0026rsquo;t a criticism aimed at anyone. It\u0026rsquo;s simply the nature of the frontier: advanced personalized medicine is often available, but it\u0026rsquo;s still expensive, still fragmented, and still unclear to navigate. There isn\u0026rsquo;t, yet, a \u0026ldquo;frontier doctor\u0026rdquo; you can make an appointment with who will tell you exactly what to do. You build this piece by piece, asking many people and reading enormously.\nAI as a compass on terrain with little data This is where my main tool comes in: artificial intelligence.\nBecause my type of cancer is rare, there isn\u0026rsquo;t a stack of studies telling me \u0026ldquo;here\u0026rsquo;s what to do.\u0026rdquo; So I use AI to do something else: to learn from diagnoses that, biologically, resemble mine.\nThere are other types of lung cancer \u0026ndash; with other genetic defects, such as EGFR or ALK \u0026ndash; that have been studied far more, because they\u0026rsquo;re more common. Their mechanisms have similarities with mine. I use AI to gather and read, systematically, what has been tried there: which personalized therapies worked, how they worked, and \u0026ndash; just as important \u0026ndash; why others didn\u0026rsquo;t.\nThe lessons from a cancer that\u0026rsquo;s a \u0026ldquo;cousin\u0026rdquo; of mine are, often, the best guide I have. It\u0026rsquo;s not magic and it doesn\u0026rsquo;t replace the doctor. But it gives me a map where otherwise I\u0026rsquo;d have nothing but fog.\nA concrete example: cancer vaccines The best example of \u0026ldquo;personalized medicine that I\u0026rsquo;m investigating\u0026rdquo; is therapeutic cancer vaccines. I want to use them to show how I think, because here you can see everything: the promise, the limits, and the loneliness of the frontier.\nFirst, what they are. A therapeutic vaccine doesn\u0026rsquo;t protect you from cancer (it\u0026rsquo;s not like the flu vaccine). It tries to teach your immune system to recognize cancer cells as something foreign and to attack them. The idea is old and seductive; the hard part has always been showing the immune system exactly what to attack.\nThere are several types, and the difference between them matters:\n\u0026ldquo;Off-the-shelf\u0026rdquo; vaccines: ready-made, targeting signs common to many patients. Advantage: cheap, available immediately. Disadvantage: they\u0026rsquo;re not tailored to your tumor. Dendritic cell vaccines: \u0026ldquo;trainer\u0026rdquo; cells are taken from your blood, taught in the lab to recognize the tumor, then returned to the body. Personalized vaccines (mRNA or peptide): your tumor is sequenced, its unique mutations are searched for (called neoantigens \u0026ndash; signs that appear only on cancer cells) and a vaccine is built to your measure. Here comes the first hard lesson about my case. Classic personalized vaccines rely on the tumor\u0026rsquo;s number of mutations: the more mutations, the more \u0026ldquo;targets.\u0026rdquo; But my cancer has few mutations (in technical terms, low TMB). It\u0026rsquo;s an immunologically \u0026ldquo;cold\u0026rdquo; cancer \u0026ndash; hard for the immune system to see. For such a cancer, the standard personalized-vaccine approach has little material to work with.\nAnd yet, there is a path that, for me, is almost perfect.\nThe ideal vaccine for my diagnosis My tumor has a defect that defines it: a fusion between two genes (in my case, KIF5B and RET). The exact place where the two genes \u0026ldquo;stick together\u0026rdquo; \u0026ndash; the junction \u0026ndash; creates a sequence that exists nowhere in the healthy body. It\u0026rsquo;s a unique sign, present in every cancer cell, exactly the kind of target an ordinary vaccine would miss, but which for me could be the tumor\u0026rsquo;s Achilles\u0026rsquo; heel.\nThe ideal vaccine for me would therefore be one built precisely around this junction. And here comes the good news: its sequence can be read directly from the genetic tests I already have \u0026ndash; I don\u0026rsquo;t necessarily need a new biopsy to find it.\nWhat\u0026rsquo;s more, in 2025 an academic lab published exactly the protein fragments corresponding to this RET junction and showed that the immune system can recognize them \u0026ndash; including in people with my type of HLA (a kind of immune \u0026ldquo;fingerprint\u0026rdquo; that decides what can be presented to the defense system). For my case, the pieces fit surprisingly well.\nWhat would such a vaccine ideally look like? From what I\u0026rsquo;ve understood while reading, it would combine:\nthe RET junction peptides \u0026ndash; the main, sure target; a few additional neoantigens from my tumor, as a safety net; possibly, targets that anticipate tomorrow\u0026rsquo;s resistance mutations; and a strong adjuvant \u0026ndash; an \u0026ldquo;amplifier\u0026rdquo; that wakes up the immune system. Important: for me, the vaccine should be given alongside the targeted pill, not instead of it. And not combined with classic checkpoint immunotherapy \u0026ndash; because my tumor has a particularity (an amplification of the MDM2 gene) that makes that type of immunotherapy risky in my case. Details like these are exactly why \u0026ldquo;personalized\u0026rdquo; truly means personalized.\nWhat worked and what didn\u0026rsquo;t in similar diagnoses Here honesty is needed, because hope without data is just wishing.\nThe sober news: there isn\u0026rsquo;t, yet, a single patient with a RET fusion treated with such a vaccine. Zero direct human data. All I have are analogies and a study in mice.\nBut the analogies are encouraging. In lung cancer with an ALK fusion \u0026ndash; a close \u0026ldquo;cousin\u0026rdquo; of my case \u0026ndash; a vaccine built on the same logic, given together with the targeted pill, eradicated tumors and prevented brain metastases in mice. It\u0026rsquo;s only an animal model, but the mechanism is exactly the one I would use too.\nThe news that calls for caution: in lung cancer, \u0026ldquo;classic\u0026rdquo; personalized vaccines, based on many mutations, have disappointed in controlled trials. They proved safe and triggered an immune response, but didn\u0026rsquo;t clearly extend life. That\u0026rsquo;s precisely why, for me, the stake isn\u0026rsquo;t a generic vaccine, but one built on that unique junction.\nWarning Hope without data is just wishing. For my cancer there isn\u0026rsquo;t yet a single patient treated with such a vaccine \u0026ndash; only analogies and a study in mice. That\u0026rsquo;s why I investigate with caution, not with blind enthusiasm. So, what am I doing now? The answer might surprise you: for now, I\u0026rsquo;m not starting any vaccine. And, from what I understand now, this seems the most correct choice \u0026ndash; though I keep it open, not set in stone.\nThe pill is working too well to disturb it, and the best programs have real barriers: some require a biopsy from fresh tissue (which, in a deep response, I have no way to obtain), others require measurable disease which, fortunately, I don\u0026rsquo;t have now. And almost all of them are still expensive \u0026ndash; a complete personalized vaccine can reach around 80,000 euros, with no guarantees.\nBut \u0026ldquo;I\u0026rsquo;m not starting anything now\u0026rdquo; doesn\u0026rsquo;t mean I\u0026rsquo;m standing still. What I\u0026rsquo;m doing, concretely: I do my routine monitoring, I take the pill we know works, and I contact the labs and companies that could build the kind of vaccine I\u0026rsquo;d need \u0026ndash; or similar ones. In parallel, I try to understand from the experiences of other patients with diagnoses close to mine what worked and what didn\u0026rsquo;t.\nThere\u0026rsquo;s another reason I\u0026rsquo;m starting to look now: a personalized vaccine usually takes between 6 and 12 months to be created. It\u0026rsquo;s not something you can decide \u0026ldquo;when needed,\u0026rdquo; overnight. That\u0026rsquo;s precisely why I try, actively, to understand the options while I have calm \u0026ndash; so that, if the moment for a decision comes, it will be as informed as possible, one I can be at peace with afterward.\nThis is what I call \u0026ldquo;keeping the target warm\u0026rdquo;: I prepare the ground and wait for two moments that could reopen the door \u0026ndash; the next follow-up scan, or a possible progression that would bring a lesion from which tissue could be taken.\nThoughts, not conclusions I don\u0026rsquo;t have a nice conclusion to put here, and I think that\u0026rsquo;s okay.\nEverything I\u0026rsquo;ve written are things I\u0026rsquo;ve found so far and that I\u0026rsquo;m sharing with you. Some might turn out to be wrong later \u0026ndash; that\u0026rsquo;s how it is on terrain that moves fast. I\u0026rsquo;m not giving advice; I\u0026rsquo;m rather thinking out loud.\nWhere I actually am: I have a standard treatment that works well, and which I value. And I have, in parallel, a map I\u0026rsquo;m trying to draw for myself \u0026ndash; with the help of AI, of reading, and of many generous people \u0026ndash; toward personalized medicine options that could, one day, mean more than \u0026ldquo;control.\u0026rdquo; Maybe. I don\u0026rsquo;t know yet.\nMaybe none of the options I\u0026rsquo;m investigating will reach me. Maybe one will. For now I keep asking, reading, and seeing where it leads.\nA resource I found useful Along this road I came across a place that struck me as genuinely valuable, and I want to leave it here for you.\nThe Sijbrandij Foundation \u0026ndash; created by Sid Sijbrandij, the co-founder of GitLab, after his own experience with cancer \u0026ndash; has a free program for patients, called FCCT (Future of Cancer Care Today). It doesn\u0026rsquo;t replace your doctor and doesn\u0026rsquo;t make decisions for you. What it does is help you navigate the options beyond the standard treatment: they have a clean list of suppliers (from tissue preservation and molecular profiling, to vaccines and cell therapies) and \u0026ndash; the part I found most useful \u0026ndash; they offer you a free 30-minute conversation with someone from their team, who can guide you or put you in touch with people they collaborate with.\nFor someone who, like me, sometimes feels alone on this frontier, it\u0026rsquo;s exactly the kind of helping hand that matters.\nTip Sijbrandij Foundation \u0026ndash; FCCT, free for patients: the list of suppliers and the 30-minute consultation. sijbrandijfoundation.org/fcct#suppliers Let\u0026rsquo;s talk If you\u0026rsquo;re reading this from a place similar to mine \u0026ndash; a related diagnosis, maybe the same curiosity about vaccines or other personalized therapies \u0026ndash; I\u0026rsquo;d love to hear from you.\nIf you\u0026rsquo;ve been through something similar and want to share your experience with me, write to me . Maybe we\u0026rsquo;ll learn from each other \u0026ndash; and maybe we\u0026rsquo;ll make the road a little easier for those who come after us.\nWhat to do now Ask for complete molecular testing (NGS) as early as possible \u0026ndash; the exact biology of the tumor decides which personalized treatments are available to you. Ask your doctor not just \u0026ldquo;what do we do now,\u0026rdquo; but also \u0026ldquo;what comes next if resistance appears\u0026rdquo; \u0026ndash; you want to know the map before you need it. If you have a good response to treatment, ask what you can do with this window: careful monitoring, consolidation options, clinical trials. For rare cancers, look for analogies: what has been tried in related, better-studied types can be the best available guide. Treat information with the same care as treatment: write down your questions, ask for a second opinion, and make the important decisions together with your doctor. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/blog/standard-of-care-vs-personalized-medicine/","summary":"\u003cp\u003e\u003cstrong\u003eIn short:\u003c/strong\u003e I\u0026rsquo;m the patient behind this blog. Five months after diagnosis, my treatment is going well \u0026ndash; and that\u0026rsquo;s exactly why I found myself asking a question I didn\u0026rsquo;t expect: what do you do with good news, when you know it won\u0026rsquo;t last forever? This article is about what I\u0026rsquo;ve understood, from the inside, about the difference between \u0026ldquo;standard treatment\u0026rdquo; and personalized medicine \u0026ndash; and about the options I\u0026rsquo;m exploring now, while I have a good window.\u003c/p\u003e","title":"Standard of care, personalized care, personalized medicine: what I've understood so far"},{"content":"In short: I had my six-month follow-up PET-CT. The big news is good: no new lesions, anywhere. But the main tumour looks a little more intense than in April, and the lymph nodes that had shrunk are still, at a millimetre scale, a little active. This article is about what the numbers actually show, about why the comparison between two scans did not come out as clean as I had planned \u0026ndash; even though I used the same machine \u0026ndash; and about the decision I made: stereotactic radiotherapy on the lung tumour, as soon as possible.\nWhere I was before the scan Since February I have been taking a targeted pill for the RET fusion in my tumour. (The story from the beginning is here , and I wrote about how I think about strategy here .)\nThe response was profound. At the three-month check, the lung tumour had dropped in metabolic activity almost completely, the spine lesion \u0026ndash; treated with radiotherapy at the start \u0026ndash; had quietened down, and the pelvic metastasis had disappeared.\nSo the six-month scan was the first real test of the question: does it hold?\nWhat the scan showed The most important thing first, because it is what counts most: no new lesions, anywhere. Brain, neck, abdomen, pelvis, liver, spleen, adrenals, pancreas \u0026ndash; all clear. The brain MRI done separately, a week earlier, came back clear for the third time in a row.\nThe rest is more nuanced, and that is exactly why it deserves an honest telling.\nThe main lung tumour is the same size as in April, around 16 mm. But the radiologist describes it as \u0026ldquo;metabolically more evident than on the previous study\u0026rdquo;. In numbers: the SUV (a measure of how much radioactive sugar the tissue consumes, that is, an indirect indicator of activity) went up from 2.0 in April to 3.2 in July. For context, at diagnosis it was 19.2.\nThe lymph nodes in the mediastinum are under 10 mm and are described as \u0026ldquo;similar, with regression in places\u0026rdquo; compared with April, at a value of 5. Their trajectory, from the beginning until now, looks like this: 13.7, then 8.3, now 5. Which is exactly what I said at the start: officially regressed, millimetre-sized \u0026ndash; but the conclusion of the report still calls them hypermetabolic. They have not gone out completely. Activity has remained, and it is now the highest of the lesions I have left.\nThe spine lesion, treated at the start, is stable. And an area of consolidation that appeared in April at the base of the left lung, about which nobody knew whether it was inflammation or something else, has disappeared from this report. That was, in fact, the news that unblocked the decision below.\nTip If you are reading a PET-CT report: the SUV is not \u0026ldquo;how big the cancer is\u0026rdquo;. It is how much glucose that tissue consumes at the moment of the scan. Inflammation consumes it too. Healing consumes it too. That is why a single number, without context and without a proper comparison, says less than it seems to. I used the same machine. And it still did not come out as a clean comparison. This is the part I really want to leave written down, because it is the most useful lesson I learned this month.\nI thought about comparability in advance. I insisted on having all the scans on the same machine, in the same centre, with the same protocol. I thought that was enough to be able to compare two numbers honestly.\nIt is not. I looked into the raw DICOM files \u0026ndash; the technical data the machine writes into every image \u0026ndash; and I found several differences between April and July. None of them is anybody\u0026rsquo;s mistake. All of them together mean that the two numbers are not rigorously comparable.\nThe uptake time after injection. In April I waited 99 minutes between the tracer injection and the scan. In July, 55 minutes. A tumour keeps taking up tracer for hours, so a shorter time underestimates the value. Which means this factor works against the observed rise, not in favour of it. Respiratory motion correction. In July a motion correction algorithm was applied that had not been applied in April. A lesion that moves with breathing appears \u0026ldquo;smeared\u0026rdquo; and diluted; when you correct for motion, you recover the signal and the value goes up, for the same biology. The reconstruction software version was updated between the two scans, including an additional scatter correction. My weight went up from 77 to 79 kg. SUV is normalized to body weight, so that alone mechanically adds about 2.6 per cent. The amount of oral contrast was roughly half of what it was in April. It does not affect the lung, but it does affect how well the structures in the abdomen separate. EARL standardization \u0026ndash; a procedure by which a lab can additionally deliver a reconstruction calibrated to a European standard, precisely so that values are comparable over time. Neither of the two scans included such a standardized reconstruction. I reached a conclusion I did not know before: the same machine does not automatically mean the same conditions. Comparability is not a property of the machine, it is a procedure you have to ask for explicitly, in writing, every single time.\nImportant What I ask for from now on, at every PET-CT booking, and what I would suggest you ask for in writing too:\nThe same uptake time after injection as at the previous scan (the standard tolerance is plus/minus 15 minutes). The same corrections applied (motion, scatter) and the same reconstruction version, or at least an explicit mention of them in the report. An additional standardized EARL reconstruction \u0026ndash; asked for at booking, because it cannot be done retroactively once the raw data have been deleted. The same contrast protocol. A fixed list of target lesions, reported with numerical values at every follow-up and compared with all the previous scans, not just the last one. So did it grow, or not? The honest answer is: it went up a little, but the rise does not mean progression. And it is worth explaining why, because this is exactly the kind of nuance that frightens people for nothing.\nThere is a set of international criteria for deciding when a change on PET means progression, called PERCIST . To speak of metabolic progression you need a rise of at least 30 per cent and, at the same time, an absolute rise of at least 0.8 units. In my case, the rise was about 25 per cent and 0.32 units in absolute terms. It reaches neither threshold.\nMore than that: for a lesion this small, the normal variability between two repeated scans of the same unchanged tumour is on the order of 30-50 per cent. The observed rise fits comfortably inside the measurement noise.\nAnd one more thing: at both time points, my lesion is below the threshold at which PERCIST considers a lesion measurable. Its values are below the liver level. In practice, the criteria were not even designed for a target this small.\nBut the most important argument comes from somewhere else. The PET has all the confounders above. The CT component of the same scan has none of them \u0026ndash; it does not depend on the uptake time, on motion correction or on the PET software version. And the CT says, April versus July: diameter 13.5 mm, unchanged. Solid component volume, slightly lower. Density, unchanged. (These measurements are my own, calculated at home from the raw images with AI tools \u0026ndash; they do not appear as such in the radiologist\u0026rsquo;s report.)\nSo: stable, not progression, with a sub-threshold metabolic change. I am not saying \u0026ldquo;flat\u0026rdquo;, because there is a small and real rise. And I am not saying \u0026ldquo;artefact\u0026rdquo;, because the biggest factor \u0026ndash; the uptake time \u0026ndash; was working against it. I am saying exactly what it is: a lesion that is not growing, with a metabolic flicker I cannot certify.\nTip One clarification I think is useful. The numbers above \u0026ndash; the solid component volume, the density, the comparisons between the two scans \u0026ndash; do not come from the report. I calculated them myself, at home, from the raw DICOM files, with AI tools.\nThis is not something reserved for specialists. The raw images are yours and you can ask for them on a USB stick or on a CD at every scan. In my case, the difference between \u0026ldquo;I read the report\u0026rdquo; and \u0026ldquo;I measured the same images myself\u0026rdquo; was the difference between panic and a calm decision.\nRead the report word by word A little mishap worth telling, because I nearly published something else.\nFor a few days I was convinced that the report gave no numerical value at all for the lymph nodes. I had already built a small theory around that: that it was a reporting omission, that I should ask for an addendum.\nI was wrong. The number was there. It sat inside a parenthesis, at the end of a four-line sentence that started with something else and finished over the page. I missed it, and then I built on top of that miss.\nThe lesson, for anyone keeping a long-term medical file: read the report yourself, sentence by sentence, and pull the numbers out into a table of your own. The values usually sit in parentheses at the end of a sentence, not in obvious places, and a single sentence can describe three different groups of lesions with three different values. And if something really is missing, a report can be amended \u0026ndash; you ask politely, it is free and it takes little time.\nThe decision: radiotherapy on the lung tumour, now Here I get to the action part.\nThe logic I follow is the one I wrote about last time: the fewest cancer cells I will ever have are the ones I have now, while the pill keeps the disease down. If there is a moment worth hitting what is left, that moment is now, not later.\nThe lung tumour is small, anatomically stable, but it has not disappeared. It is a good target for SBRT \u0026ndash; stereotactic body radiotherapy, that is, a high dose delivered very precisely, in few sessions, with very small margins around the target.\nOne thing unblocked the decision: the area of consolidation that appeared in April at the base of the left lung, about which nobody knew whether it was infection, treatment-related inflammation or disease, has disappeared. As long as it was there, any thoracic irradiation was on hold, because I did not want to irradiate without knowing what I was irradiating.\nThe simulation was done on 21 July, and treatment starts on Monday, 27 July, at Anadolu Medical Center in Istanbul, on a Varian Edge.\nWhat I do not know yet: the exact dose, the number of sessions and the rule about the pill \u0026ndash; whether and for how many days it is stopped around the radiotherapy. The team is due to tell me. I asked for it in writing, because it is the kind of detail you do not want to be remembering from a conversation.\nI have been through SBRT once before, in January, for the spine lesion: three sessions, on CyberKnife. The back pain that had brought me to the doctor went away. So I am not stepping onto unknown ground.\nThree machines under one roof The part that genuinely impressed me was the conversation with the radiation oncologist. I did not know that a single centre could have three different stereotactic radiotherapy platforms, each with its own role. I am leaving them here because this is the kind of thing I would have liked to know earlier.\nCyberKnife. An industrial robotic arm with a small linear accelerator mounted on the end, with no gantry. It can aim from over a thousand different positions. Its particularity is continuous respiratory tracking: it correlates the movement of the body surface with the internal position of the tumour, checks periodically with real-time X-rays, and moves the beam after the tumour throughout the session. You do not need to hold your breath. The cost: long sessions.\nMR-Linac (at Anadolu, a 1.5 tesla Elekta Unity, the first in Turkey, since October 2024). A diagnostic MRI combined with a linear accelerator. During irradiation you see the tumour directly, as a continuous film, not through a surrogate. And you can redo the treatment plan at every session, adapting it to how the body looks that day. It is the right machine when the target sits up against soft organs that move and fill differently from one day to the next: pancreas, liver, pelvis, or a lymph node next to the oesophagus or the bowel. The cost: the longest sessions of all.\nVarian Edge. A classic C-arm accelerator, configured specifically for radiosurgery and SBRT. It brings a precision package: continuous optical monitoring of the body surface, with automatic beam hold if you move outside tolerance; delivery gated to the phase of the breath; a cone-beam CT taken right before treatment, to verify position; a robotic couch that corrects on six axes, including rotations; a fine-leaf collimator, which cuts the dose off sharply around a small target; and high intensity beams, which considerably shorten the effective irradiation time.\nThe difference in philosophy, if you want to remember it simply: CyberKnife and MR-Linac track the target continuously, each in its own way. Edge gates and verifies \u0026ndash; it treats in the right phase of the breath and confirms the position with imaging, with much shorter sessions.\nFor my case, the team proposed the Edge. The \u0026ldquo;sub-millimetre\u0026rdquo; accuracy figure you see in any manufacturer\u0026rsquo;s materials is a number obtained under test conditions, not a guarantee for a particular patient \u0026ndash; all three manufacturers display it. What matters is the concrete chain of motion control, on your lesion.\nTip A good question to ask your radiotherapy team, wherever you are treated: \u0026ldquo;Why this machine, for my lesion, and not the other one?\u0026rdquo; The answer is usually dosimetric \u0026ndash; how much the surrounding organs receive \u0026ndash; and it is a conversation worth having, not one to assume. What struck me as remarkable is that all three are in the same building, and access was quick. For a patient looking for this technology, the fact that you do not have to choose between centres, but that the right machine for you can be chosen inside the same centre, matters enormously.\nThe question I am still weighing: radiotherapy and a possible vaccine There is one single thing left for me to weigh, and it is only honest to say that it is not resolved.\nIn parallel with treatment, I am actively investigating a personalized vaccine built on the genetic particularity of my tumour. I am talking right now with several centres that do this sort of thing. (I write about that at length in the next article .)\nThe question is whether irradiation helps or hinders such a vaccine. The arguments go in both directions:\nIn favour. Radiotherapy kills cells in a way that can release tumour antigens and can draw the immune system\u0026rsquo;s attention \u0026ndash; a sort of in situ vaccination. There is an interesting technical detail: above a certain dose threshold per session, the cell activates a mechanism that destroys the DNA in the cytoplasm and cancels out the very immune signal you wanted (Vanpouille-Box, 2017 ). In other words, several sessions at a moderate dose can preserve more immune effect than a single very large one.\nAgainst. Radiotherapy also destroys lymphocytes \u0026ndash; exactly the cells a vaccine wants to train. And there is a large randomized trial in oligometastatic lung cancer, NRG-LU002 , which did not show a benefit for adding local radiotherapy to systemic treatment. That is a result I am not allowed to ignore just because it does not suit me.\nTo be fair in the other direction as well: that trial included unselected patients, not patients on a targeted pill like me. The trial that tested exactly the \u0026ldquo;targeted pill plus local radiotherapy\u0026rdquo; scenario \u0026ndash; SINDAS, in a different mutation from mine \u0026ndash; did show a benefit. The truth is probably somewhere in the middle: local radiotherapy is not a universal panacea, but the context in which you give it matters enormously.\nOne thing is clear and worth saying, because it is an easy confusion to make: radiotherapy does not touch the tissue the vaccine would be built from. That is the paraffin-embedded block from this year\u0026rsquo;s biopsy, which I physically have with me. They are two completely separate things.\nI put the direct question to one of the centres: whether it would be better for the cells to be collected before radiotherapy. I am waiting for the answer. The rule I have set myself in the meantime is simple: I do not delay radiotherapy for a vaccine that has not yet passed its own thresholds. The radiotherapy is decided, paid for, simulated, on a real target. The vaccine, for now, is not.\nWhat comes next in monitoring From month 6 I move to an alternating rhythm, one scan every three months:\nmonth 9 (October 2026) \u0026ndash; CT, this time with intravenous contrast; month 12 (January 2027) \u0026ndash; PET-CT plus brain MRI; month 15 \u0026ndash; CT; month 18 \u0026ndash; PET-CT plus MRI. And so on. A technical detail I only found out now and which is worth knowing: the CT component of a PET-CT has no intravenous contrast and never will, because its role is a different one \u0026ndash; attenuation correction. The bottle you drink beforehand is oral contrast, for the bowel, and the two syringes are the tracer and the flush. If you need a fine anatomical measurement, it comes from a separate diagnostic CT, with intravenous contrast \u0026ndash; not from the PET.\nWhere I actually am Six months. No new lesions. A tumour that is not growing, with a metabolic flicker I cannot certify. Some millimetre-sized lymph nodes that have not gone out completely. And a good window, in which I choose to act instead of waiting.\nIt is not a cure and I do not claim it is. It is a good position, and I am trying to use it well.\nWhat to do now Ask for all follow-up scans to be done on the same machine, in the same centre \u0026ndash; that is the minimum condition, not the guarantee. Ask in writing, at booking, for the same acquisition parameters as at the previous scan: uptake time after injection, corrections applied, reconstruction version, contrast protocol. Ask for a standardized EARL reconstruction as an additional series. It cannot be done retroactively. If a value is missing from the report, ask for an addendum. It is free, it takes little time, and it saves the chart you will be looking at two years from now. Do not interpret a single SUV in isolation. Ask about the PERCIST thresholds, about the normal variability for a lesion of your size, and about what the CT component says. If stereotactic radiotherapy is proposed to you, ask why that machine for your lesion \u0026ndash; and ask in writing for the dose, the number of sessions and the rule about the targeted pill. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/blog/pet-ct-at-month-6/","summary":"\u003cp\u003e\u003cstrong\u003eIn short:\u003c/strong\u003e I had my six-month follow-up PET-CT. The big news is good: no new lesions, anywhere. But the main tumour looks a little more intense than in April, and the lymph nodes that had shrunk are still, at a millimetre scale, a little active. This article is about what the numbers actually show, about why the comparison between two scans did not come out as clean as I had planned \u0026ndash; even though I used the same machine \u0026ndash; and about the decision I made: stereotactic radiotherapy on the lung tumour, as soon as possible.\u003c/p\u003e","title":"PET-CT at Month 6"},{"content":"In short: I have spent the last few months reading, asking questions and writing to centres that make therapeutic cancer vaccines. This article is the map I wish I had had at the start: what types of vaccine exist and how they differ, what worked and what did not work in trials, what the real limits are, what the ideal vaccine for my case would look like \u0026ndash; and the list of centres I found, sorted by how well they fit my biology. It is written both for patients and for doctors or oncology navigators running into this subject for the first time.\nWhy I came back to this subject Last time I wrote that I was looking into vaccines, but that I was not starting any of them for now. That position has changed.\nThe reason is simple, and it has to do with the month 6 result : I have very little disease, the treatment is holding, and I feel well. Immunologically, this is the best possible moment for a vaccine \u0026ndash; not one to postpone.\nA personalized vaccine takes, in any case, between six months and a year until it is ready. If you start it when you need it, you have started too late.\nSo I am now treating it as an active direction, in parallel with the pill (which does not stop) and with radiotherapy. What follows is what I found out.\nWhat a therapeutic vaccine actually is A therapeutic cancer vaccine does not prevent cancer. It is not like the flu shot.\nIt tries to teach your immune system to recognize tumour cells as foreign and to attack them. The idea is more than a century old. The hard part has always been the same: what exactly do you show the immune system?\nThe target is called an antigen. If the target also appears on healthy cells, either you do not attack, or you attack the healthy ones too. If the target appears only on some cancer cells, you kill those and the rest grow. A good vaccine stands or falls on the choice of target.\nRemember this sentence, because it is the conclusion of the whole article: it is not the technology that decides, it is the target.\nThe types of vaccine, briefly I came across six families. I put them here with what matters in practice: how they work, what material they ask of you and how long they take.\n1. Off-the-shelf vaccines, on shared antigens. Fixed peptides or proteins, which target markers present in many patients with the same type of cancer. They need nothing from you \u0026ndash; no biopsy, no sequencing. They are ready-made and cheap. The downside: they do not look at your tumour at all.\n2. Dendritic cell vaccines. Dendritic cells are the \u0026ldquo;teachers\u0026rdquo; of the immune system. They are collected from your blood, matured in the lab, \u0026ldquo;loaded\u0026rdquo; with the tumour antigen, then given back. There is a subtlety here that took me time to understand and that changes everything: what you load them with matters. There are three variants:\nwith lysate from your own tumour \u0026ndash; you need viable, fresh tumour tissue; with defined peptides \u0026ndash; you only need the sequence, not fresh tissue; with mRNA \u0026ndash; again, sequence. So \u0026ldquo;dendritic cell vaccine\u0026rdquo; does not automatically mean \u0026ldquo;I need fresh tissue\u0026rdquo;. Only some variants do. That confusion cost me weeks.\n3. Personalized mRNA vaccines on neoantigens. Your tumour and a normal sample are sequenced, the tumour\u0026rsquo;s unique mutations (neoantigens) are looked for, they are encoded into mRNA and packaged into lipid nanoparticles. A few weeks of manufacturing once the analysis is done.\n4. Personalized peptide vaccines. The same discovery logic, but the final product is a chemically synthesized peptide plus an adjuvant \u0026ndash; a substance that wakes up the immune system. If the target is a single one and is already known, you only need the sequence.\n5. Viral vector vaccines. A modified virus, unable to replicate, carries the instructions for your neoantigens.\n6. Dendritic cells primed with an oncolytic virus. A virus that selectively destroys tumour cells releases the antigen, which then loads the dendritic cells. The mechanism needs tumour mass to destroy.\nTip The two questions that quickly separate what fits you from what does not:\n1. What material does it need? Fresh-frozen tissue? An archival paraffin block? Only blood? Only a sequence on paper? 2. Is the target yours, or is it a shared one? An off-the-shelf vaccine and one built on your tumour\u0026rsquo;s mutations are fundamentally different things, even if both are called a \u0026ldquo;vaccine\u0026rdquo;.\nWhat has worked and what has not, so far Honesty is needed here, otherwise the article becomes an advertisement.\nThe sobering part: in lung cancer, off-the-shelf vaccines have failed, consistently. Large phase III trials, with thousands of patients: MAGRIT (on the MAGE-A3 antigen), START (tecemotide, on MUC1), STOP (belagenpumatucel-L), TG4010. All were safe. All produced a measurable immune response. None of them clearly prolonged life.\nThat is not a detail. It is the dominant pattern of the field in lung cancer, and anyone selling you enthusiasm without mentioning it is not telling you everything.\nAnd there are two more failures that concern me directly, because they hit exactly at my idea.\nThe first: a vaccine built on a single marker invites the tumour to lose that marker. It was tested seriously, in a phase III trial with 745 patients, on an antigen called EGFRvIII. It failed \u0026ndash; no survival benefit. And at relapse, the antigen was missing in almost six out of ten patients. Not because the vaccine did not work, but because it did work: it cleared the cells that carried the marker, and the ones that did not carry it were left.\nThe second is even closer to my case. In an analysis published in 2025, a lung cancer patient on a targeted pill received a vaccine built on his clonal driver \u0026ndash; exactly the structure I am thinking of. He progressed. The targeted clone disappeared, but an older clone, which did not carry the vaccine\u0026rsquo;s target, expanded in its place. And the disease transformed and lost the vaccine\u0026rsquo;s targets. All of this while a real immune response was being measured in the blood.\nWarning The lesson I take from this, and which changed my own plan: a measurable immune response does not mean disease control. You can see the lymphocytes working and the disease advance anyway, because you trained the defence against a single thing, and the tumour is a population, not an individual.\nThat is why the vaccine I am looking for is no longer \u0026ldquo;one peptide on the junction\u0026rdquo;, but several targets at once \u0026ndash; the junction, plus at least one anticipated resistance mutation, plus a target that recruits the helper cells.\nThe encouraging part comes from the vaccines built on the patient\u0026rsquo;s own target.\nIn melanoma, a personalized mRNA vaccine combined with immunotherapy significantly reduced the risk of relapse after surgery, with the benefit maintained at a few years (KEYNOTE-942 ). It is the best result in the whole class. But mind the context: melanoma has very many mutations, and the vaccine was given together with immunotherapy. Two things I do not have.\nIn resected pancreatic cancer, a personalized mRNA vaccine produced T cells that persisted for years in half of the patients \u0026ndash; and those patients did better.\nAnd one result that interests me directly: a peptide vaccine built on a single mutation of the KRAS gene produced an immune response in the great majority of the patients treated and a drop in circulating tumour DNA in some of them, in a context with few mutations. That is exactly the demonstration I needed: a single well-chosen target can be enough, even when the tumour is \u0026ldquo;poor\u0026rdquo; in mutations.\nWarning A recap, because it is easy to lose: the platform (mRNA, peptide, dendritic cells) did not decide the results. The target decided. The vaccines on shared antigens failed one after another, whatever the technology. The ones built on something specific to that patient\u0026rsquo;s tumour have started to show something. The real limits, in my case Now the unpleasant part: most of these options do not fit me, and it is important that you understand why, because it may help you do your own triage.\nI have few mutations. My tumour has a low tumour mutational burden. Classic personalized vaccines look for point mutations and build from them. In my case they find few, and most of them are too weakly represented to pass the technical thresholds. The raw material is thin.\nThe tumour is immunologically \u0026ldquo;cold\u0026rdquo;. Low PD-L1, few mutations. And in RET fusion lung cancers, classic checkpoint immunotherapy works poorly \u0026ndash; response rates on the order of 6-17 per cent. That automatically rules out all the programmes that require, as a condition, a checkpoint inhibitor alongside the vaccine. Not because it would be dangerous, but because in my case it probably simply does not help.\nI have no fresh-frozen tissue, and nowhere to get it from. I have never had surgery \u0026ndash; only a needle biopsy. And now, with such a deep response, I have no lesion worth biopsying. That closes off all the platforms that require fresh tissue.\nI only have paraffin blocks, in an unknown quantity. Their quality is confirmed by the lab. The quantity left, after the tests already done, has never been inventoried. It is a distinction everyone confuses, myself included: \u0026ldquo;the tissue is good\u0026rdquo; and \u0026ldquo;I still have enough tissue\u0026rdquo; are two different things. I cannot promise any lab that I have enough material until someone counts.\nMy HLA typing is incomplete. HLA is a kind of immune fingerprint that decides which protein fragments can be shown to the defence system. Mine has only been determined at a coarse level, at two digits. The study that validates the target I am interested in works on a precise subtype, at four digits. Mine may be a different one \u0026ndash; and then the whole construction collapses.\nImportant If you take a single practical idea from this article, take this one: inventory your tissue and get your HLA typed at four digits early. They are the cheapest tests in the whole chain, they are done once, and they decide whether the rest makes sense. I only discovered they were blocking after months of discussions with centres. What the ideal vaccine for me would look like My tumour is defined by a fusion between two genes. The exact place where the two join \u0026ndash; the junction \u0026ndash; produces a sequence that exists nowhere in the healthy body.\nIt is the perfect target, in theory: it is specific to the tumour, it is present in practically every cancer cell, and it is kept even as the disease evolves, because it is the very engine of it. An ordinary vaccine, which looks for point mutations, would miss it completely.\nSo the ideal vaccine for me would have: the junction peptide as the main target, a few extra targets as a safety net, a strong adjuvant, and it would be given alongside the targeted pill, not instead of it.\nTwo construction details I found out late and that change a lot.\nThe peptide has to be long, not short. A short peptide, of eight to eleven \u0026ldquo;letters\u0026rdquo;, sticks directly onto the surface of any cell and wakes up only the killer lymphocytes, without help \u0026ndash; and those get tired and can end up tolerating the target. A long peptide, of twenty-five to thirty-five letters, is too big to stick directly: it first has to be \u0026ldquo;chewed\u0026rdquo; by the dendritic cells, which then show it both to the killers and to the helper cells. The result is a stronger and more durable response. It is the school of Melief, at Leiden, who invented the concept.\nAnd it must not be a single target \u0026ndash; for the reason told above. A vaccine on a single marker invites the tumour to lose that marker, and that has already happened, in real people, including in a case almost identical to mine. So: the junction as the anchor, plus a target that anticipates a known resistance mutation, plus one that recruits the helper cells.\nThere is one more step I would want done before any manufacturing: confirmation that the junction really is displayed naturally on the surface of the tumour cell, through direct analysis of the presented peptides. So far nobody has shown this for any RET junction.\nAnd here comes the asterisk I did not anticipate.\nLast time I wrote that the junction sequence can be read from the genetic tests I already have. That is true \u0026ndash; but it was not in the report. My report says which the two genes are, at a general level. It does not say exactly where they join.\nThe difference matters enormously: depending on the exact breakpoint, the left half of the peptide is an entirely different one. You cannot synthesize a peptide you cannot write down.\nThe good news: the lab that did the analysis used instruments that normally produce exactly those coordinates. The data almost certainly exists already \u0026ndash; it just did not make it into the clinical report. So I do not need a new test, I need a data request. I have sent it.\nWarning And a correction I owe my readers. In the previous article I wrote that checkpoint immunotherapy would be risky in my case, because of a genetic particularity (MDM2). I went back over the basis of that statement and it does not hold up: the evidence was thin, in a very small number of patients, not replicated. The real reason I avoid checkpoint immunotherapy is a different one, and a more mundane one: in RET fusion cancers it works poorly. It does not block a vaccine. I prefer to correct it rather than leave standing something that sounds convincing and is not. There is one more thing I have to say about the study the whole idea leans on. In 2025 a paper was published showing that peptides built on this junction can be recognized by the immune system (Castillo et al., 2025 ). It is encouraging. But it has four limits I am not allowed to hide:\nit assumes a certain breakpoint \u0026ndash; mine is not yet known; the demonstration was done on cells from healthy donors, with the peptide added artificially, not on a real tumour; the validated HLA subtype is not confirmed in me; when I ran the predictions myself on my own profile, the top-scoring peptide came out as a different one from the one validated in the paper. There is nowhere in the literature the proof that such a junction is really displayed naturally on the surface of a tumour cell. It is a well-argued hypothesis, not a fact.\nHow I will know if it is working \u0026ndash; and how I catch it coming back in time A vaccine is not something you give and then forget. You have to know, as you go, whether it is doing anything \u0026ndash; and, separately, you have to catch in time the moment the disease tries to come back. Two different questions, with two different instruments.\nThe first: does the vaccine actually train the defence? How many targets a vaccine includes is not the same as how many actually provoke a response. The prediction on the computer says what might work; only a measurement in the blood, after the first doses, says what actually worked. Some clinics do exactly this, halfway through the course. The question I have learned to ask is what they do with a weak result: redesign the peptides, or add a checkpoint inhibitor? For someone like me, in whom the checkpoint probably does not help, the difference is large.\nThe second question is about the disease: how do I catch the first sign that it is coming back, before it shows up on a scan? The instrument is a blood test that reads the fragments of DNA the tumour leaves in the circulation. It can detect a relapse months before imaging \u0026ndash; and, often, it can also tell what kind of relapse it is. Because there is not just one kind: a disease held in check by a targeted pill comes back either because the driver changes a little but stays the same engine \u0026ndash; in which case a next-generation pill can still work \u0026ndash; or because the tumour finds a completely new way to survive, independent of the driver, and the pill no longer helps at all. (More rarely, it transforms into a different type of cancer.) Which of these appears decides the next move.\nTip Hence the reason a vaccine makes sense alongside the pill, not instead of it: they fail differently. The pill holds in check the bulk of the driver-dependent disease; the vaccine is an immune layer that can reach cells the pill does not touch, through an entirely different mechanism. And the blood DNA test is the radar that tells you when to adapt \u0026ndash; including, if the disease comes back, when to build a new vaccine on its new form. One last nuance, connected to the thread about tissue above: the most sensitive version of this blood test is not the generic one, but one built specially from your tumour\u0026rsquo;s mutations \u0026ndash; and that one needs, a single time, a sequencing of the tumour. That is, the same rare tissue the vaccine needs. The good news is that a single sequencing can serve both: the same mutations that go into the vaccine are the ones the blood test tracks.\nWhy Germany, and why the legislation matters One thing I did not know at all: if you want a treatment built specially for you, outside a clinical trial, the question is not only who can manufacture it. It is where it is legal to give it to you.\nIn Europe, the only place where I found a mechanism that actually works in practice is Germany. The German medicines law allows a doctor to produce a preparation for a particular patient, without the full industrial authorization, under a formula called an \u0026ldquo;individual therapeutic trial\u0026rdquo;. It is not a clinical trial: it has no mandatory ethics approval, no public registry. The liability is the doctor\u0026rsquo;s.\nThere is also a second mechanism, European, not only German: the \u0026ldquo;hospital exemption\u0026rdquo;, which allows a hospital to manufacture cell therapies for individual patients. On paper it exists across the whole Union. In practice, in other countries it is almost unused \u0026ndash; in Belgium, for example, it has been granted only once. Switzerland has no equivalent.\nAnd here is the paradox I did not anticipate. German university hospitals can build personalized products \u0026ndash; some of them even have the best expertise in the world on exactly the type of vaccine I would need. But as a rule they offer it to you only within a trial. And a trial has fixed criteria: if your disease is not the one in the protocol, you do not get in, however well you fit biologically.\nWhich means that, in practice, the personalized product outside a trial comes rather from private clinics, for a fee \u0026ndash; not from the academic centre that invented it.\nOutside Europe: Japan has its own law, from 2014, on the safety of regenerative medicine, which allows accredited clinics to legally offer autologous cell therapies to patients who pay. Taiwan has a similar framework, updated in 2024.\nImportant A warning I keep repeating to myself: a manufacturing licence is not proof of efficacy. The fact that a clinic has the legal right to produce something says nothing about whether that something works. The same authorizations are held by serious academic centres and by commercial clinics alike. Check the mechanism and the evidence separately from the authorization. The centres I found I want to be very clear about the criterion, because otherwise the list below can be read wrongly. I am not splitting centres into good and bad. I am splitting them into fitting and not fitting for my biology.\nEvery programme below is built seriously by serious people, and each one fits somebody. A tumour lysate vaccine is a reasonable choice for a patient who has just had surgery and has fresh tissue in abundance. For me, who do not have it, it is impossible to manufacture \u0026ndash; and that says nothing bad about it.\nMy filter has never been \u0026ldquo;it is paid for\u0026rdquo; or \u0026ldquo;it is not a clinical trial\u0026rdquo;. If that had been the filter, the options I am pursuing now would have fallen too. The filter is the mechanism fit.\nWhere the bottleneck actually is This is the conclusion that changed how I search the most, and I wish I had had it from the start.\nI started out asking \u0026ldquo;who can manufacture my vaccine\u0026rdquo;. It is the wrong question. A long peptide built on my junction can be synthesized under pharmaceutical conditions, directly from the sequence, without a single gram of tissue, by almost a dozen specialized laboratories in Europe, Australia and the United States \u0026ndash; piCHEM in Austria, Mimotopes in Australia, Eurogentec in Belgium, Biosynth in the Netherlands and others. Synthesis is not the barrier. It is almost a commodity.\nThe barrier is who formulates the adjuvant, who takes the liability and who administers it \u0026ndash; as an individual treatment, without checkpoint immunotherapy bundled in. There is almost no place that does the whole chain end to end.\nImportant If you are in my situation, look for a willing doctor, not another manufacturer. I lost weeks asking laboratories whether they could build something that, it turns out, almost all of them can build. The rare link is clinical, not chemical. Fitting for my profile CeCurio / CeGaT, Tübingen (Germany) \u0026ndash; personalized peptide vaccine, derived from full sequencing of the tumour\u0026rsquo;s exome and transcriptome. That last part matters: transcriptome analysis is what allows fusions to be detected, not just point mutations. From what I understood about their platform, a peptide built on a fusion junction can be included, provided it passes the usual filters for stability and for difference from the normal protein \u0026ndash; and they already have experience with peptides of this kind, which I have not found anywhere else. Nobody can promise in advance that a usable peptide will come out; that is only known after the analysis, and it seems scientifically honest to me for it to be said that way, not an evasion. Their constraint: they do not work with sequencing done elsewhere, they want their own data, so they need tissue.\nWhat I have learned to ask for explicitly, in writing, from any supplier of this kind: (a) that they run fusion detection, not just the point mutation scan, and (b) that they include the peptide defined on my junction. A standard analysis, however well done, can walk right past exactly the thing that matters, because it was not asked to look for it.\nDr. Morisaki\u0026rsquo;s clinic, Fukuoka (Japan) \u0026ndash; dendritic cell vaccine loaded with neoantigens, injected under ultrasound guidance directly into the lymph node. It accepts tissue from paraffin blocks, which for me is decisive. Fusion analysis is not part of their standard workflow \u0026ndash; as with most platforms, the search starts from point mutations \u0026ndash; but a junction can be assessed separately if the exact sequence is made available to them. That is exactly why the data request to the lab is on the critical path.\nISEIKAI / meneki-clinic, Osaka (Japan) \u0026ndash; dendritic cells again, but with a structural particularity I have not found anywhere else: the peptides can be added individually, as distinct line items. That is, a peptide built on my junction could go in separately, instead of the whole product having to be renegotiated. It is the only place where this lever seems to exist.\nTübingen University Hospital, the academic team (Germany) \u0026ndash; scientifically, the most experienced team in the world on vaccines built exactly on fusion junctions. They also have a real human precedent: a patient with another cancer also driven by a fusion, vaccinated on the junction, without immunotherapy, on top of his usual treatment, with no relapse at over twenty months. A single case, not a trial \u0026ndash; but exactly the structure I am looking for.\nTheir situation has a nuance I got wrong at first. They have two routes: a personalized one, which starts from direct analysis of the peptides displayed by the tumour and requires fresh-frozen tissue \u0026ndash; that one is closed to me. And one built from sequence, which requires no tissue at all. The problem with the second is not the material, but the catalogue: the junction they have built from so far is a different one from mine. So it is not a closed door, but a special request to be made.\nThe builders in the United States I discovered them late and I am sorry about it, because they change the calculation.\nThe Gunaratne lab (University of Houston, with MD Anderson) \u0026ndash; they are the ones who published exactly the KIF5B-RET junction science that my whole line of reasoning leans on. On paper it is the best fit in the world for my case: it targets exactly the junction, it is built from sequence, without checkpoint. The limit is brutally simple: their programme does not reach patients before 2027. For now, all I can do is exist on their list.\nJaime Leandro Foundation, with Washington University (Saint Louis) \u0026ndash; a non-profit foundation that coordinates, for each individual patient, a consortium: one lab does the genomic design, another synthesizes, and the patient\u0026rsquo;s own treating doctor administers it through a US legal route for expanded access. It accepts paraffin tissue, it is checkpoint-free, and it does not disqualify you if you are responding well to treatment \u0026ndash; that is, it cuts exactly three of the barriers that block me elsewhere. The warning is the same as everywhere: their search also starts from the broad scan, so it could miss the junction if you do not explicitly ask for the defined peptide to be included.\nHouston Methodist, the RNA therapeutics programme (Cooke and Gollihar) \u0026ndash; the only group I found that has actually built a personalized RNA vaccine for a single patient, as an act of compassion, and administered it. Without checkpoint, and it can encode the junction directly from sequence, so it does not even need my tissue. Availability for RET fusion lung cancer and the access conditions remain to be confirmed.\nThere is also a strategic move I am considering: at Johns Hopkins a trial is running that combines exactly a fusion peptide with a targeted pill, without checkpoint \u0026ndash; but for the ALK fusion. The natural question is whether they would extend it to a RET fusion. It costs nothing to ask.\nBNT116 (BioNTech) \u0026ndash; an mRNA vaccine in clinical trials, which needs no tissue from you and can be combined with a targeted pill. The advantage: it is a real, open route. The limit: it targets shared antigens, not my junction. It is exactly the category I wrote about above as having failed repeatedly in lung cancer \u0026ndash; but it is open and accessible, which counts.\nLess fitting for me I group them by the reason for the mismatch, not alphabetically. If you have a different diagnosis, chances are you will find yourself in one of the categories, even if the company names differ.\nThe ones that need tissue I do not have LANEX-DC (LDG Laboratories, Germany) \u0026ndash; dendritic cells loaded with lysate from your own tumour. That is where the problem is, and it is purely mechanical: the lysate is made from viable tumour tissue. I only have formalin-fixed, paraffin-embedded tissue, which is not a functional source of lysate. The product simply cannot be manufactured for me \u0026ndash; and, on top of that, it does not look at the fusion that drives my disease. I have no doubt it is an option for patients in a different tissue situation.\nIOZK, Cologne (Germany) \u0026ndash; here the dendritic cells are grown from your blood, but the antigen is produced in the body: an oncolytic virus plus targeted hyperthermia make the tumour cells die in a way the immune system notices. So the mechanism needs tumour mass to work on. In my case, precisely because the treatment has gone so well, I have almost nothing for it to work with. It is an approach designed for someone with visible disease \u0026ndash; I keep it as a reserve option if the situation changes.\nMIDRIXNEO, Ghent (Belgium) \u0026ndash; dendritic cell vaccine loaded with neoantigen mRNA, a scientifically elegant construction. Three barriers: the trial is closed, it required fresh-frozen surgical tissue in large quantity, and RET fusions were explicitly excluded from the inclusion criteria.\nThe ones built on a target other than mine Moderna (United States) \u0026ndash; two different products, unsuitable for different reasons. mRNA-4157, their personalized vaccine, is given in the lung programme together with pembrolizumab \u0026ndash; and checkpoint immunotherapy is the wrong backbone for my biology, with response rates on the order of 6-17 per cent in RET fusion cancers. mRNA-4359 is, on the contrary, off-the-shelf: it encodes fragments of PD-L1 and IDO1, evasion mechanisms common to many tumours. It contains nothing from my fusion. They are the programmes with the most clinical experience in the class \u0026ndash; it is just that both are built around releasing the same immune brakes that, in my case, seem to matter little.\nELI-002 (Elicio Therapeutics, United States) \u0026ndash; here is an irony I prefer to point out myself. It is exactly the trial I cite above as being encouraging: the proof that a single well-chosen target can produce a durable immune response in a mutation-poor tumour. But ELI-002 is not personalized \u0026ndash; it is a fixed set of peptides built on mutations of the KRAS gene, and the confirmed driver in my case is a KIF5B::RET fusion. It validates my principle, but it is not my product.\nThe ones that look for point mutations, not junctions NeoVax (Dana-Farber, United States) \u0026ndash; one of the most respected academic platforms for personalized peptide vaccines. Its method is to scan the tumour exome and build from the point mutations found there. It is excellent for mutation-rich tumours.\nMine has around four mutations per megabase, and the only strong target is a fusion junction \u0026ndash; exactly the kind of thing such a scan is not built to look for. Technically, the platform could synthesize my peptide if you gave it the sequence. It is just that this is not how it gets to the target, and that is a distinction that cost me a lot of time to understand.\nWhat makes a centre interesting for a case like mine If you have a similar profile \u0026ndash; disease driven by a gene fusion, few mutations, low PD-L1, little disease and only archival tissue \u0026ndash; these are the questions that triaged my list most efficiently. You can use them as they are:\nDo you accept tissue from archived paraffin blocks, or do you require fresh-frozen tissue? That one alone eliminates half the options. Does your analysis detect fusions, or only point mutations? That is, do you also do the transcriptome, not just the exome? Can you include a peptide built on a fusion junction that I supply to you? Does the product require a checkpoint inhibitor alongside it? If so, in a fusion-driven cancer it is probably not for you. Do you require measurable disease? A good response to treatment can disqualify you \u0026ndash; paradoxical, but real. What happens if the analysis finds nothing usable? Do I get the data? Is there a stopping point before the expensive stage? Ask for the answer in writing, before any payment. Is the peptide long or short? A peptide of twenty-five to thirty-five amino acids also recruits the helper cells; a short one does not. How many targets does the product have? A single one invites the tumour to escape. Ask whether they can also include an anticipated resistance mutation. What do you do if, halfway through the course, the immune response is weak \u0026ndash; do you redesign the peptides, or add a checkpoint inhibitor? In a fusion-driven cancer, where the checkpoint helps little, the response matters a great deal. And the two question-zeros, the ones I wish I had asked myself earlier: how much tissue do I actually have left? And, more important than all of the above: who agrees to administer it to me?\nWe reason by analogy, because RET data does not exist It has to be said plainly, because it is the foundation of the whole line of reasoning: there is not a single RET fusion patient ever treated with such a vaccine. Zero human data. Neither positive nor negative.\nSo everything I am doing is reasoning by analogy \u0026ndash; I learn from situations that biologically resemble mine. Concretely, I lean on three:\nThe ALK fusion, in mice. ALK is the close \u0026ldquo;cousin\u0026rdquo; of my case: also lung cancer, also driven by a fusion. A vaccine built on the fusion peptide, given together with the targeted pill, eradicated the tumours and prevented brain metastases in mice (Mota et al., 2023 ). It is only an animal model \u0026ndash; but it is exactly the mechanism I would use. The idea has also reached a human clinical trial, ARCHER , open to patients with ALK. Not to those with RET.\nOne fusion, in one human being, in Germany. In a rare liver cancer also driven by a fusion, a junction peptide vaccine was built and administered, without immunotherapy, exactly through the legal route described above (published in 2022 ). It does not prove that it works at scale. It proves that this thing can be built and given to a real human being \u0026ndash; which, when I had started out, I did not know.\nKRAS, a single target, few mutations. The trial mentioned above, which shows that a single well-chosen epitope can raise a durable immune response even in a mutation-poor tumour.\nNone of them is proof that my vaccine would work. Together they tell me only this much: the mechanism is plausible, the manufacturing route exists, and a single well-chosen target can be enough. The rest is hypothesis.\nWarning Hope without data stays a wish. I am writing this article as a map, not as a recommendation. If you are looking at the same options, look also at the part I do not like: most of the vaccines rigorously tested in lung cancer did not prolong life, and for my specific situation there is not a single patient treated before me. A resource I recommend again I wrote about it last time too, but here it is even more in place.\nSijbrandij Foundation \u0026ndash; created by Sid Sijbrandij, the co-founder of GitLab, after his own experience with cancer \u0026ndash; keeps a clean list of suppliers for exactly the things in this article: tissue preservation, molecular profiling, vaccines, cell therapies. And the part that seemed most valuable to me is that it offers you, free of charge, a thirty-minute conversation with someone from their team.\nThey do not make your decision and they do not replace your doctor. But through the patients who have passed through them they have seen solutions I could never have found on my own, and they can put you in touch with people they already work with. For someone stuck on exactly the link I wrote about above \u0026ndash; who agrees to administer \u0026ndash; it is the kind of conversation that can shorten months of searching.\nTip Sijbrandij Foundation \u0026ndash; FCCT, free for patients: the supplier list and the 30-minute consultation. sijbrandijfoundation.org/fcct#suppliers Where I am now I have paid nothing and I have signed nothing. I have three gates to pass, in this order:\nHow much tissue I have left. I am going to the lab in person, with the blocks, so that someone who has them in hand can count. HLA typing at four digits. It tells me whether the target is real or only plausible on paper. The exact sequence of the junction. The data request has been sent. Only after these three does a conversation about money with anyone make sense.\nIt is a strange position: I have a very clear strategy and zero certainties. But I prefer that to buying something expensive that does not look at my tumour.\nIf you are a doctor, an oncology navigator or a patient and you have experience with any of these centres \u0026ndash; or with others I have not found \u0026ndash; write to me . I got here by asking people, and that is how I want to keep going.\nWhat to do now Inventory your tissue. Ask the lab that ran your tests how many sections you have left and what percentage of tumour the block has now. \u0026ldquo;The tissue is good\u0026rdquo; and \u0026ldquo;I still have enough\u0026rdquo; are different things. Ask for HLA typing at four digits. It is cheap, it is done once, and it decides whether a peptide target makes sense for you. If your tumour is driven by a fusion, ask for the report with the exact junction \u0026ndash; the exons involved and the coordinates \u0026ndash; not just the names of the two genes. Usually the data already exists, it just does not make it into the clinical report. Ask any centre, before any payment, what material their product needs: fresh tissue, paraffin, blood or just a sequence. Ask in writing what happens if the analysis finds nothing usable \u0026ndash; what you get, where you can stop, what data stays yours. Do not confuse a manufacturing authorization with proof of efficacy, and do not confuse a fast reply with a good fit. If you want to track the disease through the DNA in your blood, ask whether a single sequencing of the tumour can serve both the blood test and the vaccine \u0026ndash; so that you do not use up the same rare tissue twice. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/blog/personalized-cancer-vaccines/","summary":"\u003cp\u003e\u003cstrong\u003eIn short:\u003c/strong\u003e I have spent the last few months reading, asking questions and writing to centres that make therapeutic cancer vaccines. This article is the map I wish I had had at the start: what types of vaccine exist and how they differ, what worked and what did not work in trials, what the real limits are, what the ideal vaccine for my case would look like \u0026ndash; and the list of centres I found, sorted by how well they fit \u003cstrong\u003emy biology\u003c/strong\u003e. It is written both for patients and for doctors or oncology navigators running into this subject for the first time.\u003c/p\u003e","title":"Personalized cancer vaccines"},{"content":"In short: This is a follow-up to my main piece on personalized cancer vaccines . That one was about which vaccine could fit my biology. This one is about a much more basic thing that almost stopped me before biology even mattered: tissue. A personalized vaccine can need far more tumour material than the test that first diagnosed you — often fresh-frozen, not paraffin — and if your treatment works well, there may be nothing left to biopsy when you finally need it. I am writing this because I wish someone had told me at the first biopsy. Maybe it reaches you before yours.\nWhat happened to me My tumour tissue was collected once, at diagnosis, by a core-needle biopsy — two small cores. That was enough to diagnose the cancer and to run a large molecular panel. It felt like plenty.\nMonths later, chasing a personalized vaccine, I asked the laboratory that holds my paraffin blocks to measure what was actually left. The answer, from the pathologist who put the blocks under a microscope: less than a millimetre of tissue per block — an estimated three to five thin sections each. Not enough for what a vaccine centre needs. The safest way to get more, he wrote, would be to re-biopsy.\nExcept I cannot re-biopsy. My treatment has worked so well that there is no tumour left that is safe or sensible to sample — nothing large enough, active enough, or reachable enough for a needle. The thing that makes my situation hopeful is the same thing that closed the door on new tissue.\nThat is the trap in one sentence: the tissue you can get early may be the only tissue you will ever get.\nWhy a vaccine needs so much more tissue than a diagnosis A routine diagnostic panel is efficient. It reads a defined list of cancer genes, deeply, from a tiny amount of material. That is why a small biopsy is usually \u0026ldquo;enough\u0026rdquo;.\nA personalized (neoantigen) vaccine asks a bigger question — what makes my tumour look different from every healthy cell in my body? — and answering it can take a lot more:\nWhole-exome sequencing (all the protein-coding genes, not a short list), to find the tumour\u0026rsquo;s mutations. Often whole-transcriptome sequencing (RNA) on top of that, to see which of those mutations are actually switched on — and to catch gene fusions, which is exactly where my own target lives. And several centres strongly prefer fresh-frozen tissue rather than paraffin-embedded, because frozen tissue preserves higher-quality DNA and RNA. Paraffin (the standard archival form) works for many tests, but it degrades the material, and some vaccine pipelines will not accept it — or need more of it to compensate. So the very analysis that designs the vaccine is the most tissue-hungry step in the whole journey, and it often comes last — long after the biopsy, when the material is already spoken for.\nNot every vaccine needs the same amount — this is your lever Here is the useful part, the thing that gives you options even when tissue is short. Different vaccine platforms need very different amounts of tissue, because they get their two ingredients — the immune cells and the target — from different places:\nThe cells. Some vaccines (dendritic-cell vaccines) grow immune cells from your blood, through a simple blood draw or an apheresis. No tumour tissue at all for this part. The target. If the tumour\u0026rsquo;s mutations are already known — from sequencing you already have — some centres can build the vaccine from defined peptides (short pieces matching those mutations), which are chemically synthesised. Again, no fresh tissue needed for this part. Put those together and you get a real distinction:\nCentres that do their own whole-exome + whole-transcriptome sequencing from your tissue need the most material — and if you are short, they may be out of reach. Centres that build defined peptides from data you already hold, with cells from your blood, need little or no new tissue — and can stay open even when the block is nearly empty. Knowing which kind a centre is before you commit money is one of the most important questions you can ask.\nWhat I would ask at the first biopsy, if I could do it again None of this requires you to have decided on a vaccine. It just keeps the door open, cheaply, at the one moment it is open:\nAsk for extra cores. One or two more passes, when the needle is already there and the tumour is active, is the whole game. It is far easier than a second procedure later. Ask whether a portion can be kept fresh-frozen, not only fixed in paraffin. This has to be arranged before the procedure — it cannot be done afterwards. Ask that the diagnostic block not be completely consumed by the first test — that some tumour is preserved for later. Ask for a written inventory after each test: how many sections remain, and what percentage is still tumour. \u0026ldquo;The tissue is good\u0026rdquo; and \u0026ldquo;there is enough tissue left\u0026rdquo; are two different sentences, and I learned that the hard way. If your cancer is driven by a fusion, ask for the exact junction (the exons and coordinates), not just the two gene names — usually the data already exists in the lab\u0026rsquo;s files. There is a fuller, calmer version of this checklist in our companion guide, Preserving your tumour tissue — read it before a biopsy if you can.\nIf you are already past that point So am I. It is not the end of the road, it just narrows it:\nUse what data you already have. The molecular report from your diagnosis already contains most of what a defined-peptide vaccine needs. You may not need new sequencing at all — only a centre willing to work from it. Favour the blood-and-peptide platforms over the tissue-hungry ones. Tell each centre your tissue is limited and ask, plainly, whether they can design from existing data with cells from your blood. Bank the next opportunity. If the disease ever progresses and a new, biopsiable lesion appears, that is the moment to collect generously — including fresh-frozen — because it may not come again. Do not overpay for a dead end. Ask, in writing, what happens to your money and your data if the limited tissue turns out to be unusable, before you transfer anything. Why I am publishing this I have a clear strategy and no guarantees, and I have spent weeks working around a limitation that a single sentence at my first biopsy would have prevented. The tissue was there once. Nobody told me to keep more of it, and by the time I understood why it mattered, the tumour I would have sampled was gone.\nIf you are earlier in this than I am — if a biopsy is still ahead of you, or the tumour is still there to sample — please ask for more than the minimum. It costs almost nothing now and it can be worth everything later.\nWhat to do now At any biopsy, ask for extra cores and a fresh-frozen portion — arranged before the procedure, not after. Do not let the first test consume the whole block. Ask that some tumour be preserved for later. Get a written inventory after each test — sections remaining and current tumour percentage. Before paying any vaccine centre, ask what material their product needs — fresh tissue, paraffin, blood, or just a sequence — and whether they can work from data you already have. Ask in writing what you get, and where you can stop, if the tissue proves too little to complete the analysis. If treatment is working, treat any biopsiable lesion as a rare chance to bank tissue — a good response can remove the option entirely. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/blog/personalized-cancer-vaccines-tissue/","summary":"\u003cp\u003e\u003cstrong\u003eIn short:\u003c/strong\u003e This is a follow-up to my \u003ca href=\"/en/blog/personalized-cancer-vaccines/\"\u003emain piece on personalized cancer vaccines\u003c/a\u003e\n. That one was about \u003cem\u003ewhich\u003c/em\u003e vaccine could fit my biology. This one is about a much more basic thing that almost stopped me before biology even mattered: \u003cstrong\u003etissue.\u003c/strong\u003e A personalized vaccine can need far more tumour material than the test that first diagnosed you — often \u003cem\u003efresh-frozen\u003c/em\u003e, not paraffin — and if your treatment works well, there may be nothing left to biopsy when you finally need it. I am writing this because I wish someone had told me at the \u003cstrong\u003efirst\u003c/strong\u003e biopsy. Maybe it reaches you before yours.\u003c/p\u003e","title":"Personalized cancer vaccines, part 2: the tissue you need — and why to secure it early"},{"content":"In short: As a cancer patient, you end up reading a lot. Some of what you read is solid science. Another part is the grey zone: observations from individual doctors, stories from other patients, mechanisms demonstrated in mice but unproven in humans. This article is about that second category. I\u0026rsquo;m not asking you to believe anything that follows \u0026ndash; I\u0026rsquo;m just showing you six ideas that have stuck with me, with links, so you can see I didn\u0026rsquo;t invent them, and with an honest label on each one: how much is science and how much is story.\nWhy I\u0026rsquo;m writing about unproven things The rule I set for myself: every observation below gets a label. Demonstrated mechanism means there are published studies showing how it could happen \u0026ndash; usually in animals. Anecdotal means stories: real, but not filtered through a study. None of them is a treatment recommendation. All of them, however, are good questions to ask your doctor.\nSome of these ideas I came across on X, from Dr. Jason Williams , an American interventional radiologist who runs a private oncology clinic in Mexico and wrote a book about immunotherapy injected directly into the tumor . To be upfront with you from the start: his clinic\u0026rsquo;s results come from conference presentations and his own materials, not from independently replicated randomized trials. That doesn\u0026rsquo;t automatically make him wrong \u0026ndash; but it makes him a source of hypotheses, not certainties. That\u0026rsquo;s exactly how I read him.\n1. Surgery heals the wound \u0026ndash; and may wake up sleeping cells The idea that has stuck with me the most: after an operation, the body launches a massive regeneration program \u0026ndash; growth factors, inflammation, \u0026ldquo;rebuild here\u0026rdquo;. Except that signal doesn\u0026rsquo;t distinguish between healthy tissue and any cancer cells still left in the body. It feeds them all.\nThe label: mechanism demonstrated in animals; the magnitude in humans \u0026ndash; unproven.\nThe solid part: in 2018, MIT researchers showed in mice that a simple surgical wound \u0026ndash; completely unrelated to the tumor \u0026ndash; was enough for dormant metastases, held in check by the immune system, to start growing (the full study ). In humans, researchers like Retsky and Demicheli noticed long ago that relapses after breast cancer surgery cluster suspiciously in the first 8-18 months \u0026ndash; a pattern that fits the idea of awakening, not slow, uniform growth.\nThe honest part: when the obvious solution was tested \u0026ndash; an anti-inflammatory given around the time of surgery \u0026ndash; the randomized trial came out negative . So the mechanism is real, but no one has yet demonstrated in humans either how big the effect is or how to prevent it. My conclusion as a patient is not \u0026ldquo;avoid operations\u0026rdquo; \u0026ndash; surgery cures people every day. It\u0026rsquo;s just this: the period around an operation is a vulnerable window, and it deserves to be treated as one.\n2. The pulled tooth, the broken arm, and the cancer that comes back I\u0026rsquo;ve heard, anecdotally, several stories with the same pattern: a patient stable for years on treatment has a tooth pulled, gets a dental implant, breaks a bone, or goes through some other seemingly unrelated insult \u0026ndash; and shortly afterward the cancer comes back, aggressively.\nThe label: anecdotal in humans; plausible mechanism, demonstrated in animals.\nThere is no study linking dental extractions to relapse in humans. There is, however, a mechanism published in Science in 2018: inflammation \u0026ndash; anywhere in the body \u0026ndash; recruits a type of immune cell that throws out sticky webs of DNA, and those webs can wake up dormant cancer cells . Blocking them, in mice, kept the cells asleep. The important detail: in these experiments the awakening didn\u0026rsquo;t come from an operation, but from a bacterial infection and from cigarette smoke \u0026ndash; that is, from pure inflammation. Which suggests that the key word isn\u0026rsquo;t surgery or the tooth, but any major insult that triggers massive repair and systemic inflammation: a fracture, serious trauma, a nasty infection. Same category, same signal. A 2025 study added another piece: inflammation changes the state of dormant cells and pushes them toward awakening. Even more uncomfortably, a recent lung cancer study suggests that, through the same inflammatory mechanism, even chemotherapy can wake up dormant cells \u0026ndash; one more reason why the question \u0026ldquo;how much and when\u0026rdquo; is just as important as \u0026ldquo;which treatment\u0026rdquo;.\nThe tooth stories remain stories. But the mechanism that could explain them exists, in black and white.\n3. The advice I received myself: postpone what isn\u0026rsquo;t vital This one isn\u0026rsquo;t something I read on the internet \u0026ndash; it\u0026rsquo;s my own experience. I had a non-cancerous medical problem, a bothersome one, for which an operation was being discussed. My doctor in Turkey told me simply: as long as the disease is under control, we do no intervention that isn\u0026rsquo;t absolutely necessary. He didn\u0026rsquo;t lecture me about dormant cells. But placed next to observations 1 and 2, his recommendation makes sense.\nThe label: prudent clinical practice; there is no official guideline requiring it.\nNo oncology guideline says \u0026ldquo;postpone non-essential operations\u0026rdquo;. What the literature on the perioperative period does say is that the days around any operation are a window of immunological vulnerability \u0026ndash; and medicine\u0026rsquo;s answer is to optimize that window, not to avoid surgery. My patient\u0026rsquo;s translation: an elective procedure, in a cancer patient, is not an administrative decision. It\u0026rsquo;s a decision to discuss with your oncologist, with a risk and a benefit laid out on the table.\n4. Does a biopsy spread cells? Yes, rarely \u0026ndash; and there are techniques that reduce the risk This is the observation I dug into the deepest, because it concerns me directly: my diagnosis started with biopsies. The fear circulates widely among patients: \u0026ldquo;don\u0026rsquo;t let them stick a needle in you, it spreads the cancer\u0026rdquo;.\nThe label: a real, documented phenomenon, but rare \u0026ndash; and the consensus is clear that the diagnostic benefit dominates.\nThe actual numbers: for lung biopsies, needle-tract seeding is on the order of 1 in several thousand . For the liver, with older techniques, around 2-3% \u0026ndash; and with the modern coaxial technique, close to zero . Without a biopsy there is no molecular diagnosis, and without a molecular diagnosis I would never have received the pill that melted my tumors. Refusing a biopsy is, statistically, a far more dangerous decision than the biopsy itself.\nBut \u0026ndash; and this is what I find genuinely useful \u0026ndash; modern interventional radiology treats this risk as a real one and designs around it. What a patient can ask before a biopsy:\nDo you use the coaxial technique? (a single outer sheath through which all samples pass, so the needle doesn\u0026rsquo;t re-touch fresh tissue on the way out) Do you seal the tract on withdrawal? (cauterization or a hemostatic plug, described here ) Could a liquid biopsy \u0026ndash; a blood sample \u0026ndash; answer the same question? Guidelines for advanced lung cancer increasingly accept it as a first step; be careful though, a negative blood result rules out nothing \u0026ndash; it sends you back to tissue. Are you taking enough samples in a single pass for complete genomic testing? One good biopsy now is safer than two thin ones a month apart. 5. If the needle is already in the tumor, why does it come out empty? The idea from Dr. Williams that intrigued me the most: at the moment of a biopsy, the needle is already in the tumor. His argument : why use that pass only to take material out, when you could, in the same gesture, also inject something \u0026ndash; immunotherapy, an immune stimulant \u0026ndash; directly into the lesion?\nThe label: the field is legitimate; the practice of \u0026ldquo;treating at every biopsy\u0026rdquo; is experimental.\nThe solid context: intratumoral therapy \u0026ndash; injecting treatment directly into the tumor \u0026ndash; is a real field, with an FDA-approved drug for melanoma since 2015 and a serious review in Radiology in 2024. The logic is beautiful: you turn the tumor itself into a vaccine, with much smaller systemic doses. A phase 1 study in metastatic prostate cancer , which combines partially freezing the tumor with a locally injected immune cocktail, reported unusually good responses and received fast-track status from the FDA.\nThe counterweight, just as real: the largest randomized test of an immune stimulant injected into the tumor, in melanoma, failed clearly . And the old version of the idea \u0026ndash; chemotherapy injected directly into the tumor to bypass systemic toxicity \u0026ndash; worked exactly as promised on toxicity (no kidney, nerve, or hearing damage), but it didn\u0026rsquo;t prolong life and never became standard. Its accepted relatives do exist, though: chemoembolization for liver tumors, where the drug is delivered through the tumor\u0026rsquo;s artery, is standard treatment .\nSo: an idea with a foundation, now being tested in real trials \u0026ndash; but if a private clinic is selling it to you today as a proven treatment, that\u0026rsquo;s a different conversation.\n6. Do everything that can be done BEFORE you start treatment The last observation is again from my own experience, and it\u0026rsquo;s the one I wish I had read somewhere at diagnosis. In my case, radiotherapy on the spinal lesion was done right away, before I started the targeted pill. It seemed like a scheduling detail. It wasn\u0026rsquo;t: many local treatments require temporarily interrupting systemic treatment. Done at the start, the radiotherapy cost me nothing. Done later, it would have meant days without the pill that keeps my disease under control \u0026ndash; exactly what I lived through last month, when a second course of radiotherapy required a treatment pause.\nThe label: logistics and clinical common sense; not controversial, just rarely said explicitly to the patient.\nThe formulation I\u0026rsquo;ve arrived at: at the beginning of treatment there is a window that never comes back \u0026ndash; the diagnosis is complete, systemic treatment hasn\u0026rsquo;t started yet, and any local procedure, tissue collection, or necessary intervention can be done without stopping anything. The good question for your medical team, in the first week: \u0026ldquo;What else would be worth doing NOW, while I haven\u0026rsquo;t started yet?\u0026rdquo;\nWhat remains of all this Rereading the list, I see a common thread: the body reacts to any insult \u0026ndash; an operation, a needle, a fracture, an infection, inflammation \u0026ndash; with a powerful repair program, and that program doesn\u0026rsquo;t know whose side it\u0026rsquo;s on. Nothing here translates into \u0026ldquo;refuse procedures\u0026rdquo;. It translates into better questions: is it necessary now? is there a gentler technique? what do we do with the window at the beginning?\nI\u0026rsquo;m not a doctor. I\u0026rsquo;m a patient who reads a lot and who prefers to also know what\u0026rsquo;s in the grey zone, with the labels applied honestly. If one of these observations sparks a good conversation with your doctor, this article has done its job.\nWhat to do now Before any elective operation, ask your oncologist: \u0026ldquo;Is this the right time, or do we postpone while the disease is under control?\u0026rdquo; Before a biopsy, ask: coaxial technique? tract sealing? could a liquid biopsy answer the question? are there enough samples for genomic testing from a single pass? At diagnosis, ask your team: \u0026ldquo;What procedures or interventions would be worth doing NOW, before starting systemic treatment?\u0026rdquo; Treat stories from the internet as hypotheses, not evidence \u0026ndash; but don\u0026rsquo;t throw them away: ask your doctor to tell you what is a demonstrated mechanism and what is just a story. Don\u0026rsquo;t refuse a necessary biopsy or operation out of fear of spreading: the documented risk is small, and the price of a missing diagnosis is much higher. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/blog/observations-from-the-grey-zone/","summary":"\u003cp\u003e\u003cstrong\u003eIn short:\u003c/strong\u003e As a cancer patient, you end up reading a lot. Some of what you read is solid science. Another part is the grey zone: observations from individual doctors, stories from other patients, mechanisms demonstrated in mice but unproven in humans. This article is about that second category. I\u0026rsquo;m not asking you to believe anything that follows \u0026ndash; I\u0026rsquo;m just showing you six ideas that have stuck with me, with links, so you can see I didn\u0026rsquo;t invent them, and with an honest label on each one: how much is science and how much is story.\u003c/p\u003e","title":"Observations from the grey zone: things I carry with me as a cancer patient"},{"content":"In short: In the previous article I wrote about the grey zone \u0026ndash; anecdotal observations, honestly labeled as such. This article is the opposite: an idea backed by randomized trials, one I believe patients hear far too little about. The idea: the total amount of tumor in your body is not just a staging number. It\u0026rsquo;s a strategic variable \u0026ndash; and there are serious arguments that reducing it as much as possible, as early as possible, with every tool available, changes your odds. Including the uncomfortable part: the trials that say otherwise.\nA simple question nobody asks out loud When you\u0026rsquo;re diagnosed with metastatic cancer, systemic treatment \u0026ndash; targeted pill, chemotherapy, immunotherapy \u0026ndash; becomes the center of the world. Radiotherapy and other local treatments usually enter the conversation only \u0026ldquo;when needed\u0026rdquo;: when a lesion hurts, when it grows, when it threatens something.\nThe question I eventually came to ask myself: why \u0026ldquo;when needed\u0026rdquo;? If systemic treatment keeps the disease under control but doesn\u0026rsquo;t wipe it out completely, what happens to what\u0026rsquo;s left? A reservoir remains. And that reservoir is not passive.\nWhy volume matters: three mechanisms 1. The resistance lottery. Treatment resistance arises through random mutations. And in that lottery, every extra tumor cell is an extra ticket \u0026ndash; it\u0026rsquo;s an idea four decades old in oncology (the Goldie-Coldman hypothesis): the probability that a resistant cell already exists somewhere in the body grows with the total number of cells. Less tumor = fewer tickets = more time before the treatment gives out.\nEven more interesting: each lesion is a separate evolutionary reservoir , developing its own mutations, independently of the others. In one melanoma patient, three different lesions developed three different resistance mechanisms , simultaneously. Every lesion you eliminate isn\u0026rsquo;t just \u0026ldquo;less disease\u0026rdquo; \u0026ndash; it\u0026rsquo;s a resistance laboratory shut down.\n2. High volume smothers immunity. The immune system fights cancer every day, but the fight wears it down. Studies show that a high tumor burden exhausts T cells \u0026ndash; pushing them into an \u0026ldquo;exhaustion\u0026rdquo; state they recover from with difficulty \u0026ndash; and that patients with high tumor volume respond worse to immunotherapy . Less tumor doesn\u0026rsquo;t just mean less enemy; it means an immune system that\u0026rsquo;s less overwhelmed.\n3. Residual lesions harbor the survivors. Even when targeted treatment works spectacularly, the remaining lesions hide drug-tolerant cells \u0026ndash; not mutants, just adapted, in partial hibernation. From them, true genetic resistance is later born . That \u0026ldquo;stable, small, we won\u0026rsquo;t touch it\u0026rdquo; lesion on your report is exactly their shelter.\nThe lesson hematology learned decades ago In leukemias, this idea has a name and sits at the center of treatment: minimal residual disease (MRD). In chronic myeloid leukemia, the explicit target isn\u0026rsquo;t \u0026ldquo;the patient feels fine\u0026rdquo; \u0026ndash; it\u0026rsquo;s reducing the disease by four orders of magnitude, measured molecularly , because the depth of response predicts survival and even the chance of stopping treatment. In acute leukemia, therapy is escalated or de-escalated based on MRD .\nIn solid tumors, the equivalent is only now being built: circulating tumor DNA (ctDNA) in the blood. The data are already impressive as prognosis \u0026ndash; patients whose ctDNA clears on treatment have a threefold lower risk of progression , and ctDNA can announce relapse months before the scan . The honest label: for now ctDNA predicts, but no trial has yet shown that acting on it prolongs life. It\u0026rsquo;s the direction, not the standard.\nBut the principle behind it \u0026ndash; the depth of the response matters, not just its direction \u0026ndash; strikes me as the most important idea a solid-tumor patient can borrow from hematology.\nThe evidence: what happens when you ablate the residual Here we\u0026rsquo;re no longer in the grey zone. Randomized trials:\nSABR-COMET (various cancers, 1-5 metastases): stereotactic radiotherapy to all lesions doubled long-term survival \u0026ndash; at 8 years, 27% of aggressively treated patients were alive, versus 14% in the standard group. Gomez (lung cancer, up to 3 lesions remaining after initial treatment): local consolidation moved median survival from 17 to 41 months . SINDAS (phase 3, EGFR-mutant lung cancer on a targeted pill): stereotactic radiotherapy done upfront, to all lesions, not on demand, extended survival from 17.4 to 25.5 months \u0026ndash; with acceptable toxicity. It\u0026rsquo;s the trial closest to the situation of patients with \u0026ldquo;driver-dependent\u0026rdquo; disease, like mine. And when the disease escapes in just a few spots under targeted treatment, the strategy of ablating them and continuing the same pill \u0026ndash; dubbed by oncologists \u0026ldquo;weeding the garden\u0026rdquo; \u0026ndash; is today recommended by guidelines : you pull out the resistant weeds and keep the treatment that controls the rest of the garden. Where caution gets it right \u0026ndash; the part other articles leave out If I stopped here, this article would be propaganda. The full picture:\nNRG-LU002, the most recent large American trial, tested exactly this aggressive consolidation in lung cancer patients \u0026ndash; most on immunotherapy \u0026ndash; and came out completely negative : zero benefit. CURB showed that in oligoprogressive lung cancer radiotherapy quadrupled time to progression, but in breast cancer it delivered nothing . The biology of the disease decides \u0026ndash; \u0026ldquo;radiate everything\u0026rdquo; is not a universal rule. SABR-COMET itself has serious critiques : a small trial, imbalanced arms, and 4.5% treatment-related deaths. Aggressive radiotherapy isn\u0026rsquo;t free: pneumonitis, forced pauses of the targeted pill, organ-specific risks. How do I reconcile the pro camp with the con camp? By looking at who was in each trial. The positive trials: disease with few lesions, often dependent on a genetic driver, under a systemic treatment that\u0026rsquo;s working. The negative trial: the immunotherapy era, a different biology. My conclusion as a patient is not \u0026ldquo;everyone should be irradiated early\u0026rdquo;. It\u0026rsquo;s: if your disease is oligometastatic and systemically controlled, aggressive local consolidation has randomized data in its favor \u0026ndash; and it\u0026rsquo;s worth asking for proactively, not waiting until something hurts.\nBut didn\u0026rsquo;t the last article say the opposite? Attentive readers will notice the tension: two articles ago I wrote that assaults on the body \u0026ndash; surgeries, trauma \u0026ndash; can wake dormant cancer cells. Now I\u0026rsquo;m advocating aggressive local treatments. A contradiction?\nNo, and the difference is worth stating explicitly. One thing is elective trauma to healthy tissue, without cover \u0026ndash; which sets off the body\u0026rsquo;s repair alarm without killing a single cancer cell. Another is the targeted destruction of tumor tissue, under the cover of an active systemic treatment patrolling the rest of the body. The first only sounds the alarm. The second empties the reservoir while the guard is on duty. Same body, same signals \u0026ndash; but the balance sheet is the opposite.\nThe personal thread At diagnosis, my spinal lesion was irradiated immediately, before starting the targeted pill. Months later, when the main lung tumor \u0026ndash; metabolically melted, but not gone \u0026ndash; started to flicker, I chose stereotactic radiotherapy on it, even though \u0026ldquo;it could have waited\u0026rdquo;. I can never know the counterfactual. But the strategy behind both decisions is exactly the one in this article: don\u0026rsquo;t let the reservoir exist just because it\u0026rsquo;s quiet.\nWhat remains Standard of care isn\u0026rsquo;t bad \u0026ndash; it\u0026rsquo;s cautious, and the negative trials above show why the caution exists. But between \u0026ldquo;cautious\u0026rdquo; and \u0026ldquo;passive\u0026rdquo; there\u0026rsquo;s a difference the patient can influence. Depth of response matters. Every lesion eliminated is a resistance laboratory shut down. And the question \u0026ldquo;why are we waiting?\u0026rdquo; \u0026ndash; asked politely, with these trials in hand \u0026ndash; is one of the most valuable questions you can bring to a consultation.\nWhat to do now Ask your oncologist: \u0026ldquo;Is my disease oligometastatic? Exactly how many active lesions do I have?\u0026rdquo; If you have few lesions and systemic treatment is working: \u0026ldquo;Which lesions could be treated locally \u0026ndash; stereotactic radiotherapy, ablation \u0026ndash; and why are we waiting?\u0026rdquo; If a single lesion is progressing while the rest sit quiet: ask about the strategy of local ablation while keeping your current treatment, before switching the entire regimen. Ask what radiotherapy would mean for your systemic treatment: does it need to be interrupted? for how long? what pneumonitis risks? Ask whether a ctDNA test could measure your residual disease \u0026ndash; and what you would do differently depending on the result. If the answer is \u0026ldquo;nothing\u0026rdquo;, ask why. Bring the trials into the conversation by name: SABR-COMET, Gomez, SINDAS \u0026ndash; oncologists know them, and the conversation becomes concrete. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/blog/minimal-residual-disease/","summary":"\u003cp\u003e\u003cstrong\u003eIn short:\u003c/strong\u003e In the previous article I wrote about the grey zone \u0026ndash; anecdotal observations, honestly labeled as such. This article is the opposite: an idea backed by randomized trials, one I believe patients hear far too little about. The idea: the total amount of tumor in your body is not just a staging number. It\u0026rsquo;s a strategic variable \u0026ndash; and there are serious arguments that reducing it as much as possible, as early as possible, with every tool available, changes your odds. Including the uncomfortable part: the trials that say otherwise.\u003c/p\u003e","title":"Minimal residual disease: why every gram of tumor matters"},{"content":"In short: Each of us, patients with RET-positive cancer, holds a treasure: our own data \u0026ndash; the genetic test, the treatments, the response, the side effects, the progression. Put together, this data would answer the questions that keep us up at night. Today it sits fragmented: part of it in institutional registries we cannot access, part of it in our own drawers. Other patient communities solved this problem by building their own registries \u0026ndash; and changed the research on their disease. We believe it is time for the RET community to do the same. This article explains why, what we propose concretely, and how you can register your interest. Nothing is being collected yet \u0026ndash; first we want to know how many of us there are.\nThe problem: the information exists, but it does not circulate Our disease is rare \u0026ndash; RET fusions occur in 1-2% of lung cancers. That means no hospital, no city, often no country sees enough patients to learn quickly. The only way to learn quickly is to pool the data.\nThe good news: pooling already exists, partially. International academic registries \u0026ndash; for example the Global RET Registry (GLORY) or the European RET-MAP registry, from which valuable analyses have been published \u0026ndash; gather data from dozens of hospitals. We are grateful to those who built them: without them we would know far less.\nThe bad news, said with all due respect: for the patient, this system is opaque. Hospitals decide whether they contribute and what they contribute \u0026ndash; often only part of the genetic data of each case. Results appear years later, compressed into a few slides at conferences you have to hunt down on social media. And if a patient asks \u0026ldquo;how long, on average, does the response to treatment last for someone with exactly my fusion?\u0026rdquo; \u0026ndash; there is nowhere to ask that question. There is no mechanism through which a patient can query the registries built, in part, from the data of patients like them.\nThe European Union has already recognized the problem: the European Health Data Space (EHDS) , in force since 2025, will gradually create the right of access to anonymized health data for secondary use. But full implementation is scheduled toward the end of the decade. Some of us do not have that kind of time.\nThe questions that keep us up at night \u0026ndash; and that no one can answer today Be honest: how many of these have you asked yourself, at 2 a.m., after a scan?\nHow long does selpercatinib actually last for someone with my exact fusion partner and my co-mutations? Not the trial average \u0026ndash; my configuration. Today, no doctor on Earth can answer that, because the data to answer it has never been put in one place. When my treatment stops working, what did the patients who were exactly where I am do next \u0026ndash; and how did it go? Hundreds of RET+ patients have already crossed that bridge. Their experience exists. It is just not written down anywhere you or your oncologist can read it. Are my side effects normal? How many of us reduced the dose \u0026ndash; and did the response hold? Every one of us negotiates this alone with their oncologist, as if no one had ever done it before. Which resistance mechanism should I be watched for, given my fusion? Somewhere out there is probably a patient with your exact profile, twelve months ahead of you on the same road. Right now, the two of you have no way to learn from each other. When a researcher decides what to study next in RET, whose questions are on the table? Not ours \u0026ndash; because ours have never been collected. If a registry of a few hundred of us existed, none of these would be unanswerable. That is the whole argument, and it fits in one sentence: the answers exist, scattered across our lives \u0026ndash; they just have never been added up.\nAnd to the most skeptical among us \u0026ndash; the ones thinking \u0026ldquo;my one case won\u0026rsquo;t change anything\u0026rdquo;: in a disease this rare, the opposite is true. When the worldwide pool of comparable cases is measured in hundreds, one patient is not a rounding error \u0026ndash; one patient is a percentage point. Rare disease math is the one place where a single \u0026ldquo;count me in\u0026rdquo; genuinely moves the needle.\nProof that it can be done: the patients who already did it We are not proposing a utopia. We are proposing to copy, honestly, what worked for others:\nEGFR Resisters \u0026ndash; a community of patients with EGFR+ lung cancer, started from a Facebook group. Through Project PRIORITY , patients directly donated their clinical and genomic data, with consent, for research \u0026ndash; including in partnership with industry. The result: published studies, patients\u0026rsquo; questions placed on researchers\u0026rsquo; agendas, and a community that no longer waits to be studied \u0026ndash; it studies itself. And the results flow back to the community: the public EGFR Data Explorer dashboard shows anyone what was learned from the donated data. ACCELERATE (Castleman disease) and FibroRegistry (fibrolamellar liver cancer) \u0026ndash; two of the strongest patient-driven stories in medicine: ACCELERATE , the registry founded by a patient-physician, hit its 5-year enrollment target in just 2 years and contributed directly to finding a repurposed treatment; FibroRegistry was founded by a patient who, as a teenager, co-discovered the very driver mutation of her own disease \u0026ndash; and the patient- and family-governed registry has already produced published scientific papers. The ROS1ders and ALK Positive \u0026ndash; communities built precisely around rare drivers, like ours, which went from support groups to funding their own research and data programs: ALK Positive has committed over $10 million to research since 2017 and has a scientific advisory board of 12 leading oncologists, and The ROS1ders created 9 new cell lines \u0026ndash; doubling the worldwide supply available to researchers. NORD IAMRARE and RARE-X \u0026ndash; proof that this model already has mature infrastructure: the IAMRARE program of the US National Organization for Rare Disorders hosts over 40 registries led by patient organizations, with thousands of participants, and RARE-X (Global Genes) built a platform where the data stays owned by the patient, with individually chosen sharing options \u0026ndash; exactly the granular consent model we are proposing. The pattern is identical everywhere: a rare disease, fragmented data, slow institutions \u0026ndash; and patients who decided that speed matters more than inertia. All of them did it legally, with explicit consent, without violating anyone\u0026rsquo;s confidentiality.\nWhat we propose: a community RET registry The OncoGuide Association \u0026ndash; a non-profit patient organization, legally registered in Romania, which runs this site \u0026ndash; is committing to build the infrastructure: an online registry of RET+ patients, made by patients, for everyone.\nThe principles, non-negotiable:\nVoluntary, entirely. Only those who want to contribute do, as much as they want. Anyone can withdraw at any time, and their data is deleted on request. Explicit and granular consent. Each participant decides separately: can the data be used for public statistics? for academic research? can it be shared with pharmaceutical companies developing treatments for us? Each \u0026ldquo;yes\u0026rdquo; is ticked individually, nothing is assumed. Real pseudonymization. Identity and consent are kept separately and privately. In the registry and in any public statistic, a participant is \u0026ldquo;RET-0042\u0026rdquo; \u0026ndash; never a name, never a combination of details that could identify someone in a disease this rare. Anonymization is not a checkbox \u0026ndash; it is a craft, and we treat it as one. Protected under GDPR, wherever it is processed. Before you consent, you are told exactly who processes your data and where. Any transfer outside the EU rests on a named GDPR safeguard. GDPR is not the obstacle here \u0026ndash; the patient\u0026rsquo;s explicit consent is exactly the mechanism GDPR provides for this. Open access to results. The aggregate statistics \u0026ndash; how many of us there are, which fusions we have, how long responses last, what comes after progression \u0026ndash; will be public, for patients, doctors and researchers alike. That is the whole point: for all of us to run faster. Correction (2 September 2026): this principle originally promised that data would be hosted in the EU. We withdrew that promise so the registry can use the best available tools (including AI providers that process data outside the EU under GDPR safeguards). What does not change: GDPR applies to every step, and you are told exactly who processes your data and where, before you consent.\nWhat data would matter To be useful, the registry would gather, from those who choose to contribute: the diagnosis and its date, the RET fusion with its partner (KIF5B, CCDC6\u0026hellip;) and the co-mutations from the genetic report (ideally the report itself, as a document), the treatments in order \u0026ndash; what, from when, until when \u0026ndash;, the response to them, the significant side effects, the local treatments (radiotherapy, ablation, surgery), the time and manner of progression, and what followed. Simply put: each person\u0026rsquo;s medical story, in a comparable format.\nWe know from our own experience how valuable every item on that list is \u0026ndash; because these are exactly the questions we ask ourselves at every treatment decision.\nPartner, not rival We see the community registry as a partner of the academic registries, not a rival \u0026ndash; and we will work transparently with researchers as this effort takes shape. The data patients collect \u0026ndash; adherence, real-world side effects, the decisions between treatment lines \u0026ndash; is exactly what hospital registries lack. We invite any academic group that wants to collaborate to write to us.\nAnd the same goes \u0026ndash; even more so \u0026ndash; for the patient communities that already hold this ecosystem together: RETpositive, the RET Renegades, the national lung cancer groups, the forums. The registry is not a new organization competing for members \u0026ndash; it is shared infrastructure, offered to all of them. Concretely: any patient community that joins gets a voice in the registry\u0026rsquo;s governance, the aggregate results to power its own advocacy and research agenda, and full credit for what its members contribute. Your groups have the trust and the reach; we are building the plumbing. To the international RET patient communities we propose explicitly: let\u0026rsquo;s build this together, not in parallel \u0026ndash; under your umbrella, if that is what it takes.\nWe are getting to work \u0026ndash; and this is only the beginning This article is the intro, not the whole plan. In the coming days we will publish here, step by step: the interest sign-up form, the exact list of data we will ask for, the consent form, and what the registry will look like. We are building in public, so you can see every decision and challenge it.\nUntil then, only one thing matters: finding each other. Every patient who raises their hand now makes the registry more valuable for everyone else.\nWhat to do now Raise your hand NOW: write to us through the contact page with the subject \u0026ldquo;REGISTRY\u0026rdquo; \u0026ndash; a single message, even an empty one. We will count you in, keep you updated at every step, and you will be among the first invited when the form is ready, in the coming days. Be the bridge. You are probably the only person who will bring this to YOUR corner of the community \u0026ndash; your Facebook group, your WhatsApp thread, your oncologist\u0026rsquo;s other RET patient, your country\u0026rsquo;s lung cancer forum, X/Bluesky. Share it there, in your own words, in your own language. In a 1-in-100 disease there is no advertising campaign that can find us \u0026ndash; we can only find each other. Critical mass is everything, and it is built one share at a time. Come back here: the next article in the series brings the interest form and the data list. We are building in public, in the coming days, step by step. If you are a doctor, a researcher or a RET patient organization: write to us \u0026ndash; we are looking for partners and critics in equal measure, and we prefer a joint registry to a parallel one. Do not send medical data yet. Collection begins only after we publish the consent form, the pseudonymization procedure and the platform \u0026ndash; all announced here. The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/registry/ret-patient-registry/","summary":"\u003cp\u003e\u003cstrong\u003eIn short:\u003c/strong\u003e Each of us, patients with RET-positive cancer, holds a treasure: our own data \u0026ndash; the genetic test, the treatments, the response, the side effects, the progression. Put together, this data would answer the questions that keep us up at night. Today it sits fragmented: part of it in institutional registries we cannot access, part of it in our own drawers. Other patient communities solved this problem by building their own registries \u0026ndash; and changed the research on their disease. We believe it is time for the RET community to do the same. This article explains why, what we propose concretely, and how you can register your interest. Nothing is being collected yet \u0026ndash; first we want to know how many of us there are.\u003c/p\u003e","title":"Our data, together: why we want a patient-built RET registry"},{"content":"Our mission OncoGuide exists for a simple reason: no one should have to navigate a cancer diagnosis without clear, accurate, and accessible information.\nWhen you are diagnosed with cancer, the world stops. Then comes an avalanche of medical terms, urgent decisions, and conflicting information from across the internet. We have been through it. We know how overwhelming it is.\nThat is why we created this guide: a place where medical information is explained in plain language, grounded in scientific evidence, free of advertising and commercial interests. Free. Always.\nWhy anonymous? This project is not about who writes. It is about who reads.\nWe choose to remain anonymous because the message matters more than the messenger. We do not want our personal story to distract from the real purpose: providing useful, verified, and easy-to-understand information.\nAnonymity also allows us to write freely, without external pressure.\nWho writes this? OncoGuide is written by a cancer patient who has been through the diagnostic journey \u0026ndash; from first symptoms, through investigations, biopsy, diagnosis, and treatment decisions.\nWe are not doctors. We do not replace medical advice. But we know what it means to be a patient searching desperately for answers at 2 in the morning.\nEverything we publish is documented from authoritative medical sources: ESMO and NCCN clinical guidelines, peer-reviewed publications, and official healthcare system resources.\nHow you can help Are you a patient or caregiver? Share your experience. What information were you missing at the time of diagnosis? What do you wish you had known sooner? Flag errors. If you find inaccurate or incomplete information, let us know. Spread the word. If an article helped you, it might help someone else too. Are you a medical professional? Review our content. We need expert eyes. If you spot inaccuracies or information that needs updating, please write to us. Suggest topics. What questions do your patients ask most often? What could we explain better? Collaborate. If you would like to contribute articles or reviews, we welcome you. Contact You can reach us any time at: contact@oncoguide.xyz We read every message. We reply whenever we can. We appreciate every suggestion.\nOncoGuide is an independent, non-commercial project, created by patients, for patients.\nThe content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/about/","summary":"Who we are, why we exist, and how you can contribute to OncoGuide.","title":"About OncoGuide"},{"content":"We\u0026rsquo;d love to hear from you OncoGuide is a project created by a patient, for patients. Every message matters to us.\nYour message Your name Your email Subject Your message Website Send Preparing the secure form...\nPlease do not send medical documents or sensitive health data through this form. Cloudflare and Resend process the message only to deliver it to our mailbox.\nEnable JavaScript to use the form, or email contact@oncoguide.xyz.\nGeneral questions or feedback Have a question about the content on this site? Want to tell us what was helpful or what could be improved?\nWe\u0026rsquo;d love to hear from you — just fill in the form above.\nAre you a medical professional who wants to contribute? If you are a doctor, pharmacist, nurse, or other healthcare professional and would like to help review or improve our articles, we warmly invite you to get in touch.\nEvery professional contribution makes the information safer for patients.\nFound an error or outdated information? We do our best to keep information accurate and up to date, but medicine evolves rapidly.\nIf you notice something that is no longer accurate or an error of any kind, please let us know. You\u0026rsquo;ll be helping us and everyone who reads this guide.\nAre you from outside Romania? We would be very interested to learn how patient rights and treatment access work in your country.\nYour experience could help other patients around the world. Write to us and share your story.\nImportant note: We do not provide individual medical advice. The information on this site is educational and does not replace consultation with your doctor. For any medical decision, please speak with your treatment team.\nThe content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/contact/","summary":"Reach out with questions, suggestions, or to collaborate","title":"Contact"},{"content":"This page explains, in plain language, what happens to your data when you use the OncoGuide donation pages. Our principle: collect as little as possible \u0026ndash; ideally, nothing.\nProcessing happens in your browser The forms on the donation pages (calculator, contract data, Form 230 data) run exclusively in your browser, on your device. Documents are generated locally. The data you enter \u0026ndash; including the CNP (personal numeric code) for Form 230 \u0026ndash; is not sent to, stored by, or visible to us or anyone else.\nIf you close the page, the data is gone. We use no tracking cookies, no analytics, and we have no servers receiving anything.\nThe copy sent to the association \u0026ndash; only with your consent After generating a document, we offer the option to email us a copy so we can track the incoming payment. This sending:\nhappens only if you choose it, via an explicit consent checkbox; leaves from your own email client, directly to the association\u0026rsquo;s address \u0026ndash; the document passes through no other service; makes the association a controller, in the GDPR sense, of the data in the received copy (name, identification data). Received copies are kept in the association\u0026rsquo;s private archive (locally and in private storage), strictly for donation records and the related legal obligations. They are not shared with anyone and not used for any other purpose.\nThe no-personal-data notification When you send a copy (and only then), the page may send a minimal technical notification to the association: the document type, the page language, and the moment of generation. This notification contains no personal data whatsoever \u0026ndash; no names, no amounts, no CNP.\nThe notification goes through a Cloudflare Pages Function and Resend, the delivery service also used by our contact form. It contains only the donation-flow type and page language \u0026ndash; no document or donor information. The providers may retain operational logs according to their own policies, but this notification does not contain your personal data.\nForm 230 sent by post \u0026ndash; we file it with ANAF for you If you choose the simplest route \u0026ndash; mailing us the signed paper original of Form 230 \u0026ndash; the association takes it from there, per the official procedure (ANAF Order 103/2025 ):\nwe transmit to ANAF, electronically, the centralizing statement with the form\u0026rsquo;s data (name, personal identification number, amount) by the legal deadline of 25 May \u0026ndash; the association\u0026rsquo;s legal obligation as beneficiary entity; we keep the paper original, to present it to the tax authority on request, for as long as the law requires; your data is used exclusively for this filing and the legally required records: it is not entered into other systems, not shared with anyone besides ANAF, and not used for any other purpose. Legal basis: the beneficiary entity\u0026rsquo;s legal obligation under the ANAF procedure, triggered by your choice to send us the form. For any question about your form, write to us via the contact page .\nYour rights For any request about your data (access, rectification, deletion of a sent copy), write to us via the contact page . We answer every message.\nIn short What Where it goes Data entered in the forms Your browser only; gone when you close the page Generated documents (contract, Form 230) Downloaded to your device The copy to the association Only with your explicit checkbox, from your own email, into the association\u0026rsquo;s private archive The technical notification No personal data; Cloudflare Pages and Resend The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/donor-privacy/","summary":"\u003cp\u003eThis page explains, in plain language, what happens to your data when you use the OncoGuide donation pages. Our principle: \u003cstrong\u003ecollect as little as possible \u0026ndash; ideally, nothing\u003c/strong\u003e.\u003c/p\u003e\n\u003ch2 id=\"processing-happens-in-your-browser\"\u003eProcessing happens in your browser\u003c/h2\u003e\n\u003cp\u003eThe forms on the donation pages (calculator, contract data, Form 230 data) run \u003cstrong\u003eexclusively in your browser, on your device\u003c/strong\u003e. Documents are generated locally. The data you enter \u0026ndash; including the CNP (personal numeric code) for Form 230 \u0026ndash; \u003cstrong\u003eis not sent to, stored by, or visible to us or anyone else\u003c/strong\u003e.\u003c/p\u003e","title":"Donor privacy"},{"content":"This tax mechanism applies to employees paying income tax in Romania: they can redirect 3.5% of their already-paid tax to OncoGuide via Form 230, at zero personal cost.\nThe step-by-step guide and the automatic form pre-fill are available on the Romanian page:\nOpen the Romanian individuals page Not a Romanian taxpayer? You can still support us with a direct donation, available worldwide:\nBack to the donate page The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/donate/persoane-fizice/","summary":"\u003cp\u003eThis tax mechanism applies to employees paying income tax in Romania: they can redirect 3.5% of their already-paid tax to OncoGuide via Form 230, at zero personal cost.\u003c/p\u003e\n\u003cp\u003eThe step-by-step guide and the automatic form pre-fill are available on the Romanian page:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"/ro/donate/persoane-fizice/\"\u003eOpen the Romanian individuals page\u003c/a\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eNot a Romanian taxpayer? You can still support us with a direct donation, available worldwide:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"/en/donate/\"\u003eBack to the donate page\u003c/a\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cdiv class=\"onco-disclaimer\" role=\"note\" aria-label=\"Medical Disclaimer\"\u003e\n  \n    The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately.\n  \n\u003c/div\u003e","title":"Redirect 3.5% of your income tax (Romanian employees)"},{"content":"This tax mechanism applies to companies paying profit tax in Romania: they can redirect up to 20% of their profit tax to OncoGuide through a sponsorship contract.\nThe step-by-step guide and the automatic contract generator are available on the Romanian page:\nOpen the Romanian companies page Not a Romanian company? You can still support us with a direct donation, available worldwide:\nBack to the donate page The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately. ","permalink":"https://oncoguide.xyz/en/donate/firme/","summary":"\u003cp\u003eThis tax mechanism applies to companies paying profit tax in Romania: they can redirect up to 20% of their profit tax to OncoGuide through a sponsorship contract.\u003c/p\u003e\n\u003cp\u003eThe step-by-step guide and the automatic contract generator are available on the Romanian page:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"/ro/donate/firme/\"\u003eOpen the Romanian companies page\u003c/a\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eNot a Romanian company? You can still support us with a direct donation, available worldwide:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"/en/donate/\"\u003eBack to the donate page\u003c/a\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cdiv class=\"onco-disclaimer\" role=\"note\" aria-label=\"Medical Disclaimer\"\u003e\n  \n    The content of this article is for informational purposes only and does not constitute medical advice. Discuss any medical decision with your oncologist. If you have urgent symptoms, contact a doctor immediately.\n  \n\u003c/div\u003e","title":"Sponsorship for companies (Romanian taxpayers)"}]